A O O
long O O
terminal O O
repeat O O
of O O
the O O
human O O
endogenous O O
retrovirus O O
ERV O O
- O O
9 O O
is O O
located O O
in O O
the O O
5 O O
' O O
boundary O O
area O O
of O O
the O O
human O O
beta O O
- O O
globin O O
locus O O
control O O
region O O
. O O

Transcription O O
of O O
the O O
human O O
beta O O
- O O
like O O
globin O O
genes O O
in O O
erythroid O O
cells O O
is O O
regulated O O
by O O
the O O
far O O
- O O
upstream O O
locus O O
control O O
region O O
( O O
LCR O O
) O O
. O O

In O O
an O O
attempt O O
to O O
define O O
the O O
5 O O
' O O
border O O
of O O
the O O
LCR O O
, O O
we O O
have O O
cloned O O
and O O
sequenced O O
5 O O
kb O O
of O O
new O O
upstream O O
DNA O O
. O O

We O O
found O O
an O O
LTR O O
retrotransposon O O
belonging O O
to O O
the O O
ERV O O
- O O
9 O O
family O O
of O O
human O O
endogenous O O
retroviruses O O
in O O
the O O
apparent O O
5 O O
' O O
boundary O O
area O O
of O O
the O O
LCR O O
. O O

This O O
ERV O O
- O O
9 O O
LTR O O
contains O O
an O O
unusual O O
U3 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
composed O O
of O O
14 O O
tandem O O
repeats O O
with O O
recurrent O O
GATA O O
, O O
CACCC O O
, O O
and O O
CCAAT O O
motifs O O
. O O

This O O
LTR O O
is O O
conserved O O
in O O
human O O
and O O
gorilla O O
, O O
indicating O O
its O O
evolutionary O O
stability O O
in O O
the O O
genomes O O
of O O
the O O
higher O O
primates O O
. O O

In O O
both O O
recombinant O O
constructs O O
and O O
the O O
endogenous O O
human O O
genome O O
, O O
the O O
LTR B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
promoter O O
activate O O
the O O
transcription O O
of O O
cis O O
- O O
linked O O
DNA O O
preferentially O O
in O O
erythroid O O
cells O O
. O O

Our O O
findings O O
suggest O O
the O O
possibility O O
that O O
this O O
LTR O O
retrotransposon O O
may O O
serve O O
a O O
relevant O O
host O O
function O O
in O O
regulating O O
the O O
transcription O O
of O O
the O O
beta O O
- O O
globin O O
LCR O O
. O O

An O O
insulator O O
blocks O O
spreading O O
of O O
histone O O
acetylation O O
and O O
interferes O O
with O O
RNA O O
polymerase O O
II O O
transfer O O
between O O
an O O
enhancer B-Enhancer B-Enhancer
and O O
gene O O
. O O

We O O
studied O O
the O O
mechanism O O
by O O
which O O
an O O
insulator O O
interrupts O O
enhancer O O
signaling O O
to O O
a O O
gene O O
using O O
stably O O
replicated O O
chromatin O O
templates O O
containing O O
the O O
human O O
beta B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
globin I-Enhancer I-Enhancer
locus I-Enhancer I-Enhancer
control I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
HS2 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
a O O
target O O
globin O O
gene O O
. O O
We O O
studied O O
the O O
mechanism O O
by O O
which O O
an O O
insulator O O
interrupts O O
enhancer O O
signaling O O
to O O
a O O
gene O O
using O O
stably O O
replicated O O
chromatin O O
templates O O
containing O O
the O O
human O O
beta B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
globin I-Enhancer I-Enhancer
locus I-Enhancer I-Enhancer
control I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
HS2 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
a O O
target O O
globin O O
gene O O
. O O

The O O
chicken O O
beta O O
- O O
globin O O
5 O O
' O O
HS4 O O
( O O
cHS4 O O
) O O
insulator O O
acted O O
as O O
a O O
positional O B-Enhancer
enhancer B-Enhancer I-Enhancer
blocker O O
, O O
inhibiting O O
promoter O O
remodeling O O
and O O
transcription O O
activation O O
only O O
when O O
placed O O
between O O
the O O
enhancer O B-Enhancer
and O O
gene O O
. O O

Enhancer O O
blocking O O
by O O
cHS4 O O
reduced O O
histone O O
hyperacetylation O O
across O O
a O O
zone O O
extending O O
from O O
the O O
enhancer B-Enhancer B-Enhancer
to O O
the O O
gene O O
and O O
inhibited O O
recruitment O O
of O O
CBP O O
and O O
p300 O O
to O O
HS2 O O
. O O

Enhancer O O
blocking O O
also O O
led O O
to O O
accumulation O O
of O O
RNA O O
polymerase O O
II O O
at O O
HS2 O O
and O O
within O O
cHS4 O O
, O O
accompanied O O
by O O
its O O
diminution O O
at O O
the O O
gene O O
promoter O O
. O O

The O O
enhancer O O
blocking O O
effects O O
were O O
completely O O
attributable O O
to O O
the O O
CTCF O O
binding O O
site O O
in O O
cHS4 O O
. O O
The O O
enhancer O B-Enhancer
blocking O O
effects O O
were O O
completely O O
attributable O O
to O O
the O O
CTCF O O
binding O O
site O O
in O O
cHS4 O O
. O O

These O O
findings O O
provide O O
experimental O O
evidence O O
for O O
the O O
involvement O O
of O O
spreading O O
in O O
establishment O O
of O O
a O O
broad O O
zone O O
of O O
histone O O
modification O O
by O O
an O O
enhancer B-Enhancer B-Enhancer
, O O
as O O
well O O
as O O
for O O
blocking O O
by O O
an O O
insulator O O
of O O
the O O
transfer O O
of O O
RNA O O
polymerase O O
II O O
from O O
an O O
enhancer B-Enhancer B-Enhancer
to O O
a O O
promoter O O
. O O

The O O
BCL2 O O
gene O O
is O O
regulated O O
by O O
a O O
special O O
AT O O
- O O
rich O O
sequence O O
binding O O
protein O O
1 O O
- O O
mediated O O
long O O
range O O
chromosomal O O
interaction O O
between O O
the O O
promoter O O
and O O
the O O
distal O O
element O O
located O O
within O O
the O O
3 O O
' O O
- O O
UTR O O
. O O

The O O
279 O O
- O O
bp O O
major O O
breakpoint O O
region O O
( O O
mbr O O
) O O
within O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
( O O
3 O O
' O O
- O O
UTR O O
) O O
of O O
the O O
BCL2 O O
gene O O
is O O
a O O
binding O O
site O O
of O O
special O O
AT O O
- O O
rich O O
sequence O O
binding O O
protein O O
1 O O
( O O
SATB1 O O
) O O
that O O
is O O
well O O
known O O
to O O
participate O O
in O O
the O O
long O O
- O O
range O O
regulation O O
of O O
gene O O
transcription O O
. O O
The O O
279 O O
- O O
bp O O
major O O
breakpoint O O
region O O
( O O
mbr O O
) O O
within O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
( O O
3 O O
' O O
- O O
UTR O O
) O O
of O O
the O O
BCL2 O O
gene O O
is O O
a O O
binding O O
site O O
of O O
special O O
AT O O
- O O
rich O O
sequence O O
binding O O
protein O O
1 O O
( O O
SATB1 O O
) O O
that O O
is O O
well O O
known O O
to O O
participate O O
in O O
the O O
long O O
- O O
range O O
regulation O O
of O O
gene O O
transcription O O
. O O

Our O O
previous O O
studies O O
have O O
revealed O O
that O O
the O O
mbr O O
could O O
regulate O O
BCL2 O O
transcription O O
over O O
a O O
200 O O
- O O
kb O O
distance O O
and O O
this O O
regulatory O O
function O O
was O O
closely O O
related O O
to O O
SATB1 O O
. O O

This O O
study O O
is O O
to O O
explore O O
the O O
underlying O O
mechanism O O
and O O
its O O
relevance O O
to O O
cellular O O
apoptosis O O
. O O

With O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
and O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
assays O O
we O O
demonstrated O O
that O O
the O O
mbr O O
could O O
physically O O
interact O O
with O O
BCL2 O O
promoter O O
through O O
SATB1 O O
- O O
mediated O O
chromatin O O
looping O O
, O O
which O O
was O O
required O O
for O O
epigenetic O O
modifications O O
of O O
the O O
promoter O O
, O O
CREB O O
accessibility O O
and O O
high O O
expression O O
of O O
the O O
BCL2 O O
gene O O
. O O
With O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
and O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
assays O O
we O O
demonstrated O O
that O O
the O O
mbr O O
could O O
physically O O
interact O O
with O O
BCL2 O O
promoter O O
through O O
SATB1 O O
- O O
mediated O O
chromatin O O
looping O O
, O O
which O O
was O O
required O O
for O O
epigenetic O O
modifications O O
of O O
the O O
promoter O O
, O O
CREB O O
accessibility O O
and O O
high O O
expression O O
of O O
the O O
BCL2 O O
gene O O
. O O

During O O
early O O
apoptosis O O
, O O
SATB1 O O
was O O
a O O
key O O
regulator O O
of O O
BCL2 O O
expression O O
. O O

Inhibition O O
of O O
SATB1 O O
cleavage O O
by O O
treatment O O
of O O
cells O O
with O O
a O O
caspase O O
- O O
6 O O
inhibitor O O
or O O
overexpression O O
of O O
mutant O O
SATB1 O O
that O O
was O O
resistant O O
to O O
caspase O O
- O O
6 O O
, O O
inhibited O O
disassembly O O
of O O
the O O
SATB1 O O
- O O
mediated O O
chromatin O O
loop O O
and O O
restored O O
the O O
BCL2 O O
mRNA O O
level O O
in O O
Jurkat O O
cells O O
. O O

These O O
data O O
revealed O O
a O O
novel O O
mechanism O O
of O O
BCL2 O O
regulation O O
and O O
mechanistically O O
link O O
SATB1 O O
- O O
mediated O O
long O O
- O O
range O O
interaction O O
with O O
the O O
regulation O O
of O O
a O O
gene O O
controlling O O
apoptosis O O
pathway O O
for O O
the O O
first O O
time O O
. O O

The O O
gonadotropin O O
- O O
releasing O O
hormone O O
cell O O
- O O
specific O O
element O O
is O O
required O O
for O O
normal O O
puberty O O
and O O
estrous O O
cyclicity O O
. O O

Appropriate O O
tissue O O
- O O
specific O O
gene O O
expression O O
of O O
gonadotropin O O
- O O
releasing O O
hormone O O
( O O
GnRH O O
) O O
is O O
critical O O
for O O
pubertal O O
development O O
and O O
maintenance O O
of O O
reproductive O O
competence O O
. O O

In O O
these O O
studies O O
, O O
a O O
common O O
element O O
in O O
the O O
mouse O O
GnRH O O
( O O
mGnRH O O
) O O
promoter O O
, O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
, O O
is O O
shown O O
to O O
mediate O O
differential O O
regulation O O
of O O
hypothalamic O O
and O O
ovarian O O
mGnRH O O
expression O O
. O O
In O O
these O O
studies O O
, O O
a O O
common O O
element O O
in O O
the O O
mouse O O
GnRH O O
( O O
mGnRH O O
) O O
promoter O O
, O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
, O O
is O O
shown O O
to O O
mediate O O
differential O O
regulation O O
of O O
hypothalamic O O
and O O
ovarian O O
mGnRH O O
expression O O
. O O

To O O
further O O
characterize O O
this O O
region O O
, O O
we O O
generated O O
a O O
knock O O
- O O
out O O
mouse O O
( O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
) O O
with O O
a O O
deletion O O
of O O
the O O
mGnRH O O
promoter O O
fragment O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
. O O
GnRH O O
mRNA O O
expression O O
in O O
the O O
brain O O
of O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
was O O
less O O
than O O
the O O
expression O O
in O O
wild O O
- O O
type O O
mice O O
; O O
however O O
, O O
immunohistochemical O O
analysis O O
revealed O O
no O O
difference O O
between O O
the O O
numbers O O
of O O
GnRH O O
neurons O O
among O O
groups O O
. O O
GnRH O O
mRNA O O
expression O O
in O O
the O O
ovary O O
was O O
fivefold O O
higher O O
in O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
. O O
To O O
further O O
characterize O O
this O O
region O O
, O O
we O O
generated O O
a O O
knock O O
- O O
out O O
mouse O O
( O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
) O O
with O O
a O O
deletion O O
of O O
the O O
mGnRH O O
promoter O O
fragment O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
. O O
GnRH O O
mRNA O O
expression O O
in O O
the O O
brain O O
of O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
was O O
less O O
than O O
the O O
expression O O
in O O
wild O O
- O O
type O O
mice O O
; O O
however O O
, O O
immunohistochemical O O
analysis O O
revealed O O
no O O
difference O O
between O O
the O O
numbers O O
of O O
GnRH O O
neurons O O
among O O
groups O O
. O O
GnRH O O
mRNA O O
expression O O
in O O
the O O
ovary O O
was O O
fivefold O O
higher O O
in O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
. O O

The O O
immunohistochemical O O
staining O O
for O O
GnRH O O
in O O
the O O
ovary O O
increased O O
in O O
surface O O
epithelial O O
and O O
granulosa O O
cells O O
and O O
also O O
in O O
the O O
corpora O O
lutea O O
of O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
mice O O
. O O

The O O
reproductive O O
phenotype O O
revealed O O
that O O
the O O
mean O O
day O O
of O O
vaginal O O
opening O O
was O O
delayed O O
, O O
and O O
additionally O O
, O O
there O O
was O O
a O O
significant O O
decrease O O
in O O
the O O
length O O
of O O
proestrus O O
and O O
diestrus O O
- O O
metestrus O O
phases O O
of O O
the O O
estrous O O
cycle O O
, O O
resulting O O
in O O
a O O
shortened O O
estrous O O
cycle O O
in O O
GREKO O O
( O O
- O O
/ O O
- O O
) O O
mice O O
. O O

This O O
work O O
supports O O
the O O
hypothesis O O
that O O
the O O
region O O
of O O
the O O
GnRH O O
promoter O O
contained O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
acts O O
as O O
a O O
cell B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
the O O
GnRH O O
neuron O O
and O O
as O O
a O O
repressor O O
in O O
the O O
ovary O O
. O O
This O O
work O O
supports O O
the O O
hypothesis O O
that O O
the O O
region O O
of O O
the O O
GnRH O O
promoter O O
contained O O
between O O
- B-Enhancer O
2806 I-Enhancer O
and I-Enhancer O
- I-Enhancer O
2078 I-Enhancer O
bp I-Enhancer O
acts O O
as O O
a O O
cell B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
the O O
GnRH O O
neuron O O
and O O
as O O
a O O
repressor O O
in O O
the O O
ovary O O
. O O

Deletion O O
of O O
this O O
region O O
in O O
vivo O O
implicates O O
the O O
GnRH O O
promoter O O
in O O
mediating O O
pubertal O O
development O O
and O O
periodic O O
reproductive O O
cycling O O
, O O
and O O
forms O O
the O O
foundation O O
to O O
define O O
the O O
nuclear O O
proteins O O
important O O
for O O
puberty O O
and O O
estrous O O
cycling O O
in O O
mammals O O
. O O
Deletion O O
of O O
this O O
region O O
in O O
vivo O O
implicates O O
the O O
GnRH O O
promoter O O
in O O
mediating O O
pubertal O O
development O O
and O O
periodic O O
reproductive O O
cycling O O
, O O
and O O
forms O O
the O O
foundation O O
to O O
define O O
the O O
nuclear O O
proteins O O
important O O
for O O
puberty O O
and O O
estrous O O
cycling O O
in O O
mammals O O
. O O

PU O O
. O O
1 O O
and O O
C O O
/ O O
EBP O O
( O O
alpha O O
) O O
synergistically O O
program O O
distinct O O
response O O
to O O
NF O O
- O O
kappaB O O
activation O O
through O O
establishing O O
monocyte O O
specific O O
enhancers O O
. O O

Unraveling O O
the O O
complexity O O
of O O
transcriptional O O
programs O O
coded O O
by O O
different O O
cell O O
types O O
has O O
been O O
one O O
of O O
the O O
central O O
goals O O
of O O
cell O O
biology O O
. O O

By O O
using O O
genome O O
- O O
wide O O
location O O
analysis O O
, O O
we O O
examined O O
how O O
two O O
different O O
cell O O
types O O
generate O O
different O O
responses O O
to O O
the O O
NF O O
- O O
kappaB O O
signaling O O
pathway O O
. O O

We O O
showed O O
that O O
, O O
after O O
TNF O O
- O O
alpha O O
treatment O O
, O O
the O O
NF O O
- O O
kappaB O O
p65 O O
subunit O O
binds O O
to O O
distinct O O
genome O O
locations O O
and O O
subsequently O O
induces O O
different O O
subsets O O
of O O
genes O O
in O O
human O O
monocytic O O
THP O O
- O O
1 O O
cells O O
versus O O
HeLa O O
cells O O
. O O

Interestingly O O
, O O
the O O
differential O O
p65 O O
binding O O
in O O
two O O
cell O O
types O O
correlates O O
with O O
preexisting O O
cell O O
type O O
- O O
specific O O
enhancers O O
before O O
TNF O O
- O O
alpha O O
stimulation O O
, O O
marked O O
by O O
histone O O
modifications O O
. O O

We O O
also O O
found O O
that O O
two O O
transcription O O
factors O O
, O O
PU O O
. O O
1 O O
and O O
C O O
/ O O
EBPalpha O O
, O O
appear O O
to O O
synergistically O O
mediate O O
enhancer O O
creation O O
and O O
affect O O
NF O O
- O O
kappaB O O
target O O
selection O O
in O O
THP O O
- O O
1 O O
cells O O
. O O

In O O
HeLa O O
cells O O
, O O
coexpression O O
of O O
PU O O
. O O
1 O O
and O O
C O O
/ O O
EBPalpha O O
conferred O O
TNF O O
- O O
alpha O O
responsiveness O O
to O O
a O O
subset O O
of O O
THP O O
- O O
1 O O
- O O
specific O O
NF O O
- O O
kappaB O O
target O O
genes O O
. O O

These O O
results O O
suggest O O
that O O
the O O
diversity O O
of O O
transcriptional O O
programs O O
in O O
mammalian O O
cells O O
arises O O
, O O
at O O
least O O
in O O
part O O
, O O
from O O
preexisting O O
enhancers O O
that O O
are O O
established O O
by O O
cell O O
- O O
specific O O
transcription O O
factors O O
. O O

Transcriptional O O
regulation O O
and O O
spatial O O
organisation O O
of O O
the O O
human O O
AML1 O O
/ O O
RUNX1 O O
gene O O
. O O

The O O
transcription O O
factor O O
RUNX1 O O
is O O
a O O
key O O
regulator O O
of O O
haematopoiesis O O
in O O
vertebrates O O
. O O

In O O
humans O O
, O O
the O O
260 O O
- O O
kb O O
long O O
gene O O
coding O O
for O O
this O O
transcription O O
factor O O
is O O
located O O
on O O
chromosome O O
21 O O
. O O

This O O
gene O O
is O O
transcribed O O
from O O
two O O
alternative O O
promoters O O
that O O
are O O
commonly O O
referred O O
to O O
as O O
the O O
distal O B-Enhancer
and O I-Enhancer
the O I-Enhancer
proximal O I-Enhancer
promoters O I-Enhancer
. O O

In O O
model O O
experiments O O
, O O
these O O
two O O
promoters O O
were O O
found O O
to O O
be O O
active O O
in O O
cells O O
of O O
different O O
lineages O O
, O O
although O O
RUNX1 O O
is O O
preferentially O O
expressed O O
in O O
haematopoietic O O
cells O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
attempted O O
to O O
identify O O
the O O
regulatory O O
elements O O
that O O
could O O
guide O O
tissue O O
- O O
specific O O
expression O O
of O O
the O O
RUNX1 O O
gene O O
. O O

Two O O
such O O
regulatory O O
elements O O
were O O
found O O
within O O
the O O
RUNX1 O O
gene O O
. O O

One O O
of O O
these O O
elements O O
, O O
located O O
within B-Enhancer O
intron I-Enhancer O
1 I-Enhancer O
, O O
is O O
a O O
haematopoietic B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

The O O
second O O
regulatory O O
element O O
, O O
located O O
within O O
intron O O
5 O O
. O O
2 O O
, O O
contributes O O
to O O
the O O
formation O O
of O O
an O O
active O O
chromatin O O
hub O O
, O O
which O O
integrates O O
the O O
above O B-Enhancer
- O I-Enhancer
mentioned O I-Enhancer
enhancer B-Enhancer I-Enhancer
and O O
the O O
P1 O O
and O O
P2 O O
promoters O O
. O O

Class O O
- O O
C O O
SOX O O
transcription O O
factors O O
control O O
GnRH O O
gene O O
expression O O
via O O
the O O
intronic B-Enhancer B-Enhancer
transcriptional I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
GnRH O O
is O O
a O O
pivotal O O
hypothalamic O O
neurohormone O O
governing O O
reproduction O O
and O O
sexual O O
development O O
. O O

Because O O
transcriptional O O
regulation O O
is O O
crucial O O
for O O
the O O
spatial O O
and O O
temporal O O
expression O O
of O O
the O O
GnRH O O
gene O O
, O O
a O O
region O O
approximately O O
3 O O
. O O
0 O O
kb O O
upstream O O
of O O
the O O
mammalian O O
GnRH O O
promoter O O
has O O
been O O
extensive O O
studied O O
. O O
Because O O
transcriptional O O
regulation O O
is O O
crucial O O
for O O
the O O
spatial O O
and O O
temporal O O
expression O O
of O O
the O O
GnRH O O
gene O O
, O O
a O O
region O O
approximately O O
3 O O
. O O
0 O O
kb O O
upstream O O
of O O
the O O
mammalian O O
GnRH O O
promoter O O
has O O
been O O
extensive O O
studied O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
a O O
transcription B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
( I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
A I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
GnRH I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O
In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
a O O
transcription B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
( I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
A I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
GnRH I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O

This O O
transcriptional B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
harbors O O
putative O O
sex O O
- O O
determining O O
region O O
Y O O
- O O
related O O
high O O
- O O
mobility O O
- O O
group O O
box O O
( O O
SOX O O
) O O
family O O
transcription O O
factor O O
- O O
binding O O
sites O O
, O O
which O O
are O O
well O O
conserved O O
across O O
many O O
mammalian O O
species O O
. O O

The O O
class O O
- O O
C O O
SOX O O
member O O
proteins O O
( O O
SOX O O
- O O
C O O
) O O
( O O
SOX4 O O
and O O
SOX11 O O
) O O
specifically O O
augment O O
this O O
transcriptional O O
activation O O
by O O
binding O O
to O O
these O O
SOX O O
- O O
binding O O
sites O O
. O O

In O O
accordance O O
, O O
SOX11 O O
is O O
highly O O
enriched O O
in O O
immortalized O O
GnRH O O
- O O
producing O O
GT1 O O
- O O
1 O O
cells O O
, O O
and O O
suppression O O
of O O
its O O
expression O O
significantly O O
decreases O O
GnRH O O
gene O O
expression O O
as O O
well O O
as O O
GnRH O O
secretion O O
. O O

Chromatin O O
immunoprecipitation O O
shows O O
that O O
endogenous O O
SOX O O
- O O
C O O
factors O O
recognize O O
and O O
bind O O
to O O
the O O
intronic B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
GT1 O O
- O O
1 O O
cells O O
and O O
the O O
hypothalamus O O
. O O

Accompanying O O
immunohistochemical O O
analysis O O
demonstrates O O
that O O
SOX4 O O
or O O
SOX11 O O
are O O
highly O O
expressed O O
in O O
the O O
majority O O
of O O
hypothalamic O O
GnRH O O
neurons O O
in O O
adult O O
mice O O
. O O

Taken O O
together O O
, O O
these O O
findings O O
demonstrate O O
that O O
SOX O O
- O O
C O O
transcription O O
factors O O
function O O
as O O
important O O
transcriptional O O
regulators O O
of O O
cell O O
type O O
- O O
specific O O
GnRH O O
gene O O
expression O O
by O O
acting O O
on O O
the O O
intronic B-Enhancer B-Enhancer
transcriptional I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

Phospho O O
- O O
MED1 O O
- O O
enhanced O O
UBE2C O O
locus O O
looping O O
drives O O
castration O O
- O O
resistant O O
prostate O O
cancer O O
growth O O
. O O

The O O
UBE2C O O
oncogene O O
is O O
overexpressed O O
in O O
many O O
types O O
of O O
solid O O
tumours O O
including O O
the O O
lethal O O
castration O O
- O O
resistant O O
prostate O O
cancer O O
( O O
CRPC O O
) O O
. O O

The O O
underlying O O
mechanisms O O
causing O O
UBE2C O O
gene O O
overexpression O O
in O O
CRPC O O
are O O
not O O
fully O O
understood O O
. O O

Here O O
, O O
we O O
show O O
that O O
CRPC O B-Enhancer
- O I-Enhancer
specific O I-Enhancer
enhancers O I-Enhancer
drive O O
UBE2C O O
overexpression O O
in O O
both O O
AR O O
- O O
negative O O
and O O
- O O
positive O O
CRPC O O
cells O O
. O O

We O O
further O O
show O O
that O O
co O O
- O O
activator O O
MED1 O O
recruitment O O
to O O
the O O
UBE2C B-Enhancer B-Enhancer
enhancers I-Enhancer I-Enhancer
is O O
required O O
for O O
long O O
- O O
range O O
UBE2C O B-Enhancer
enhancer O I-Enhancer
/ O O
promoter O O
interactions O O
. O O
We O O
further O O
show O O
that O O
co O O
- O O
activator O O
MED1 O O
recruitment O O
to O O
the O O
UBE2C B-Enhancer B-Enhancer
enhancers I-Enhancer I-Enhancer
is O O
required O O
for O O
long O O
- O O
range O O
UBE2C O O
enhancer O O
/ O O
promoter O O
interactions O O
. O O

Importantly O O
, O O
we O O
find O O
that O O
the O O
molecular O O
mechanism O O
underlying O O
MED1 O O
- O O
mediated O O
chromatin O O
looping O O
involves O O
PI3K O O
/ O O
AKT O O
phosphorylated O O
MED1 O O
- O O
mediated O O
recruitment O O
of O O
FoxA1 O O
, O O
RNA O O
polymerase O O
II O O
and O O
TATA O O
binding O O
protein O O
and O O
their O O
subsequent O O
interactions O O
at O O
the O O
UBE2C O O
locus O O
. O O
MED1 O O
phosphorylation O O
leads O O
to O O
UBE2C O O
locus O O
looping O O
, O O
UBE2C O O
gene O O
expression O O
and O O
cell O O
growth O O
. O O

Our O O
results O O
not O O
only O O
define O O
a O O
causal O O
role O O
of O O
a O O
post O O
- O O
translational O O
modification O O
( O O
phosphorylation O O
) O O
of O O
a O O
co O O
- O O
activator O O
( O O
MED1 O O
) O O
in O O
forming O O
or O O
sustaining O O
an O O
active O O
chromatin O O
structure O O
, O O
but O O
also O O
suggest O O
that O O
development O O
of O O
specific O O
therapies O O
for O O
CRPC O O
should O O
take O O
account O O
of O O
targeting O O
phosphorylated O O
MED1 O O
. O O

A O O
functional O O
variant O O
in O O
ZNF512B O O
is O O
associated O O
with O O
susceptibility O O
to O O
amyotrophic O O
lateral O O
sclerosis O O
in O O
Japanese O O
. O O
Amyotrophic O O
lateral O O
sclerosis O O
( O O
ALS O O
) O O
is O O
a O O
neurodegenerative O O
disease O O
characterized O O
by O O
the O O
selective O O
loss O O
of O O
motor O O
neurons O O
. O O

Several O O
susceptibility O O
genes O O
for O O
ALS O O
have O O
been O O
reported O O
; O O
however O O
, O O
ALS O O
etiology O O
and O O
pathogenesis O O
remain O O
largely O O
unknown O O
. O O

To O O
identify O O
further O O
ALS O O
- O O
susceptibility O O
genes O O
, O O
we O O
conducted O O
a O O
large O O
- O O
scale O O
case O O
- O O
control O O
association O O
study O O
using O O
gene O O
- O O
based O O
tag O O
single O O
- O O
nucleotide O O
polymorphisms O O
( O O
SNPs O O
) O O
. O O

A O O
functional O O
SNP O O
( O O
rs2275294 O O
) O O
was O O
found O O
to O O
be O O
significantly O O
associated O O
with O O
ALS O O
through O O
a O O
stepwise O O
screening O O
approach O O
( O O
combined O O
P O O
= O O
9 O O
. O O
3 O O
x O O
10 O O
( O O
- O O
10 O O
) O O
, O O
odds O O
ratio O O
= O O
1 O O
. O O
32 O O
) O O
. O O

The O O
SNP O O
was O O
located O O
in O O
an O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
ZNF512B I-Enhancer I-Enhancer
, O O
a O O
transcription O O
factor O O
of O O
unknown O O
biological O O
function O O
, O O
and O O
the O O
susceptibility O O
allele O O
showed O O
decreased O O
activity O O
and O O
decreased O O
binding O O
to O O
nuclear O O
proteins O O
. O O
ZNF512B O O
over O O
- O O
expression O O
increased O O
transforming O O
growth O O
factor O O
- O O
beta O O
( O O
TGF O O
- O O
beta O O
) O O
signaling O O
, O O
while O O
knockdown O O
had O O
the O O
opposite O O
effect O O
. O O
ZNF512B O O
expression O O
was O O
increased O O
in O O
the O O
anterior O O
horn O O
motor O O
neurons O O
of O O
the O O
spinal O O
cord O O
of O O
ALS O O
patients O O
when O O
compared O O
with O O
controls O O
. O O
The O O
SNP O O
was O O
located O O
in O O
an O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
ZNF512B I-Enhancer I-Enhancer
, O O
a O O
transcription O O
factor O O
of O O
unknown O O
biological O O
function O O
, O O
and O O
the O O
susceptibility O O
allele O O
showed O O
decreased O O
activity O O
and O O
decreased O O
binding O O
to O O
nuclear O O
proteins O O
. O O
ZNF512B O O
over O O
- O O
expression O O
increased O O
transforming O O
growth O O
factor O O
- O O
beta O O
( O O
TGF O O
- O O
beta O O
) O O
signaling O O
, O O
while O O
knockdown O O
had O O
the O O
opposite O O
effect O O
. O O
ZNF512B O O
expression O O
was O O
increased O O
in O O
the O O
anterior O O
horn O O
motor O O
neurons O O
of O O
the O O
spinal O O
cord O O
of O O
ALS O O
patients O O
when O O
compared O O
with O O
controls O O
. O O

Our O O
results O O
strongly O O
suggest O O
that O O
ZNF512B O O
is O O
an O O
important O O
positive O O
regulator O O
of O O
TGF O O
- O O
beta O O
signaling O O
and O O
that O O
decreased O O
ZNF512B O O
expression O O
increases O O
susceptibility O O
to O O
ALS O O
. O O

Combinatorial O O
regulation O O
of O O
photoreceptor O O
differentiation O O
factor O O
, O O
neural O O
retina O O
leucine O O
zipper O O
gene O O
NRL O O
, O O
revealed O O
by O O
in O O
vivo O O
promoter O O
analysis O O
. O O

Development O O
and O O
homeostasis O O
require O O
stringent O O
spatiotemporal O O
control O O
of O O
gene O O
expression O O
patterns O O
that O O
are O O
established O O
, O O
to O O
a O O
large O O
extent O O
, O O
by O O
combinatorial O O
action O O
of O O
transcription O O
regulatory O O
proteins O O
. O O

The O O
bZIP O O
transcription O O
factor O O
NRL O O
( O O
neural O O
retina O O
leucine O O
zipper O O
) O O
is O O
critical O O
for O O
rod O O
versus O O
cone O O
photoreceptor O O
cell O O
fate O O
choice O O
during O O
retinal O O
development O O
and O O
acts O O
as O O
a O O
molecular O O
switch O O
to O O
produce O O
rods O O
from O O
postmitotic O O
precursors O O
. O O

Loss O O
of O O
Nrl O O
in O O
mouse O O
leads O O
to O O
a O O
cone O O
- O O
only O O
retina O O
, O O
whereas O O
ectopic O O
expression O O
of O O
Nrl O O
in O O
photoreceptor O O
precursors O O
generates O O
rods O O
. O O

To O O
decipher O O
the O O
transcriptional O O
regulatory O O
mechanisms O O
upstream O O
of O O
Nrl O O
, O O
we O O
identified O O
putative O O
cis O O
- O O
control O O
elements O O
in O O
the O O
Nrl O O
promoter O O
/ O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
by O O
examining O O
cross O O
- O O
species O O
sequence O O
conservation O O
. O O
To O O
decipher O O
the O O
transcriptional O O
regulatory O O
mechanisms O O
upstream O O
of O O
Nrl O O
, O O
we O O
identified O O
putative O O
cis O O
- O O
control O O
elements O O
in O O
the O O
Nrl O O
promoter O O
/ O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
by O O
examining O O
cross O O
- O O
species O O
sequence O O
conservation O O
. O O

Using O O
in O O
vivo O O
transfection O O
of O O
promoter O O
- O O
reporter O O
constructs O O
into O O
the O O
mouse O O
retina O O
, O O
we O O
show O O
that O O
a O O
0 O O
. O O
9 O O
- O O
kb O O
sequence O O
upstream O O
of O O
the O O
Nrl O O
transcription O O
initiation O O
site O O
is O O
sufficient O O
to O O
drive O O
reporter O O
gene O O
expression O O
in O O
photoreceptors O O
. O O

We O O
further O O
define O O
a O O
0 O O
. O O
3 O O
- O O
kb O O
sequence O O
including O O
a O O
proximal O O
promoter O O
( O O
cluster O O
A1 O O
) O O
and O O
an O O
enhancer B-Enhancer B-Enhancer
( O O
cluster B-Enhancer O
B I-Enhancer O
) O O
that O O
can O O
direct O O
rod O O
- O O
specific O O
expression O O
in O O
vivo O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
using O O
mouse O O
retinal O O
nuclear O O
extracts O O
, O O
in O O
combination O O
with O O
specific O O
antibodies O O
, O O
demonstrate O O
the O O
binding O O
of O O
retinoid O O
- O O
related O O
orphan O O
nuclear O O
receptor O O
beta O O
( O O
RORbeta O O
) O O
, O O
cone O O
rod O O
homeobox O O
, O O
orthodenticle O O
homolog O O
2 O O
, O O
and O O
cyclic O O
AMP O O
response O O
element O O
- O O
binding O O
protein O O
to O O
predicted O O
consensus O O
elements O O
within O O
clusters O O
A O O
and O O
B O O
. O O

Our O O
studies O O
demonstrate O O
Nrl O O
as O O
a O O
direct O O
transcriptional O O
target O O
of O O
RORbeta O O
and O O
suggest O O
that O O
combinatorial O O
action O O
of O O
multiple O O
regulatory O O
factors O O
modulates O O
the O O
expression O O
of O O
Nrl O O
in O O
developing O O
and O O
mature O O
retina O O
. O O

A O O
Tcf O O
/ O O
Lef O O
element O O
within O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
plays O O
a O O
role O O
in O O
promoter O O
activation O O
. O O
NANOG O O
is O O
a O O
homeodomain O O
- O O
containing O O
transcription O O
factor O O
that O O
is O O
essential O O
for O O
the O O
maintenance O O
of O O
pluripotency O O
and O O
self O O
- O O
renewal O O
in O O
embryonic O O
stem O O
cells O O
. O O
A O O
Tcf O O
/ O O
Lef O O
element O O
within O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
plays O O
a O O
role O O
in O O
promoter O O
activation O O
. O O
NANOG O O
is O O
a O O
homeodomain O O
- O O
containing O O
transcription O O
factor O O
that O O
is O O
essential O O
for O O
the O O
maintenance O O
of O O
pluripotency O O
and O O
self O O
- O O
renewal O O
in O O
embryonic O O
stem O O
cells O O
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
underlying O O
the O O
regulation O O
of O O
NANOG O O
expression O O
in O O
human O O
cells O O
remain O O
largely O O
unknown O O
. O O

Here O O
, O O
we O O
investigated O O
the O O
role O O
of O O
Tcf O O
/ O O
Lef O O
response O O
elements O O
located O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O
Here O O
, O O
we O O
investigated O O
the O O
role O O
of O O
Tcf O O
/ O O
Lef O O
response O O
elements O O
located O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O

We O O
found O O
that O O
forced O O
expression O O
of O O
Lef1 O O
or O O
beta O O
- O O
catenin O O
stimulated O O
human O O
NANOG O O
promoter O O
activity O O
, O O
while O O
shRNA O O
- O O
mediated O O
knockdown O O
of O O
beta O O
- O O
catenin O O
reduced O O
Lef1 O O
- O O
induced O O
NANOG O O
promoter O O
activation O O
. O O
We O O
found O O
that O O
forced O O
expression O O
of O O
Lef1 O O
or O O
beta O O
- O O
catenin O O
stimulated O O
human O O
NANOG O O
promoter O O
activity O O
, O O
while O O
shRNA O O
- O O
mediated O O
knockdown O O
of O O
beta O O
- O O
catenin O O
reduced O O
Lef1 O O
- O O
induced O O
NANOG O O
promoter O O
activation O O
. O O

Deletion O O
or O O
mutation O O
of O O
the O O
Tcf O O
/ O O
Lef O O
element O O
within O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
completely O O
abrogated O O
Lef1 O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
. O O
Deletion O O
or O O
mutation O O
of O O
the O O
Tcf O O
/ O O
Lef O O
element O O
within O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
completely O O
abrogated O O
Lef1 O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
. O O

The O O
results O O
of O O
a O O
chromatin O O
immunoprecipitation O O
assay O O
demonstrated O O
that O O
Lef1 O O
and O O
beta O O
- O O
catenin O O
bind O O
to O O
the O O
Tcf O O
/ O O
Lef O O
element O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O
The O O
results O O
of O O
a O O
chromatin O O
immunoprecipitation O O
assay O O
demonstrated O O
that O O
Lef1 O O
and O O
beta O O
- O O
catenin O O
bind O O
to O O
the O O
Tcf O O
/ O O
Lef O O
element O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O

Forced O O
expression O O
of O O
GSK O O
- O O
3beta O O
inhibited O O
basal O O
, O O
Lef1 O O
- O O
induced O O
, O O
and O O
beta O O
- O O
catenin O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
, O O
while O O
treatment O O
with O O
the O O
GSK O O
- O O
3beta O O
inhibitor O O
SB216763 O O
resulted O O
in O O
the O O
accumulation O O
of O O
beta O O
- O O
catenin O O
and O O
NANOG O O
protein O O
. O O
Forced O O
expression O O
of O O
GSK O O
- O O
3beta O O
inhibited O O
basal O O
, O O
Lef1 O O
- O O
induced O O
, O O
and O O
beta O O
- O O
catenin O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
, O O
while O O
treatment O O
with O O
the O O
GSK O O
- O O
3beta O O
inhibitor O O
SB216763 O O
resulted O O
in O O
the O O
accumulation O O
of O O
beta O O
- O O
catenin O O
and O O
NANOG O O
protein O O
. O O

Furthermore O O
, O O
Dvl O O
- O O
1 O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
was O O
abrogated O O
by O O
the O O
expression O O
of O O
beta O O
- O O
catenin O O
shRNA O O
. O O
Furthermore O O
, O O
Dvl O O
- O O
1 O O
- O O
induced O O
NANOG O O
promoter O O
activity O O
was O O
abrogated O O
by O O
the O O
expression O O
of O O
beta O O
- O O
catenin O O
shRNA O O
. O O

Stable O O
overexpression O O
of O O
Dvl O O
- O O
1 O O
caused O O
beta O O
- O O
catenin O O
and O O
NANOG O O
to O O
accumulate O O
. O O

These O O
results O O
indicate O O
that O O
the O O
Tcf O O
/ O O
Lef O O
response O O
element O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
is O O
able O O
to O O
stimulate O O
NANOG O O
gene O O
transcription O O
. O O
These O O
results O O
indicate O O
that O O
the O O
Tcf O O
/ O O
Lef O O
response O O
element O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
human I-Enhancer I-Enhancer
NANOG I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
is O O
able O O
to O O
stimulate O O
NANOG O O
gene O O
transcription O O
. O O

Extensive O O
promoter O O
- O O
centered O O
chromatin O O
interactions O O
provide O O
a O O
topological O O
basis O O
for O O
transcription O O
regulation O O
. O O

Higher O O
- O O
order O O
chromosomal O O
organization O O
for O O
transcription O O
regulation O O
is O O
poorly O O
understood O O
in O O
eukaryotes O O
. O O

Using O O
genome O O
- O O
wide O O
Chromatin O O
Interaction O O
Analysis O O
with O O
Paired O O
- O O
End O O
- O O
Tag O O
sequencing O O
( O O
ChIA O O
- O O
PET O O
) O O
, O O
we O O
mapped O O
long O O
- O O
range O O
chromatin O O
interactions O O
associated O O
with O O
RNA O O
polymerase O O
II O O
in O O
human O O
cells O O
and O O
uncovered O O
widespread O O
promoter O O
- O O
centered O O
intragenic O O
, O O
extragenic O O
, O O
and O O
intergenic O O
interactions O O
. O O

These O O
interactions O O
further O O
aggregated O O
into O O
higher O O
- O O
order O O
clusters O O
, O O
wherein O O
proximal O O
and O O
distal O O
genes O O
were O O
engaged O O
through O O
promoter O O
- O O
promoter O O
interactions O O
. O O

Most O O
genes O O
with O O
promoter O O
- O O
promoter O O
interactions O O
were O O
active O O
and O O
transcribed O O
cooperatively O O
, O O
and O O
some O O
interacting O O
promoters O O
could O O
influence O O
each O O
other O O
implying O O
combinatorial O O
complexity O O
of O O
transcriptional O O
controls O O
. O O

Comparative O O
analyses O O
of O O
different O O
cell O O
lines O O
showed O O
that O O
cell O O
- O O
specific O O
chromatin O O
interactions O O
could O O
provide O O
structural O O
frameworks O O
for O O
cell O O
- O O
specific O O
transcription O O
, O O
and O O
suggested O O
significant O O
enrichment O O
of O O
enhancer O O
- O O
promoter O O
interactions O O
for O O
cell O O
- O O
specific O O
functions O O
. O O

Furthermore O O
, O O
genetically O O
- O O
identified O O
disease O O
- O O
associated O O
noncoding O O
elements O O
were O O
found O O
to O O
be O O
spatially O O
engaged O O
with O O
corresponding O O
genes O O
through O O
long O O
- O O
range O O
interactions O O
. O O

Overall O O
, O O
our O O
study O O
provides O O
insights O O
into O O
transcription O O
regulation O O
by O O
three O O
- O O
dimensional O O
chromatin O O
interactions O O
for O O
both O O
housekeeping O O
and O O
cell O O
- O O
specific O O
genes O O
in O O
human O O
cells O O
. O O

Wnt O O
/ O O
beta O O
- O O
catenin O O
signaling O O
regulates O O
Yes O O
- O O
associated O O
protein O O
( O O
YAP O O
) O O
gene O O
expression O O
in O O
colorectal O O
carcinoma O O
cells O O
. O O

Mutations O O
in O O
the O O
Wnt O O
/ O O
beta O O
- O O
catenin O O
pathway O O
occur O O
in O O
most O O
colorectal O O
cancers O O
( O O
CRCs O O
) O O
, O O
and O O
these O O
mutations O O
lead O O
to O O
increased O O
nuclear O O
accumulation O O
of O O
the O O
beta O O
- O O
catenin O O
transcriptional O O
co O O
- O O
activator O O
. O O

In O O
the O O
nucleus O O
, O O
beta O O
- O O
catenin O O
associates O O
with O O
TCF O O
/ O O
LEF O O
sequence O O
specific O O
transcription O O
factors O O
to O O
activate O O
target O O
gene O O
expression O O
. O O

The O O
Hippo O O
pathway O O
restricts O O
cellular O O
growth O O
by O O
preventing O O
nuclear O O
accumulation O O
of O O
the O O
Yes O O
- O O
associated O O
protein O O
( O O
YAP O O
) O O
transcriptional O O
co O O
- O O
activator O O
. O O
YAP O O
expression O O
is O O
elevated O O
in O O
CRCs O O
suggesting O O
that O O
, O O
like O O
Wnt O O
/ O O
beta O O
- O O
catenin O O
signaling O O
, O O
the O O
Hippo O O
pathway O O
may O O
contribute O O
to O O
colorectal O O
carcinogenesis O O
. O O

Regulation O O
of O O
YAP O O
at O O
the O O
post O O
- O O
translational O O
level O O
has O O
been O O
well O O
studied O O
but O O
the O O
transcription O O
factors O O
that O O
control O O
YAP O O
gene O O
expression O O
are O O
unknown O O
. O O

Here O O
we O O
demonstrate O O
that O O
beta O O
- O O
catenin O O
/ O O
TCF4 O O
complexes O O
bind O O
a O O
DNA B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
within I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
YAP I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
to O O
drive O O
YAP O O
expression O O
in O O
CRC O O
cells O O
. O O
Here O O
we O O
demonstrate O O
that O O
beta O O
- O O
catenin O O
/ O O
TCF4 O O
complexes O O
bind O O
a O O
DNA B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
within I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
YAP I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
to O O
drive O O
YAP O O
expression O O
in O O
CRC O O
cells O O
. O O

As O O
such O O
, O O
reducing O O
beta O O
- O O
catenin O O
expression O O
in O O
CRC O O
cells O O
using O O
shRNAs O O
leads O O
to O O
decreased O O
YAP O O
mRNA O O
and O O
protein O O
levels O O
. O O
YAP O O
is O O
abundantly O O
expressed O O
in O O
the O O
cytoplasm O O
and O O
nuclei O O
of O O
several O O
established O O
human O O
colon O O
cancer O O
cell O O
lines O O
and O O
this O O
localization O O
pattern O O
is O O
insensitive O O
to O O
plating O O
density O O
. O O

Finally O O
, O O
we O O
show O O
that O O
YAP O O
expression O O
is O O
elevated O O
in O O
the O O
majority O O
of O O
a O O
panel O O
of O O
primary O O
human O O
colorectal O O
tumors O O
compared O O
with O O
its O O
expression O O
in O O
uninvolved O O
colonic O O
mucosa O O
, O O
and O O
that O O
YAP O O
and O O
beta O O
- O O
catenin O O
localize O O
to O O
the O O
nuclear O O
compartment O O
of O O
tumor O O
cells O O
. O O

Together O O
, O O
these O O
results O O
implicate O O
YAP O O
as O O
an O O
oncogene O O
whose O O
expression O O
is O O
driven O O
by O O
aberrant O O
Wnt O O
/ O O
beta O O
- O O
catenin O O
signaling O O
in O O
human O O
CRC O O
cells O O
. O O

Regulatory O O
variation O O
in O O
a O O
TBX5 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
leads O O
to O O
isolated O O
congenital O O
heart O O
disease O O
. O O
Regulatory O O
variation O O
in O O
a O O
TBX5 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
leads O O
to O O
isolated O O
congenital O O
heart O O
disease O O
. O O

Recent O O
studies O O
have O O
identified O O
the O O
genetic O O
underpinnings O O
of O O
a O O
growing O O
number O O
of O O
diseases O O
through O O
targeted O O
exome O O
sequencing O O
. O O

However O O
, O O
this O O
strategy O O
ignores O O
the O O
large O O
component O O
of O O
the O O
genome O O
that O O
does O O
not O O
code O O
for O O
proteins O O
, O O
but O O
is O O
nonetheless O O
biologically O O
functional O O
. O O

To O O
address O O
the O O
possible O O
involvement O O
of O O
regulatory O O
variation O O
in O O
congenital O O
heart O O
diseases O O
( O O
CHDs O O
) O O
, O O
we O O
searched O O
for O O
regulatory O O
mutations O O
impacting O O
the O O
activity O O
of O O
TBX5 O O
, O O
a O O
dosage O O
- O O
dependent O O
transcription O O
factor O O
with O O
well O O
- O O
defined O O
roles O O
in O O
the O O
heart O O
and O O
limb O O
development O O
that O O
has O O
been O O
associated O O
with O O
the O O
Holt O O
- O O
Oram O O
syndrome O O
( O O
heart O O
- O O
hand O O
syndrome O O
) O O
, O O
a O O
condition O O
that O O
affects O O
1 O O
/ O O
100 O O
000 O O
newborns O O
. O O

Using O O
a O O
combination O O
of O O
genomics O O
, O O
bioinformatics O O
and O O
mouse O O
genetic O O
engineering O O
, O O
we O O
scanned O O
~ O O
700 O O
kb O O
of O O
the O O
TBX5 O O
locus O O
in O O
search O O
of O O
cis O O
- O O
regulatory O O
elements O O
. O O

We O O
uncovered O O
three B-Enhancer B-Enhancer
enhancers I-Enhancer I-Enhancer
that O O
collectively O O
recapitulate O O
the O O
endogenous O O
expression O O
pattern O O
of O O
TBX5 O O
in O O
the O O
developing O O
heart O O
. O O

We O O
re O O
- O O
sequenced O O
these O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
in O O
a O O
cohort O O
of O O
non O O
- O O
syndromic O O
patients O O
with O O
isolated O O
atrial O O
and O O
/ O O
or O O
ventricular O O
septal O O
defects O O
, O O
the O O
predominant O O
cardiac O O
defects O O
of O O
the O O
Holt O O
- O O
Oram O O
syndrome O O
, O O
and O O
identified O O
a O O
patient O O
with O O
a O O
homozygous O O
mutation O O
in O O
an O O
enhancer B-Enhancer B-Enhancer
~ I-Enhancer I-Enhancer
90 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
downstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
TBX5 I-Enhancer I-Enhancer
. O O
We O O
re O O
- O O
sequenced O O
these O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
in O O
a O O
cohort O O
of O O
non O O
- O O
syndromic O O
patients O O
with O O
isolated O O
atrial O O
and O O
/ O O
or O O
ventricular O O
septal O O
defects O O
, O O
the O O
predominant O O
cardiac O O
defects O O
of O O
the O O
Holt O O
- O O
Oram O O
syndrome O O
, O O
and O O
identified O O
a O O
patient O O
with O O
a O O
homozygous O O
mutation O O
in O O
an O O
enhancer B-Enhancer B-Enhancer
~ I-Enhancer I-Enhancer
90 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
downstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
TBX5 I-Enhancer I-Enhancer
. O O

Notably O O
, O O
we O O
demonstrate O O
that O O
this O O
single O O
- O O
base O O
- O O
pair O O
mutation O O
abrogates O O
the O O
ability O O
of O O
the O O
enhancer B-Enhancer B-Enhancer
to O O
drive O O
expression O O
within O O
the O O
heart O O
in O O
vivo O O
using O O
both O O
mouse O O
and O O
zebrafish O O
transgenic O O
models O O
. O O

Given O O
the O O
population O O
- O O
wide O O
frequency O O
of O O
this O O
variant O O
, O O
we O O
estimate O O
that O O
1 O O
/ O O
100 O O
000 O O
individuals O O
would O O
be O O
homozygous O O
for O O
this O O
variant O O
, O O
highlighting O O
that O O
a O O
significant O O
number O O
of O O
CHD O O
associated O O
with O O
TBX5 O O
dysfunction O O
might O O
arise O O
from O O
non O O
- O O
coding O O
mutations O O
in O O
TBX5 B-Enhancer B-Enhancer
heart I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
, O O
effectively O O
decoupling O O
the O O
heart O O
and O O
hand O O
phenotypes O O
of O O
the O O
Holt O O
- O O
Oram O O
syndrome O O
. O O
Given O O
the O O
population O O
- O O
wide O O
frequency O O
of O O
this O O
variant O O
, O O
we O O
estimate O O
that O O
1 O O
/ O O
100 O O
000 O O
individuals O O
would O O
be O O
homozygous O O
for O O
this O O
variant O O
, O O
highlighting O O
that O O
a O O
significant O O
number O O
of O O
CHD O O
associated O O
with O O
TBX5 O O
dysfunction O O
might O O
arise O O
from O O
non O O
- O O
coding O O
mutations O O
in O O
TBX5 B-Enhancer B-Enhancer
heart I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
, O O
effectively O O
decoupling O O
the O O
heart O O
and O O
hand O O
phenotypes O O
of O O
the O O
Holt O O
- O O
Oram O O
syndrome O O
. O O

An O O
evolutionarily O B-Enhancer
conserved O I-Enhancer
enhancer B-Enhancer I-Enhancer
regulates O O
Bmp4 O O
expression O O
in O O
developing O O
incisor O O
and O O
limb O O
bud O O
. O O

To O O
elucidate O O
the O O
transcriptional O O
regulation O O
of O O
Bmp4 O O
expression O O
during O O
organogenesis O O
, O O
we O O
used O O
phylogenetic O O
footprinting O O
and O O
transgenic O O
reporter O O
analyses O O
to O O
identify O O
Bmp4 O O
cis O O
- O O
regulatory O O
modules O O
( O O
CRMs O O
) O O
. O O

These O O
analyses O O
identified O O
a O O
regulatory O B-Enhancer
region O I-Enhancer
located O I-Enhancer
~ O I-Enhancer
46 O I-Enhancer
kb O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
mouse O I-Enhancer
Bmp4 O I-Enhancer
transcription O I-Enhancer
start O I-Enhancer
site O I-Enhancer
that O O
had O O
previously O O
been O O
shown O O
to O O
direct O O
expression O O
in O O
lateral O O
plate O O
mesoderm O O
. O O

We O O
refined O O
this O O
regulatory O O
region O O
to O O
a O O
396 B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bp I-Enhancer I-Enhancer
minimal I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
and O O
show O O
that O O
it O O
recapitulates O O
features O O
of O O
endogenous O O
Bmp4 O O
expression O O
in O O
developing O O
mandibular O O
arch O O
ectoderm O O
and O O
incisor O O
epithelium O O
during O O
the O O
initiation O O
- O O
stage O O
of O O
tooth O O
development O O
. O O

In O O
addition O O
, O O
this O O
enhancer B-Enhancer B-Enhancer
directs O O
expression O O
in O O
the O O
apical O O
ectodermal O O
ridge O O
( O O
AER O O
) O O
of O O
the O O
developing O O
limb O O
and O O
in O O
anterior O O
and O O
posterior O O
limb O O
mesenchyme O O
. O O

Transcript O O
profiling O O
of O O
E11 O O
. O O
5 O O
mouse O O
incisor O O
dental O O
lamina O O
, O O
together O O
with O O
protein O O
binding O O
microarray O O
( O O
PBM O O
) O O
analyses O O
, O O
allowed O O
identification O O
of O O
a O O
conserved O O
DNA O O
binding O O
motif O O
in O O
the O O
Bmp4 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
for O O
Pitx O O
homeoproteins O O
, O O
which O O
are O O
also O O
expressed O O
in O O
the O O
developing O O
mandibular O O
and O O
incisor O O
epithelium O O
. O O
Transcript O O
profiling O O
of O O
E11 O O
. O O
5 O O
mouse O O
incisor O O
dental O O
lamina O O
, O O
together O O
with O O
protein O O
binding O O
microarray O O
( O O
PBM O O
) O O
analyses O O
, O O
allowed O O
identification O O
of O O
a O O
conserved O O
DNA O O
binding O O
motif O O
in O O
the O O
Bmp4 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
for O O
Pitx O O
homeoproteins O O
, O O
which O O
are O O
also O O
expressed O O
in O O
the O O
developing O O
mandibular O O
and O O
incisor O O
epithelium O O
. O O

In O O
vitro O O
electrophoretic O O
mobility O O
shift O O
assays O O
( O O
EMSA O O
) O O
and O O
in O O
vivo O O
transgenic O O
reporter O O
mutational O O
analyses O O
revealed O O
that O O
this O O
site O O
supports O O
Pitx O O
binding O O
and O O
that O O
the O O
site O O
is O O
necessary O O
to O O
recapitulate O O
aspects O O
of O O
endogenous O O
Bmp4 O O
expression O O
in O O
developing O O
craniofacial O O
and O O
limb O O
tissues O O
. O O

Finally O O
, O O
Pitx2 O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
demonstrated O O
direct O O
binding O O
of O O
Pitx2 O O
to O O
this O O
Bmp4 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
in O O
a O O
dental O O
epithelial O O
cell O O
line O O
. O O
Finally O O
, O O
Pitx2 O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
demonstrated O O
direct O O
binding O O
of O O
Pitx2 O O
to O O
this O O
Bmp4 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
in O O
a O O
dental O O
epithelial O O
cell O O
line O O
. O O

These O O
results O O
establish O O
a O O
direct O O
molecular O O
regulatory O O
link O O
between O O
Pitx O O
family O O
members O O
and O O
Bmp4 O O
gene O O
expression O O
in O O
developing O O
incisor O O
epithelium O O
. O O

Histone O O
deacetylases O O
regulate O O
gonadotropin O O
- O O
releasing O O
hormone O O
I O O
gene O O
expression O O
via O O
modulating O O
Otx2 O O
- O O
driven O O
transcriptional O O
activity O O
. O O

BACKGROUND O O
: O O
Precise O O
coordination O O
of O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
gonadal O O
axis O O
orchestrates O O
the O O
normal O O
reproductive O O
function O O
. O O

As O O
a O O
central O O
regulator O O
, O O
the O O
appropriate O O
synthesis O O
and O O
secretion O O
of O O
gonadotropin O O
- O O
releasing O O
hormone O O
I O O
( O O
GnRH O O
- O O
I O O
) O O
from O O
the O O
hypothalamus O O
is O O
essential O O
for O O
the O O
coordination O O
. O O

Recently O O
, O O
emerging O O
evidence O O
indicates O O
that O O
histone O O
deacetylases O O
( O O
HDACs O O
) O O
play O O
an O O
important O O
role O O
in O O
maintaining O O
normal O O
reproductive O O
function O O
. O O

In O O
this O O
study O O
, O O
we O O
identify O O
the O O
potential O O
effects O O
of O O
HDACs O O
on O O
Gnrh1 O O
gene O O
transcription O O
. O O

METHODOLOGY O O
/ O O
PRINCIPAL O O
FINDINGS O O
: O O
Inhibition O O
of O O
HDACs O O
activities O O
by O O
trichostatin O O
A O O
( O O
TSA O O
) O O
and O O
valproic O O
acid O O
( O O
VPA O O
) O O
promptly O O
and O O
dramatically O O
repressed O O
transcription O O
of O O
Gnrh1 O O
gene O O
in O O
the O O
mouse O O
immortalized O O
mature O O
GnRH O O
neuronal O O
cells O O
GT1 O O
- O O
7 O O
. O O

The O O
suppression O O
was O O
connected O O
with O O
a O O
specific O O
region O O
of O O
Gnrh1 O O
gene O O
promoter O O
, O O
which O O
contains O O
two O O
consensus O O
Otx2 O O
binding O O
sites O O
. O O
Otx2 O O
has O O
been O O
known O O
to O O
activate O O
the O O
basal O O
and O O
also O O
enhancer O O
- O O
driven O O
transcription O O
of O O
Gnrh1 O O
gene O O
. O O
The O O
suppression O O
was O O
connected O O
with O O
a O O
specific O O
region O O
of O O
Gnrh1 O O
gene O O
promoter O O
, O O
which O O
contains O O
two O O
consensus O O
Otx2 O O
binding O O
sites O O
. O O
Otx2 O O
has O O
been O O
known O O
to O O
activate O O
the O O
basal O O
and O O
also O O
enhancer O O
- O O
driven O O
transcription O O
of O O
Gnrh1 O O
gene O O
. O O

The O O
transcriptional O O
activity O O
of O O
Otx2 O O
is O O
negatively O O
modulated O O
by O O
Grg4 O O
, O O
a O O
member O O
of O O
the O O
Groucho O O
- O O
related O O
- O O
gene O O
( O O
Grg O O
) O O
family O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
expression O O
of O O
Otx2 O O
was O O
downregulated O O
by O O
TSA O O
and O O
VPA O O
in O O
GT1 O O
- O O
7 O O
cells O O
, O O
accompanied O O
with O O
the O O
opposite O O
changes O O
of O O
Grg4 O O
expression O O
. O O

Chromatin O O
immunoprecipitation O O
and O O
electrophoretic O O
mobility O O
shift O O
assays O O
demonstrated O O
that O O
the O O
DNA O O
- O O
binding O O
activity O O
of O O
Otx2 O O
to O O
Gnrh1 O O
gene O O
was O O
suppressed O O
by O O
TSA O O
and O O
VPA O O
. O O

Overexpression O O
of O O
Otx2 O O
partly O O
abolished O O
the O O
TSA O O
- O O
and O O
VPA O O
- O O
induced O O
downregulation O O
of O O
Gnrh1 O O
gene O O
expression O O
. O O

CONCLUSIONS O O
/ O O
SIGNIFICANCE O O
: O O
Our O O
data O O
indicate O O
that O O
HDAC O O
inhibitors O O
downregulate O O
Gnrh1 O O
gene O O
expression O O
via O O
repressing O O
Otx2 O O
- O O
driven O O
transcriptional O O
activity O O
. O O

This O O
study O O
should O O
provide O O
an O O
insight O O
for O O
our O O
understanding O O
on O O
the O O
effects O O
of O O
HDACs O O
in O O
the O O
reproductive O O
system O O
and O O
suggests O O
that O O
HDACs O O
could O O
be O O
potential O O
novel O O
targets O O
for O O
the O O
therapy O O
of O O
GnRH O O
- O O
related O O
diseases O O
. O O

Androgen O O
receptor O O
repression O O
of O O
gonadotropin O O
- O O
releasing O O
hormone O O
gene O O
transcription O O
via O O
enhancer B-Enhancer O
1 I-Enhancer O
. O O
Gonadotropin O O
- O O
releasing O O
hormone O O
( O O
GnRH O O
) O O
plays O O
a O O
major O O
role O O
in O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
gonadal O O
( O O
HPG O O
) O O
axis O O
, O O
and O O
synthesis O O
and O O
secretion O O
of O O
GnRH O O
are O O
regulated O O
by O O
gonadal O O
steroid O O
hormones O O
. O O

Disruptions O O
in O O
androgen O O
levels O O
are O O
involved O O
in O O
a O O
number O O
of O O
reproductive O O
defects O O
, O O
including O O
hypogonadotropic O O
hypogonadism O O
and O O
polycystic O O
ovarian O O
syndrome O O
. O O

Androgens O O
down O O
- O O
regulate O O
GnRH O O
mRNA O O
synthesis O O
in O O
vivo O O
and O O
in O O
vitro O O
via O O
an O O
androgen O O
receptor O O
( O O
AR O O
) O O
- O O
dependent O O
mechanism O O
. O O

Methyltrienolone O O
( O O
R1881 O O
) O O
, O O
a O O
synthetic O O
AR O O
agonist O O
, O O
represses O O
GnRH O O
expression O O
through O O
multiple O O
sites O O
in O O
the O O
proximal O O
promoter O O
. O O

In O O
this O O
study O O
, O O
we O O
show O O
AR O O
also O O
represses O O
GnRH O O
transcription O O
via O O
the O O
major B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
( O O
GnRH B-Enhancer O
- I-Enhancer O
E1 I-Enhancer O
) O O
. O O
In O O
this O O
study O O
, O O
we O O
show O O
AR O O
also O O
represses O O
GnRH O O
transcription O O
via O O
the O O
major B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
( O O
GnRH B-Enhancer O
- I-Enhancer O
E1 I-Enhancer O
) O O
. O O

A O O
multimer O O
of O O
the O O
- O O
1800 O O
/ O O
- O O
1766 O O
region O O
was O O
repressed O O
by O O
R1881 O O
treatment O O
. O O

Mutation O O
of O O
two O O
bases O O
, O O
- O O
1792 O O
and O O
- O O
1791 O O
, O O
resulted O O
in O O
decreased O O
basal O O
activity O O
and O O
a O O
loss O O
of O O
AR O O
- O O
mediated O O
repression O O
. O O
AR O O
bound O O
to O O
the O O
- O O
1796 O O
/ O O
- O O
1791 O O
sequence O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
indicating O O
a O O
direct O O
interaction O O
with O O
DNA O O
or O O
other O O
transcription O O
factors O O
in O O
this O O
region O O
. O O

We O O
conclude O O
that O O
AR O O
repression O O
of O O
GnRH B-Enhancer O
- I-Enhancer O
E1 I-Enhancer O
acts O O
via O O
multiple O O
AR O O
- O O
responsive O O
regions O O
, O O
including O O
the O O
site O O
at O O
- O O
1792 O O
/ O O
- O O
1791 O O
. O O
We O O
conclude O O
that O O
AR O O
repression O O
of O O
GnRH B-Enhancer O
- I-Enhancer O
E1 I-Enhancer O
acts O O
via O O
multiple O O
AR O O
- O O
responsive O O
regions O O
, O O
including O O
the O O
site O O
at O O
- O O
1792 O O
/ O O
- O O
1791 O O
. O O

Selection O O
of O O
a O O
common O O
multipotent O O
cardiovascular O O
stem O O
cell O O
using O O
the O O
3 O O
. O O
4 O O
- O O
kb O O
MesP1 O O
promoter O O
fragment O O
. O O
Selection O O
of O O
a O O
common O O
multipotent O O
cardiovascular O O
stem O O
cell O O
using O O
the O O
3 O O
. O O
4 O O
- O O
kb O O
MesP1 O O
promoter O O
fragment O O
. O O

Common O O
cardiovascular O O
progenitor O O
cells O O
are O O
characterized O O
and O O
induced O O
by O O
expression O O
of O O
the O O
transcription O O
factor O O
MesP1 O O
. O O

To O O
characterize O O
this O O
population O O
we O O
used O O
a O O
3 O O
. O O
4 O O
- O O
kb O O
promoter O O
fragment O O
previously O O
described O O
by O O
our O O
group O O
. O O

This O O
served O O
to O O
isolate O O
MesP1 O O
- O O
positive O O
cells O O
from O O
differentiating O O
ES O O
stem O O
cells O O
via O O
magnetic O O
cell O O
sorting O O
based O O
on O O
a O O
truncated O O
CD4 O O
surface O O
marker O O
. O O

As O O
this O O
proximal O O
promoter O O
fragment O O
omits O O
a O O
distal B-Enhancer B-Enhancer
non I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
cardiovasculogenic I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
, O O
we O O
were O O
able O O
to O O
achieve O O
a O O
synchronized O O
fraction O O
of O O
highly O O
enriched O O
cardiovascular O O
progenitors O O
. O O

These O O
led O O
to O O
about O O
90 O O
% O O
of O O
cells O O
representing O O
the O O
three O O
cardiovascular O O
lineages O O
: O O
cardiomyocytes O O
, O O
endothelial O O
cells O O
and O O
smooth O O
muscle O O
cells O O
as O O
evident O O
from O O
protein O O
and O O
mRNA O O
analyses O O
. O O

In O O
addition O O
, O O
electrophysiological O O
and O O
pharmacological O O
parameters O O
of O O
the O O
cardiomyocytic O O
fraction O O
show O O
that O O
almost O O
all O O
correspond O O
to O O
the O O
multipotent O O
early O O
/ O O
intermediate O O
cardiomyocyte O O
subtype O O
at O O
day O O
18 O O
of O O
differentiation O O
. O O

Further O O
differentiation O O
of O O
these O O
cells O O
was O O
not O O
impaired O O
as O O
evident O O
from O O
strong O O
and O O
synchronous O O
beating O O
at O O
later O O
stages O O
. O O

Our O O
work O O
contributes O O
to O O
the O O
understanding O O
of O O
the O O
earliest O O
cardiovasculogenic O O
events O O
and O O
may O O
become O O
an O O
important O O
prerequisite O O
for O O
cell O O
therapy O O
, O O
tissue O O
engineering O O
and O O
pharmacological O O
testing O O
in O O
the O O
culture O O
dish O O
using O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
as O O
well O O
as O O
directly O O
reprogrammed O O
cardiovascular O O
cell O O
types O O
. O O

Likewise O O
, O O
these O O
cells O O
provide O O
an O O
ideal O O
source O O
for O O
large O O
- O O
scale O O
transcriptome O O
and O O
proteome O O
analyses O O
. O O

Essential O O
and O O
unexpected O O
role O O
of O O
Yin O O
Yang O O
1 O O
to O O
promote O O
mesodermal O O
cardiac O O
differentiation O O
. O O

RATIONALE O O
: O O
Cardiogenesis O O
is O O
regulated O O
by O O
a O O
complex O O
interplay O O
between O O
transcription O O
factors O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
how O O
these O O
interactions O O
regulate O O
the O O
transition O O
from O O
mesodermal O O
precursors O O
to O O
cardiac O O
progenitor O O
cells O O
( O O
CPCs O O
) O O
. O O

OBJECTIVE O O
: O O
To O O
identify O O
novel O O
regulators O O
of O O
mesodermal O O
cardiac O O
lineage O O
commitment O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
We O O
performed O O
a O O
bioinformatic O O
- O O
based O O
transcription O O
factor O O
binding O O
site O O
analysis O O
on O O
upstream O O
promoter O O
regions O O
of O O
genes O O
that O O
are O O
enriched O O
in O O
embryonic O O
stem O O
cell O O
- O O
derived O O
CPCs O O
. O O

From O O
32 O O
candidate O O
transcription O O
factors O O
screened O O
, O O
we O O
found O O
that O O
Yin O O
Yang O O
1 O O
( O O
YY1 O O
) O O
, O O
a O O
repressor O O
of O O
sarcomeric O O
gene O O
expression O O
, O O
is O O
present O O
in O O
CPCs O O
in O O
vivo O O
. O O

Interestingly O O
, O O
we O O
uncovered O O
the O O
ability O O
of O O
YY1 O O
to O O
transcriptionally O O
activate O O
Nkx2 O O
. O O
5 O O
, O O
a O O
key O O
marker O O
of O O
early O O
cardiogenic O O
commitment O O
. O O
YY1 O O
regulates O O
Nkx2 O O
. O O
5 O O
expression O O
via O O
a O O
2 B-Enhancer B-Enhancer
. I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
cardiac I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
as O O
demonstrated O O
by O O
in O O
vitro O O
luciferase O O
- O O
based O O
assays O O
, O O
in O O
vivo O O
chromatin O O
immunoprecipitation O O
, O O
and O O
genome O O
- O O
wide O O
sequencing O O
analysis O O
. O O

Furthermore O O
, O O
the O O
ability O O
of O O
YY1 O O
to O O
activate O O
Nkx2 O O
. O O
5 O O
expression O O
depends O O
on O O
its O O
cooperative O O
interaction O O
with O O
Gata4 O O
at O O
a O O
nearby O O
chromatin O O
. O O
Cardiac O O
mesoderm O O
- O O
specific O O
loss O O
- O O
of O O
- O O
function O O
of O O
YY1 O O
resulted O O
in O O
early O O
embryonic O O
lethality O O
. O O

This O O
was O O
corroborated O O
in O O
vitro O O
by O O
embryonic O O
stem O O
cell O O
- O O
based O O
assays O O
in O O
which O O
we O O
showed O O
that O O
the O O
overexpression O O
of O O
YY1 O O
enhanced O O
the O O
cardiogenic O O
differentiation O O
of O O
embryonic O O
stem O O
cells O O
into O O
CPCs O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
demonstrate O O
an O O
essential O O
and O O
unexpected O O
role O O
for O O
YY1 O O
to O O
promote O O
cardiogenesis O O
as O O
a O O
transcriptional O O
activator O O
of O O
Nkx2 O O
. O O
5 O O
and O O
other O O
CPC O O
- O O
enriched O O
genes O O
. O O

Sequence O O
- O O
specific O O
promoter O O
elements O O
regulate O O
temporal O O
- O O
specific O O
changes O O
in O O
chromatin O O
required O O
for O O
testis O O
- O O
specific O O
activation O O
of O O
the O O
Pgk2 O O
gene O O
. O O

The O O
phosphoglycerate O O
kinase O O
- O O
2 O O
( O O
Pgk2 O O
) O O
gene O O
is O O
regulated O O
in O O
a O O
tissue O O
- O O
, O O
cell O O
type O O
- O O
, O O
and O O
developmental O O
stage O O
- O O
specific O O
manner O O
during O O
spermatogenesis O O
and O O
is O O
required O O
for O O
normal O O
sperm O O
motility O O
and O O
fertility O O
in O O
mammals O O
. O O

Activation O O
of O O
Pgk2 O O
transcription O O
is O O
regulated O O
by O O
testis O O
- O O
specific O O
demethylation O O
of O O
DNA O O
and O O
binding O O
of O O
testis O O
- O O
specific O O
transcription O O
factors O O
to O O
enhancer B-Enhancer O
and O O
core O O
promoter O O
elements O O
. O O

Here O O
, O O
we O O
show O O
that O O
chromatin O O
remodeling O O
including O O
reconfiguration O O
of O O
nucleosomes O O
and O O
changes O O
in O O
histone O O
modifications O O
is O O
also O O
associated O O
with O O
transcriptional O O
activation O O
of O O
the O O
Pgk2 O O
gene O O
during O O
spermatogenesis O O
. O O

Developmental O O
studies O O
indicate O O
that O O
the O O
order O O
of O O
events O O
involved O O
in O O
transcriptional O O
activation O O
of O O
the O O
Pgk2 O O
gene O O
includes O O
demethylation O O
of O O
DNA O O
in O O
T1 O O
- O O
and O O
T2 O O
- O O
prospermatogonia O O
, O O
binding O O
of O O
a O O
factor O O
to O O
the O O
CAAT O O
box O O
in O O
type O O
A O O
and O O
B O O
spermatogonia O O
, O O
followed O O
by O O
recruitment O O
of O O
chromatin O O
remodeling O O
factors O O
, O O
displacement O O
of O O
a O O
nucleosome O O
from O O
the O O
Pgk2 O O
promoter O O
region O O
, O O
binding O O
of O O
factors O O
to O O
the O O
Pgk2 O O
core O O
promoter O O
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
, O O
and O O
, O O
finally O O
, O O
initiation O O
of O O
transcription O O
in O O
primary O O
spermatocytes O O
. O O
Developmental O O
studies O O
indicate O O
that O O
the O O
order O O
of O O
events O O
involved O O
in O O
transcriptional O O
activation O O
of O O
the O O
Pgk2 O O
gene O O
includes O O
demethylation O O
of O O
DNA O O
in O O
T1 O O
- O O
and O O
T2 O O
- O O
prospermatogonia O O
, O O
binding O O
of O O
a O O
factor O O
to O O
the O O
CAAT O O
box O O
in O O
type O O
A O O
and O O
B O O
spermatogonia O O
, O O
followed O O
by O O
recruitment O O
of O O
chromatin O O
remodeling O O
factors O O
, O O
displacement O O
of O O
a O O
nucleosome O O
from O O
the O O
Pgk2 O O
promoter O O
region O O
, O O
binding O O
of O O
factors O O
to O O
the O O
Pgk2 O O
core O O
promoter O O
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
, O O
and O O
, O O
finally O O
, O O
initiation O O
of O O
transcription O O
in O O
primary O O
spermatocytes O O
. O O

Transgene O O
studies O O
show O O
that O O
Pgk2 O O
core O O
promoter O O
elements O O
are O O
required O O
to O O
direct O O
demethylation O O
of O O
DNA O O
and O O
reconfiguration O O
of O O
nucleosomes O O
, O O
whereas O O
both O O
enhancer B-Enhancer O
and O O
core O O
promoter O O
elements O O
are O O
required O O
to O O
direct O O
changes O O
in O O
histone O O
modifications O O
and O O
initiation O O
of O O
transcription O O
. O O
Transgene O O
studies O O
show O O
that O O
Pgk2 O O
core O O
promoter O O
elements O O
are O O
required O O
to O O
direct O O
demethylation O O
of O O
DNA O O
and O O
reconfiguration O O
of O O
nucleosomes O O
, O O
whereas O O
both O O
enhancer B-Enhancer O
and O O
core O O
promoter O O
elements O O
are O O
required O O
to O O
direct O O
changes O O
in O O
histone O O
modifications O O
and O O
initiation O O
of O O
transcription O O
. O O

These O O
results O O
provide O O
novel O O
insight O O
into O O
the O O
developmental O O
order O O
of O O
molecular O O
events O O
required O O
to O O
activate O O
tissue O O
- O O
specific O O
transcription O O
of O O
the O O
Pgk2 O O
gene O O
, O O
the O O
distinct O O
elements O O
in O O
the O O
5 O O
' O O
- O O
regulatory O O
region O O
of O O
the O O
Pgk2 O O
gene O O
that O O
regulate O O
each O O
of O O
these O O
events O O
, O O
and O O
the O O
relationship O O
among O O
these O O
events O O
in O O
that O O
each O O
step O O
in O O
this O O
process O O
appears O O
to O O
be O O
a O O
necessary O O
prerequisite O O
for O O
the O O
subsequent O O
step O O
. O O

The O O
control O O
of O O
hematopoietic O O
stem O O
cell O O
maintenance O O
, O O
self O O
- O O
renewal O O
, O O
and O O
differentiation O O
by O O
Mysm1 O O
- O O
mediated O O
epigenetic O O
regulation O O
. O O

Epigenetic O O
histone O O
modifications O O
play O O
critical O O
roles O O
in O O
the O O
control O O
of O O
self O O
- O O
renewal O O
and O O
differentiation O O
of O O
hematopoietic O O
stem O O
cells O O
( O O
HSCs O O
) O O
. O O
Mysm1 O O
is O O
a O O
recently O O
identified O O
histone O O
H2A O O
deubiquitinase O O
with O O
essential O O
and O O
intrinsic O O
roles O O
for O O
maintaining O O
functional O O
HSCs O O
. O O

In O O
this O O
study O O
, O O
in O O
addition O O
to O O
confirming O O
this O O
function O O
of O O
Mysm1 O O
, O O
by O O
using O O
Mysm1 O O
- O O
deficient O O
( O O
Mysm1 O O
( O O
- O O
/ O O
- O O
) O O
) O O
mice O O
, O O
we O O
provide O O
more O O
evidence O O
for O O
how O O
Mysm1 O O
controls O O
HSC O O
homeostasis O O
. O O
Mysm1 O O
deletion O O
drives O O
HSCs O O
from O O
quiescence O O
into O O
rapid O O
cycling O O
and O O
increases O O
their O O
apoptotic O O
rate O O
, O O
resulting O O
in O O
an O O
exhaustion O O
of O O
the O O
stem O O
cell O O
pool O O
, O O
which O O
leads O O
to O O
an O O
impaired O O
self O O
- O O
renewal O O
and O O
lineage O O
reconstituting O O
abilities O O
in O O
the O O
Mysm1 O O
- O O
deficient O O
mice O O
. O O

Our O O
study O O
identified O O
Gfi1 O O
as O O
one O O
of O O
the O O
candidate O O
genes O O
responsible O O
for O O
the O O
HSC O O
defect O O
in O O
Mysm1 O O
- O O
deficient O O
mice O O
. O O

Mechanistic O O
studies O O
revealed O O
that O O
Mysm1 O O
modulates O O
histone O O
modifications O O
and O O
directs O O
the O O
recruitment O O
of O O
key O O
transcriptional O O
factors O O
such O O
as O O
Gata2 O O
and O O
Runx1 O O
to O O
the O O
Gfi1 O O
locus O O
in O O
HSCs O O
. O O

We O O
found O O
that O O
Mysm1 O O
directly O O
associates O O
with O O
the O O
Gfi1 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
and O O
promotes O O
its O O
transcription O O
through O O
Gata2 O O
and O O
Runx1 O O
transactivation O O
. O O
We O O
found O O
that O O
Mysm1 O O
directly O O
associates O O
with O O
the O O
Gfi1 B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
and O O
promotes O O
its O O
transcription O O
through O O
Gata2 O O
and O O
Runx1 O O
transactivation O O
. O O

Thus O O
, O O
our O O
study O O
not O O
only O O
elaborates O O
on O O
the O O
initial O O
reports O O
of O O
Mysm1 O O
association O O
with O O
HSC O O
homeostasis O O
but O O
also O O
delineates O O
a O O
possible O O
epigenetic O O
mechanism O O
through O O
which O O
Mysm1 O O
carries O O
out O O
this O O
function O O
in O O
the O O
HSCs O O
. O O

A O O
novel O O
regulatory O O
element O O
for O O
Shh O O
expression O O
in O O
the O O
lung O O
and O O
gut O O
of O O
mouse O O
embryos O O
. O O
Hedgehog O O
( O O
Hh O O
) O O
signaling O O
plays O O
pivotal O O
roles O O
in O O
morphogenesis O O
of O O
several O O
embryonic O O
tissues O O
, O O
including O O
the O O
primitive O O
gut O O
. O O

In O O
the O O
mouse O O
embryo O O
, O O
Sonic O O
hedgehog O O
( O O
Shh O O
) O O
is O O
expressed O O
in O O
endodermal O O
epithelia O O
from O O
the O O
oral O O
cavity O O
to O O
the O O
intestine O O
, O O
and O O
contributes O O
to O O
cell O O
proliferation O O
in O O
the O O
underlying O O
mesenchyme O O
and O O
subsequent O O
differentiation O O
into O O
the O O
gastrointestinal O O
smooth O O
muscle O O
. O O

Three O O
evolutionary O O
conserved O O
non O O
- O O
coding O O
sequences O O
in O O
the O O
region O O
upstream O O
of O O
the O O
Shh O O
coding O O
sequence O O
contain O O
endoderm B-Enhancer O
- I-Enhancer O
specific I-Enhancer O
enhancers I-Enhancer O
for O O
Shh O O
expression O O
. O O
Three O B-Enhancer
evolutionary O I-Enhancer
conserved O I-Enhancer
non O I-Enhancer
- O I-Enhancer
coding O I-Enhancer
sequences O I-Enhancer
in O I-Enhancer
the O I-Enhancer
region O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
Shh O I-Enhancer
coding O I-Enhancer
sequence O I-Enhancer
contain O I-Enhancer
endoderm B-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
for O O
Shh O O
expression O O
. O O

Although O O
Shh O O
expression O O
in O O
the O O
endodermal O O
epithelial O O
lining O O
is O O
mostly O O
attributed O O
to O O
these O O
three B-Enhancer B-Enhancer
enhancers I-Enhancer I-Enhancer
, O O
none O O
of O O
them O O
regulates O O
gene O O
expression O O
in O O
the O O
gastroesophageal O O
epithelium O O
. O O

Here O O
, O O
we O O
found O O
that O O
a O O
1 O B-Enhancer
. O I-Enhancer
7Kb O I-Enhancer
fragment O I-Enhancer
located O I-Enhancer
100Kb O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
Shh O I-Enhancer
coding O I-Enhancer
sequence O I-Enhancer
contains O O
a O O
functional B-Enhancer O
element I-Enhancer O
for I-Enhancer O
Shh I-Enhancer O
expression I-Enhancer O
in O O
endodermal O O
organs O O
, O O
including O O
the O O
esophagus O O
and O O
stomach O O
. O O
Here O O
, O O
we O O
found O O
that O O
a O O
1 O B-Enhancer
. O I-Enhancer
7Kb O I-Enhancer
fragment O I-Enhancer
located O I-Enhancer
100Kb O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
Shh O I-Enhancer
coding O I-Enhancer
sequence O I-Enhancer
contains O O
a O O
functional B-Enhancer O
element I-Enhancer O
for I-Enhancer O
Shh I-Enhancer O
expression I-Enhancer O
in O O
endodermal O O
organs O O
, O O
including O O
the O O
esophagus O O
and O O
stomach O O
. O O

Compared O O
with O O
the O O
three B-Enhancer B-Enhancer
known I-Enhancer I-Enhancer
endodermal I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
, O O
this O O
novel O O
enhancer B-Enhancer B-Enhancer
shows O O
less O O
evolutionary O O
conservation O O
, O O
even O O
among O O
rodents O O
. O O

In O O
mouse O O
embryonic O O
endodermal O O
tissues O O
, O O
the O O
seamless O O
expression O O
of O O
Shh O O
is O O
achieved O O
by O O
a O O
patchwork O O
of O O
multiple O O
enhancers O O
with O O
different O O
rates O O
of O O
evolution O O
. O O

The O O
histone O O
lysine O O
demethylase O O
JMJD3 O O
/ O O
KDM6B O O
is O O
recruited O O
to O O
p53 O O
bound O O
promoters O O
and O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
in O O
a O O
p53 O O
dependent O O
manner O O
. O O
The O O
histone O O
lysine O O
demethylase O O
JMJD3 O O
/ O O
KDM6B O O
is O O
recruited O O
to O O
p53 O O
bound O O
promoters O O
and O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
in O O
a O O
p53 O O
dependent O O
manner O O
. O O

The O O
JmjC O O
domain O O
- O O
containing O O
protein O O
JMJD3 O O
/ O O
KDM6B O O
catalyses O O
the O O
demethylation O O
of O O
H3K27me3 O O
and O O
H3K27me2 O O
. O O
JMJD3 O O
appears O O
to O O
be O O
highly O O
regulated O O
at O O
the O O
transcriptional O O
level O O
and O O
is O O
upregulated O O
in O O
response O O
to O O
diverse O O
stimuli O O
such O O
as O O
differentiation O O
inducers O O
and O O
stress O O
signals O O
. O O

Accordingly O O
, O O
JMJD3 O O
has O O
been O O
linked O O
to O O
the O O
regulation O O
of O O
different O O
biological O O
processes O O
such O O
as O O
differentiation O O
of O O
embryonic O O
stem O O
cells O O
, O O
inflammatory O O
responses O O
in O O
macrophages O O
, O O
and O O
induction O O
of O O
cellular O O
senescence O O
via O O
regulation O O
of O O
the O O
INK4A O O
- O O
ARF O O
locus O O
. O O

Here O O
we O O
show O O
here O O
that O O
JMJD3 O O
interacts O O
with O O
the O O
tumour O O
suppressor O O
protein O O
p53 O O
. O O

We O O
find O O
that O O
the O O
interaction O O
is O O
dependent O O
on O O
the O O
p53 O O
tetramerization O O
domain O O
. O O

Following O O
DNA O O
damage O O
, O O
JMJD3 O O
is O O
transcriptionally O O
upregulated O O
and O O
by O O
performing O O
genome O O
- O O
wide O O
mapping O O
of O O
JMJD3 O O
, O O
we O O
demonstrate O O
that O O
it O O
binds O O
genes O O
involved O O
in O O
basic O O
cellular O O
processes O O
, O O
as O O
well O O
as O O
genes O O
regulating O O
cell O O
cycle O O
, O O
response O O
to O O
stress O O
and O O
apoptosis O O
. O O

Moreover O O
, O O
we O O
find O O
that O O
JMJD3 O O
binding O O
sites O O
show O O
significant O O
overlap O O
with O O
p53 O O
bound O O
promoters O O
and O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
. O O
Moreover O O
, O O
we O O
find O O
that O O
JMJD3 O O
binding O O
sites O O
show O O
significant O O
overlap O O
with O O
p53 O O
bound O O
promoters O O
and O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
. O O

The O O
binding O O
of O O
JMJD3 O O
to O O
p53 O O
target O O
sites O O
is O O
increased O O
in O O
response O O
to O O
DNA O O
damage O O
, O O
and O O
we O O
demonstrate O O
that O O
the O O
recruitment O O
of O O
JMJD3 O O
to O O
these O O
sites O O
is O O
dependent O O
on O O
p53 O O
expression O O
. O O
The O O
binding O O
of O O
JMJD3 O O
to O O
p53 O O
target O O
sites O O
is O O
increased O O
in O O
response O O
to O O
DNA O O
damage O O
, O O
and O O
we O O
demonstrate O O
that O O
the O O
recruitment O O
of O O
JMJD3 O O
to O O
these O O
sites O O
is O O
dependent O O
on O O
p53 O O
expression O O
. O O

Therefore O O
, O O
we O O
propose O O
a O O
model O O
in O O
which O O
JMJD3 O O
is O O
recruited O O
to O O
p53 O O
responsive O O
elements O O
via O O
its O O
interaction O O
with O O
p53 O O
and O O
speculate O O
that O O
JMJD3 O O
could O O
act O O
as O O
a O O
fail O O
- O O
safe O O
mechanism O O
to O O
remove O O
low O O
levels O O
of O O
H3K27me3 O O
and O O
H3K27me2 O O
to O O
allow O O
for O O
efficient O O
acetylation O O
of O O
H3K27 O O
. O O

Sleep O O
fragmentation O O
during O O
late O O
gestation O O
induces O O
metabolic O O
perturbations O O
and O O
epigenetic O O
changes O O
in O O
adiponectin O O
gene O O
expression O O
in O O
male O O
adult O O
offspring O O
mice O O
. O O
Sleep O O
fragmentation O O
( O O
SF O O
) O O
is O O
a O O
common O O
condition O O
among O O
pregnant O O
women O O
, O O
particularly O O
during O O
late O O
gestation O O
. O O

Gestational O O
perturbations O O
promote O O
the O O
emergence O O
of O O
adiposity O O
and O O
metabolic O O
disease O O
risk O O
in O O
offspring O O
, O O
most O O
likely O O
through O O
epigenetic O O
modifications O O
. O O
Adiponectin O O
( O O
AdipoQ O O
) O O
expression O O
inversely O O
correlates O O
with O O
obesity O O
and O O
insulin O O
resistance O O
. O O

The O O
effects O O
of O O
SF O O
during O O
late O O
gestation O O
on O O
metabolic O O
function O O
and O O
AdipoQ O O
expression O O
in O O
visceral O O
white O O
adipose O O
tissue O O
( O O
VWAT O O
) O O
of O O
offspring O O
mice O O
are O O
unknown O O
. O O

Male O O
offspring O O
mice O O
were O O
assessed O O
at O O
24 O O
weeks O O
after O O
dams O O
were O O
exposed O O
to O O
SF O O
or O O
control O O
sleep O O
during O O
late O O
gestation O O
. O O

Increased O O
food O O
intake O O
, O O
body O O
weight O O
, O O
VWAT O O
mass O O
, O O
and O O
insulin O O
resistance O O
, O O
with O O
reductions O O
in O O
AdipoQ O O
expression O O
in O O
VWAT O O
, O O
emerged O O
in O O
SF O O
offspring O O
. O O

Increased O O
DNMT3a O O
and O O
- O O
b O O
and O O
global O O
DNA O O
methylation O O
and O O
reduced O O
histone O O
acetyltransferase O O
activity O O
and O O
TET1 O O
, O O
- O O
2 O O
, O O
and O O
- O O
3 O O
expression O O
were O O
detected O O
in O O
VWAT O O
of O O
SF O O
offspring O O
. O O

Reductions O O
in O O
5 O O
- O O
hydroxymethylcytosine O O
and O O
H3K4m3 O O
and O O
an O O
increase O O
in O O
DNA O O
5 O O
- O O
methylcytosine O O
and O O
H3K9m2 O O
in O O
the O O
promoter O O
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
AdipoQ I-Enhancer I-Enhancer
emerged O O
in O O
adipocytes O O
from O O
VWAT O O
and O O
correlated O O
with O O
AdipoQ O O
expression O O
. O O
SF O O
during O O
late O O
gestation O O
induces O O
epigenetic O O
modifications O O
in O O
AdipoQ O O
in O O
male O O
offspring O O
mouse O O
VWAT O O
adipocytes O O
along O O
with O O
a O O
metabolic O O
syndrome O O
- O O
like O O
phenotype O O
. O O
Reductions O O
in O O
5 O O
- O O
hydroxymethylcytosine O O
and O O
H3K4m3 O O
and O O
an O O
increase O O
in O O
DNA O O
5 O O
- O O
methylcytosine O O
and O O
H3K9m2 O O
in O O
the O O
promoter O O
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
AdipoQ I-Enhancer I-Enhancer
emerged O O
in O O
adipocytes O O
from O O
VWAT O O
and O O
correlated O O
with O O
AdipoQ O O
expression O O
. O O
SF O O
during O O
late O O
gestation O O
induces O O
epigenetic O O
modifications O O
in O O
AdipoQ O O
in O O
male O O
offspring O O
mouse O O
VWAT O O
adipocytes O O
along O O
with O O
a O O
metabolic O O
syndrome O O
- O O
like O O
phenotype O O
. O O

Thus O O
, O O
altered O O
gestational O O
environments O O
elicited O O
by O O
SF O O
impose O O
the O O
emergence O O
of O O
adverse O O
, O O
long O O
- O O
lasting O O
metabolic O O
consequences O O
in O O
the O O
next O O
generation O O
. O O

Identification O O
of O O
two O O
regulatory O O
elements O O
controlling O O
Fucosyltransferase O O
7 O O
transcription O O
in O O
murine O O
CD4 O O
+ O O
T O O
cells O O
. O O
Fucosyltransferase O O
VII O O
encoded O O
by O O
the O O
gene O O
Fut7 O O
is O O
essential O O
in O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
for O O
the O O
generation O O
of O O
E O O
- O O
and O O
P O O
- O O
selectin O O
ligands O O
( O O
E O O
- O O
and O O
P O O
- O O
lig O O
) O O
which O O
facilitate O O
recruitment O O
of O O
lymphocytes O O
into O O
inflamed O O
tissues O O
and O O
into O O
the O O
skin O O
. O O

This O O
study O O
aimed O O
to O O
identify O O
regulatory O O
elements O O
controlling O O
the O O
inducible O O
Fut7 O O
expression O O
in O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
that O O
occurs O O
upon O O
activation O O
and O O
differentiation O O
of O O
naive O O
T O O
cells O O
into O O
effector O O
cells O O
. O O

Comparative O O
analysis O O
of O O
the O O
histone O O
modification O O
pattern O O
in O O
non O O
- O O
hematopoetic O O
cells O O
and O O
CD4 O O
( O O
+ O O
) O O
T O O
cell O O
subsets O O
revealed O O
a O O
differential O O
histone O O
modification O O
pattern O O
within O O
the O O
Fut7 O O
locus O O
including O O
a O O
conserved O O
non O O
- O O
coding O O
sequence O O
( O O
CNS O O
) O O
identified O O
by O O
cross O O
- O O
species O O
conservation O O
comparison O O
suggesting O O
that O O
regulatory O O
elements O O
are O O
confined O O
to O O
this O O
region O O
. O O

Cloning O O
of O O
the O O
CNS O B-Enhancer
located O I-Enhancer
about O I-Enhancer
500 O I-Enhancer
bp O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
Fut7 O I-Enhancer
locus O I-Enhancer
, O O
into O O
a O O
luciferase O O
reporter O O
vector O O
elicited O O
reporter O O
activity O O
after O O
transfection O O
of O O
the O O
alphabeta O O
- O O
WT O O
T O O
cell O O
line O O
, O O
but O O
not O O
after O O
transfection O O
of O O
primary O O
murine O O
CD4 O O
( O O
+ O O
) O O
Th1 O O
cells O O
. O O

As O O
quantification O O
of O O
different O O
Fut7 O O
transcripts O O
revealed O O
a O O
predominance O O
of O O
transcripts O O
lacking O O
the O O
first O O
exons O O
in O O
primary O O
Th1 O O
cells O O
we O O
searched O O
for O O
an O O
alternative O O
promoter O O
. O O

Cloning O O
of O O
an O O
intragenic O O
region O O
spanning O O
a O O
1kb O O
region O O
upstream O O
of O O
exon O O
4 O O
into O O
an O O
enhancer O B-Enhancer
- O O
containing O O
vector O O
indeed O O
elicited O O
promoter O O
activity O O
. O O

Interestingly O O
, O O
also O O
the O O
CNS O O
enhanced O O
activity O O
of O O
this O O
intragenic O O
minimal O O
promoter O O
in O O
reporter O O
assays O O
in O O
primary O O
Th1 O O
cells O O
suggesting O O
that O O
both O O
elements O O
interact O O
in O O
primary O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
to O O
induce O O
Fut7 O O
transcription O O
. O O

The O O
Runx O O
- O O
PU O O
. O O
1 O O
pathway O O
preserves O O
normal O O
and O O
AML O O
/ O O
ETO9a O O
leukemic O O
stem O O
cells O O
. O O

Runx O O
transcription O O
factors O O
contribute O O
to O O
hematopoiesis O O
and O O
are O O
frequently O O
implicated O O
in O O
hematologic O O
malignancies O O
. O O

All O O
three O O
Runx O O
isoforms O O
are O O
expressed O O
at O O
the O O
earliest O O
stages O O
of O O
hematopoiesis O O
; O O
however O O
, O O
their O O
function O O
in O O
hematopoietic O O
stem O O
cells O O
( O O
HSCs O O
) O O
is O O
not O O
fully O O
elucidated O O
. O O

Here O O
, O O
we O O
show O O
that O O
Runx O O
factors O O
are O O
essential O O
in O O
HSCs O O
by O O
driving O O
the O O
expression O O
of O O
the O O
hematopoietic O O
transcription O O
factor O O
PU O O
. O O
1 O O
. O O

Mechanistically O O
, O O
by O O
using O O
a O O
knockin O O
mouse O O
model O O
in O O
which O O
all O O
three O O
Runx O O
binding O O
sites O O
in O O
the O O
- B-Enhancer B-Enhancer
14kb I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
PU I-Enhancer I-Enhancer
. I-Enhancer O
1 I-Enhancer O
are O O
disrupted O O
, O O
we O O
observed O O
failure O O
to O O
form O O
chromosomal O O
interactions O O
between O O
the O O
PU B-Enhancer B-Enhancer
. I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
its O O
proximal O O
promoter O O
. O O
Mechanistically O O
, O O
by O O
using O O
a O O
knockin O O
mouse O O
model O O
in O O
which O O
all O O
three O O
Runx O O
binding O O
sites O O
in O O
the O O
- B-Enhancer B-Enhancer
14kb I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
PU I-Enhancer I-Enhancer
. I-Enhancer O
1 I-Enhancer O
are O O
disrupted O O
, O O
we O O
observed O O
failure O O
to O O
form O O
chromosomal O O
interactions O O
between O O
the O O
PU B-Enhancer B-Enhancer
. I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
its O O
proximal O O
promoter O O
. O O

Consequently O O
, O O
decreased O O
PU O O
. O O
1 O O
levels O O
resulted O O
in O O
diminished O O
long O O
- O O
term O O
HSC O O
function O O
through O O
HSC O O
exhaustion O O
, O O
which O O
could O O
be O O
rescued O O
by O O
reintroducing O O
a O O
PU O O
. O O
1 O O
transgene O O
. O O

Similarly O O
, O O
in O O
a O O
mouse O O
model O O
of O O
AML O O
/ O O
ETO9a O O
leukemia O O
, O O
disrupting O O
the O O
Runx O O
binding O O
sites O O
resulted O O
in O O
decreased O O
PU O O
. O O
1 O O
levels O O
. O O
Leukemia O O
onset O O
was O O
delayed O O
, O O
and O O
limiting O O
dilution O O
transplantation O O
experiments O O
demonstrated O O
functional O O
loss O O
of O O
leukemia O O
- O O
initiating O O
cells O O
. O O

This O O
is O O
surprising O O
, O O
because O O
low O O
PU O O
. O O
1 O O
levels O O
have O O
been O O
considered O O
a O O
hallmark O O
of O O
AML O O
/ O O
ETO O O
leukemia O O
, O O
as O O
indicated O O
in O O
mouse O O
models O O
and O O
as O O
shown O O
here O O
in O O
samples O O
from O O
leukemic O O
patients O O
. O O

Our O O
data O O
demonstrate O O
that O O
Runx O O
- O O
dependent O O
PU O O
. O O
1 O O
chromatin O O
interaction O O
and O O
transcription O O
of O O
PU O O
. O O
1 O O
are O O
essential O O
for O O
both O O
normal O O
and O O
leukemia O O
stem O O
cells O O
. O O

A O O
regulatory O O
network O O
controls O O
nephrocan O O
expression O O
and O O
midgut O O
patterning O O
. O O

Although O O
many O O
regulatory O O
networks O O
involved O O
in O O
defining O O
definitive O O
endoderm O O
have O O
been O O
identified O O
, O O
the O O
mechanisms O O
through O O
which O O
these O O
networks O O
interact O O
to O O
pattern O O
the O O
endoderm O O
are O O
less O O
well O O
understood O O
. O O

To O O
explore O O
the O O
mechanisms O O
involved O O
in O O
midgut O O
patterning O O
, O O
we O O
dissected O O
the O O
transcriptional O O
regulatory O O
elements O O
of O O
nephrocan O O
( O O
Nepn O O
) O O
, O O
the O O
earliest O O
known O O
midgut O O
specific O O
gene O O
in O O
mice O O
. O O

We O O
observed O O
that O O
Nepn O O
expression O O
is O O
dramatically O O
reduced O O
in O O
Sox17 O O
( O O
- O O
/ O O
- O O
) O O
and O O
Raldh2 O O
( O O
- O O
/ O O
- O O
) O O
embryos O O
compared O O
with O O
wild O O
- O O
type O O
embryos O O
. O O

We O O
further O O
show O O
that O O
Nepn O B-Enhancer
is O O
directly O O
regulated O O
by O O
Sox17 O O
and O O
the O O
retinoic O O
acid O O
( O O
RA O O
) O O
receptor O O
via O O
two B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
elements I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
. O O

Moreover O O
, O O
Nepn O O
expression O O
is O O
modulated O O
by O O
Activin O O
signaling O O
, O O
with O O
high O O
levels O O
inhibiting O O
and O O
low O O
levels O O
enhancing O O
RA O O
- O O
dependent O O
expression O O
. O O

In O O
Foxh1 O O
( O O
- O O
/ O O
- O O
) O O
embryos O O
in O O
which O O
Nodal O O
signaling O O
is O O
reduced O O
, O O
the O O
Nepn O O
expression O O
domain O O
is O O
expanded O O
into O O
the O O
anterior O O
gut O O
region O O
, O O
confirming O O
that O O
Nodal O O
signaling O O
can O O
modulate O O
its O O
expression O O
in O O
vivo O O
. O O

Together O O
, O O
Sox17 O O
is O O
required O O
for O O
Nepn O O
expression O O
in O O
the O O
definitive O O
endoderm O O
, O O
while O O
RA O O
signaling O O
restricts O O
expression O O
to O O
the O O
midgut O O
region O O
. O O

A O O
balance O O
of O O
Nodal O O
/ O O
Activin O O
signaling O O
regulates O O
the O O
anterior O O
boundary O O
of O O
the O O
midgut O O
expression O O
domain O O
. O O

Identification O O
and O O
characterization O O
of O O
the O O
novel O O
Col10a1 O O
regulatory O O
mechanism O O
during O O
chondrocyte O O
hypertrophic O O
differentiation O O
. O O

The O O
majority O O
of O O
human O O
skeleton O O
develops O O
through O O
the O O
endochondral O O
pathway O O
, O O
in O O
which O O
cartilage O O
- O O
forming O O
chondrocytes O O
proliferate O O
and O O
enlarge O O
into O O
hypertrophic O O
chondrocytes O O
that O O
eventually O O
undergo O O
apoptosis O O
and O O
are O O
replaced O O
by O O
bone O O
. O O

Although O O
at O O
a O O
terminal O O
differentiation O O
stage O O
, O O
hypertrophic O O
chondrocytes O O
have O O
been O O
implicated O O
as O O
the O O
principal O O
engine O O
of O O
bone O O
growth O O
. O O

Abnormal O O
chondrocyte O O
hypertrophy O O
has O O
been O O
seen O O
in O O
many O O
skeletal O O
dysplasia O O
and O O
osteoarthritis O O
. O O

Meanwhile O O
, O O
as O O
a O O
specific O O
marker O O
of O O
hypertrophic O O
chondrocytes O O
, O O
the O O
type O O
X O O
collagen O O
gene O O
( O O
COL10A1 O O
) O O
is O O
also O O
critical O O
for O O
endochondral O O
bone O O
formation O O
, O O
as O O
mutation O O
and O O
altered O O
COL10A1 O O
expression O O
are O O
often O O
accompanied O O
by O O
abnormal O O
chondrocyte O O
hypertrophy O O
in O O
many O O
skeletal O O
diseases O O
. O O

However O O
, O O
how O O
the O O
type O O
X O O
collagen O O
gene O O
is O O
regulated O O
during O O
chondrocyte O O
hypertrophy O O
has O O
not O O
been O O
fully O O
elucidated O O
. O O

We O O
have O O
recently O O
demonstrated O O
that O O
Runx2 O O
interaction O O
with O O
a O O
150 B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bp I-Enhancer I-Enhancer
mouse I-Enhancer I-Enhancer
Col10a1 I-Enhancer I-Enhancer
cis I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
is O O
required O O
but O O
not O O
sufficient O O
for O O
its O O
hypertrophic O O
chondrocyte O O
- O O
specific O O
reporter O O
expression O O
in O O
transgenic O O
mice O O
, O O
suggesting O O
requirement O O
of O O
additional O O
Col10a1 O O
regulators O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
in O O
silico O O
sequence O O
analysis O O
of O O
this O O
150 B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bp I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
identification O O
of O O
its O O
multiple O O
binding O O
factors O O
, O O
including O O
AP1 O O
, O O
MEF2 O O
, O O
NFAT O O
, O O
Runx1 O O
and O O
TBX5 O O
. O O

Using O O
this O O
enhancer B-Enhancer B-Enhancer
as O O
bait O O
, O O
we O O
performed O O
yeast O O
one O O
- O O
hybrid O O
assay O O
and O O
identified O O
multiple O O
candidate O O
Col10a1 O O
- O O
interacting O O
genes O O
, O O
including O O
cyclooxygenase O O
1 O O
( O O
Cox O O
- O O
1 O O
) O O
and O O
Cox O O
- O O
2 O O
. O O

We O O
have O O
also O O
performed O O
mass O O
spectrometry O O
analysis O O
and O O
detected O O
EF1 O O
- O O
alpha O O
, O O
Fus O O
, O O
GdF7 O O
and O O
Runx3 O O
as O O
components O O
of O O
the O O
specific O O
complex O O
formed O O
by O O
the O O
cis B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
nuclear O O
extracts O O
from O O
hypertrophic O O
MCT O O
( O O
mouse O O
chondrocytes O O
immortalized O O
with O O
large O O
T O O
antigen O O
) O O
cells O O
that O O
express O O
Col10a1 O O
abundantly O O
. O O

Notably O O
, O O
some O O
of O O
the O O
candidate O O
genes O O
are O O
differentially O O
expressed O O
in O O
hypertrophic O O
MCT O O
cells O O
and O O
have O O
been O O
associated O O
with O O
chondrocyte O O
hypertrophy O O
and O O
Runx2 O O
, O O
an O O
indispensible O O
Col10a1 O O
regulator O O
. O O

Intriguingly O O
, O O
we O O
detected O O
high O O
- O O
level O O
Cox O O
- O O
2 O O
expression O O
in O O
hypertrophic O O
MCT O O
cells O O
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
confirmed O O
the O O
interaction O O
between O O
Cox O O
- O O
2 O O
and O O
Col10a1 B-Enhancer B-Enhancer
cis I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
supporting O O
its O O
role O O
as O O
a O O
candidate O O
Col10a1 O O
regulator O O
. O O
Electrophoretic O O
mobility O O
shift O O
assay O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
confirmed O O
the O O
interaction O O
between O O
Cox O O
- O O
2 O O
and O O
Col10a1 B-Enhancer B-Enhancer
cis I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
supporting O O
its O O
role O O
as O O
a O O
candidate O O
Col10a1 O O
regulator O O
. O O

Together O O
, O O
our O O
data O O
support O O
a O O
Cox O O
- O O
2 O O
- O O
containing O O
, O O
Runx2 O O
- O O
centered O O
Col10a1 O O
regulatory O O
mechanism O O
, O O
during O O
chondrocyte O O
hypertrophic O O
differentiation O O
. O O

Identification O O
of O O
hypothalamic O B-Enhancer
arcuate B-Enhancer I-Enhancer
nucleus I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
Kiss1 I-Enhancer I-Enhancer
gene O I-Enhancer
in O O
mice O O
. O O
Identification O O
of O O
hypothalamic O B-Enhancer
arcuate B-Enhancer I-Enhancer
nucleus I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
Kiss1 I-Enhancer I-Enhancer
gene O I-Enhancer
in O O
mice O O
. O O

Pulsatile O O
secretion O O
of O O
GnRH O O
plays O O
a O O
pivotal O O
role O O
in O O
follicular O O
development O O
via O O
stimulating O O
tonic O O
gonadotropin O O
secretion O O
in O O
mammals O O
. O O
Kisspeptin O O
neurons O O
, O O
located O O
in O O
the O O
arcuate O O
nucleus O O
( O O
ARC O O
) O O
, O O
are O O
considered O O
to O O
be O O
an O O
intrinsic O O
source O O
of O O
the O O
GnRH O O
pulse O O
generator O O
. O O

The O O
present O O
study O O
aimed O O
to O O
determine O O
ARC B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
( I-Enhancer I-Enhancer
s I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
Kiss1 I-Enhancer I-Enhancer
gene O I-Enhancer
by O O
an O O
in O O
vivo O O
reporter O O
assay O O
. O O
The O O
present O O
study O O
aimed O O
to O O
determine O O
ARC B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
( I-Enhancer I-Enhancer
s I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
Kiss1 I-Enhancer I-Enhancer
gene O I-Enhancer
by O O
an O O
in O O
vivo O O
reporter O O
assay O O
. O O

Three O O
green O O
fluorescent O O
protein O O
( O O
GFP O O
) O O
reporter O O
constructs O O
( O O
long O O
, O O
medium O O
length O O
, O O
and O O
short O O
) O O
were O O
generated O O
by O O
insertion O O
of O O
GFP O O
cDNA O O
at O O
the O O
Kiss1 O O
locus O O
. O O

Transgenic O O
female O O
mice O O
bearing O O
the O O
long O O
and O O
medium O O
- O O
length O O
constructs O O
showed O O
apparent O O
GFP O O
signals O O
in O O
kisspeptin O O
- O O
immunoreactive O O
cells O O
in O O
both O O
the O O
ARC O O
and O O
anteroventral O O
periventricular O O
nucleus O O
, O O
in O O
which O O
another O O
population O O
of O O
kisspeptin O O
neurons O O
are O O
located O O
. O O

On O O
the O O
other O O
hand O O
, O O
transgenic O O
mice O O
bearing O O
5 O O
' O O
- O O
truncated O O
short O O
construct O O
showed O O
few O O
GFP O O
signals O O
in O O
the O O
ARC O O
kisspeptin O O
- O O
immunoreactive O O
cells O O
, O O
whereas O O
they O O
showed O O
colocalization O O
of O O
GFP O O
- O O
and O O
kisspeptin O O
- O O
immunoreactivities O O
in O O
the O O
anteroventral O O
periventricular O O
nucleus O O
. O O

In O O
addition O O
, O O
chromatin O O
immunoprecipitation O O
and O O
chromosome O O
conformation O O
capture O O
assays O O
revealed O O
recruitment O O
of O O
unoccupied O O
estrogen O O
receptor O O
- O O
alpha O O
in O O
the O O
5 O O
' O O
- O O
upstream O O
region O O
and O O
intricate O O
chromatin O O
loop O O
formation O O
between O O
the O O
5 O O
' O O
- O O
upstream O O
and O O
promoter O O
regions O O
of O O
Kiss1 O O
locus O O
in O O
the O O
ARC O O
. O O
In O O
addition O O
, O O
chromatin O O
immunoprecipitation O O
and O O
chromosome O O
conformation O O
capture O O
assays O O
revealed O O
recruitment O O
of O O
unoccupied O O
estrogen O O
receptor O O
- O O
alpha O O
in O O
the O O
5 O O
' O O
- O O
upstream O O
region O O
and O O
intricate O O
chromatin O O
loop O O
formation O O
between O O
the O O
5 O O
' O O
- O O
upstream O O
and O O
promoter O O
regions O O
of O O
Kiss1 O O
locus O O
in O O
the O O
ARC O O
. O O

Taken O O
together O O
, O O
the O O
present O O
results O O
indicate O O
that O O
5 B-Enhancer O
' I-Enhancer O
- I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
Kiss1 I-Enhancer O
locus I-Enhancer O
plays O O
a O O
critical O O
role O O
in O O
Kiss1 O O
gene O O
expression O O
in O O
an O O
ARC O O
- O O
specific O O
manner O O
and O O
that O O
the O O
recruitment O O
of O O
estrogen O O
receptor O O
- O O
alpha O O
and O O
formation O O
of O O
a O O
chromatin O O
loop O O
between O O
the O O
Kiss1 O O
promoter O O
and O O
the O O
5 B-Enhancer B-Enhancer
' I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
may O O
be O O
required O O
for O O
the O O
induction O O
of O O
ARC O O
- O O
specific O O
Kiss1 O O
gene O O
expression O O
. O O
Taken O O
together O O
, O O
the O O
present O O
results O O
indicate O O
that O O
5 B-Enhancer O
' I-Enhancer O
- I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
Kiss1 I-Enhancer O
locus I-Enhancer O
plays O O
a O O
critical O O
role O O
in O O
Kiss1 O O
gene O O
expression O O
in O O
an O O
ARC O O
- O O
specific O O
manner O O
and O O
that O O
the O O
recruitment O O
of O O
estrogen O O
receptor O O
- O O
alpha O O
and O O
formation O O
of O O
a O O
chromatin O O
loop O O
between O O
the O O
Kiss1 O O
promoter O O
and O O
the O O
5 B-Enhancer B-Enhancer
' I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
may O O
be O O
required O O
for O O
the O O
induction O O
of O O
ARC O O
- O O
specific O O
Kiss1 O O
gene O O
expression O O
. O O

These O O
results O O
suggest O O
that O O
the O O
5 B-Enhancer O
' I-Enhancer O
- I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
Kiss1 I-Enhancer O
locus I-Enhancer O
functions O O
as O O
an O O
enhancer B-Enhancer B-Enhancer
for I-Enhancer O
ARC I-Enhancer O
Kiss1 I-Enhancer O
gene O O
expression O O
in O O
mice O O
. O O
These O O
results O O
suggest O O
that O O
the O O
5 B-Enhancer O
' I-Enhancer O
- I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
Kiss1 I-Enhancer O
locus I-Enhancer O
functions O O
as O O
an O O
enhancer B-Enhancer B-Enhancer
for I-Enhancer O
ARC I-Enhancer O
Kiss1 I-Enhancer O
gene O O
expression O O
in O O
mice O O
. O O

Characterization O O
of O O
the O O
human O O
TCAM1P O O
pseudogene O O
and O O
its O O
activation O O
by O O
a O O
potential O O
dual O O
promoter O B-Enhancer
- O I-Enhancer
enhancer O I-Enhancer
: O O
comparison O O
with O O
a O O
protein O O
- O O
coding O O
mouse O O
orthologue O O
. O O
TCAM1P O O
is O O
a O O
unitary O O
pseudogene O O
, O O
which O O
was O O
disabled O O
since O O
the O O
human O O
- O O
mouse O O
divergence O O
. O O

Here O O
we O O
found O O
that O O
TCAM1P O O
was O O
specifically O O
expressed O O
in O O
the O O
human O O
testis O O
, O O
with O O
different O O
cell O O
type O O
- O O
specificity O O
from O O
mouse O O
Tcam1 O O
, O O
and O O
characterized O O
its O O
transcripts O O
. O O

At O O
the O O
mouse O O
locus O O
, O O
a O O
multifunctional O O
dual O B-Enhancer
promoter O I-Enhancer
- O I-Enhancer
enhancer O I-Enhancer
( O O
DPE O B-Enhancer
) O O
controls O O
the O O
expression O O
of O O
Tcam1 O O
and O O
Smarcd2 O O
genes O O
. O O

The O O
corresponding O O
human O O
sequence O O
was O O
found O O
to O O
potentially O O
function O O
as O O
a O O
DPE O O
, O O
although O O
the O O
molecular O O
mechanism O O
was O O
different O O
from O O
mouse O O
. O O

Interestingly O O
, O O
the O O
change O O
in O O
DPE O O
activity O O
occurred O O
before O O
pseudogenization O O
of O O
TCAM1P O O
. O O

These O O
data O O
suggest O O
the O O
presence O O
of O O
a O O
DPE O O
in O O
the O O
human O O
genome O O
for O O
the O O
first O O
time O O
, O O
and O O
provide O O
an O O
important O O
model O O
of O O
evolutionary O O
changes O O
in O O
the O O
regulatory O O
mechanism O O
of O O
a O O
pseudogene O O
. O O

Condensin O O
I O O
and O O
II O O
Complexes O O
License O O
Full O O
Estrogen O B-Enhancer
Receptor O I-Enhancer
alpha O I-Enhancer
- O I-Enhancer
Dependent O I-Enhancer
Enhancer O I-Enhancer
Activation O O
. O O

Enhancers O O
instruct O O
spatio O O
- O O
temporally O O
specific O O
gene O O
expression O O
in O O
a O O
manner O O
tightly O O
linked O O
to O O
higher O O
- O O
order O O
chromatin O O
architecture O O
. O O

Critical O O
chromatin O O
architectural O O
regulators O O
condensin O O
I O O
and O O
condensin O O
II O O
play O O
non O O
- O O
redundant O O
roles O O
controlling O O
mitotic O O
chromosomes O O
. O O

But O O
the O O
chromosomal O O
locations O O
of O O
condensins O O
and O O
their O O
functional O O
roles O O
in O O
interphase O O
are O O
poorly O O
understood O O
. O O

Here O O
we O O
report O O
that O O
both O O
condensin O O
complexes O O
exhibit O O
an O O
unexpected O O
, O O
dramatic O O
estrogen O O
- O O
induced O O
recruitment O O
to O O
estrogen B-Enhancer O
receptor I-Enhancer O
alpha I-Enhancer O
( I-Enhancer O
ER I-Enhancer O
- I-Enhancer O
alpha I-Enhancer O
) I-Enhancer O
- I-Enhancer O
bound I-Enhancer O
eRNA I-Enhancer O
( I-Enhancer O
+ I-Enhancer O
) I-Enhancer O
active I-Enhancer O
enhancers I-Enhancer O
in O O
interphase O O
breast O O
cancer O O
cells O O
, O O
exhibiting O O
non O O
- O O
canonical O O
interaction O O
with O O
ER O O
- O O
alpha O O
via O O
its O O
DNA O O
- O O
binding O O
domain O O
( O O
DBD O O
) O O
. O O
Here O O
we O O
report O O
that O O
both O O
condensin O O
complexes O O
exhibit O O
an O O
unexpected O O
, O O
dramatic O O
estrogen O O
- O O
induced O O
recruitment O O
to O O
estrogen B-Enhancer O
receptor I-Enhancer O
alpha I-Enhancer O
( I-Enhancer O
ER I-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
alpha I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
bound I-Enhancer I-Enhancer
eRNA I-Enhancer I-Enhancer
( I-Enhancer O
+ I-Enhancer O
) I-Enhancer O
active I-Enhancer O
enhancers I-Enhancer O
in O O
interphase O O
breast O O
cancer O O
cells O O
, O O
exhibiting O O
non O O
- O O
canonical O O
interaction O O
with O O
ER O O
- O O
alpha O O
via O O
its O O
DNA O O
- O O
binding O O
domain O O
( O O
DBD O O
) O O
. O O

Condensins O O
positively O O
regulate O O
ligand O O
- O O
dependent O O
enhancer O O
activation O O
at O O
least O O
in O O
part O O
by O O
recruiting O O
an O O
E3 O O
ubiquitin O O
ligase O O
, O O
HECTD1 O O
, O O
to O O
modulate O O
the O O
binding O O
of O O
enhancer O O
- O O
associated O O
coactivators O O
/ O O
corepressors O O
, O O
including O O
p300 O O
and O O
RIP140 O O
, O O
permitting O O
full O O
eRNA B-Enhancer O
transcription O O
, O O
formation O O
of O O
enhancer O O
: O O
promoter O O
looping O O
, O O
and O O
the O O
resultant O O
coding O O
gene O O
activation O O
. O O

Collectively O O
, O O
our O O
results O O
reveal O O
an O O
important O O
, O O
unanticipated O O
transcriptional O O
role O O
of O O
interphase O O
condensins O O
in O O
modulating O O
estrogen O O
- O O
regulated O O
enhancer O O
activation O O
and O O
coding O O
gene O O
transcriptional O O
program O O
. O O

Long O O
- O O
Range O O
Modulation O O
of O O
PAG1 O O
Expression O O
by O O
8q21 O O
Allergy O O
Risk O O
Variants O O
. O O

The O O
gene O O
( O O
s O O
) O O
whose O O
expression O O
is O O
regulated O O
by O O
allergy O O
risk O O
variants O O
is O O
unknown O O
for O O
many O O
loci O O
identified O O
through O O
genome O O
- O O
wide O O
association O O
studies O O
. O O

Addressing O O
this O O
knowledge O O
gap O O
might O O
point O O
to O O
new O O
therapeutic O O
targets O O
for O O
allergic O O
disease O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
identify O O
the O O
target O O
gene O O
( O O
s O O
) O O
and O O
the O O
functional O O
variant O O
( O O
s O O
) O O
underlying O O
the O O
association O O
between O O
rs7009110 O O
on O O
chromosome O O
8q21 O O
and O O
allergies O O
. O O

Eight O O
genes O O
are O O
located O O
within O O
1 O O
Mb O O
of O O
rs7009110 O O
. O O

Multivariate O O
association O O
analysis O O
of O O
publicly O O
available O O
exon O O
expression O O
levels O O
from O O
lymphoblastoid O O
cell O O
lines O O
( O O
LCLs O O
) O O
identified O O
a O O
significant O O
association O O
between O O
rs7009110 O O
and O O
the O O
expression O O
of O O
a O O
single O O
gene O O
, O O
PAG1 O O
( O O
p O O
= O O
0 O O
. O O
0017 O O
) O O
, O O
732 O O
kb O O
away O O
. O O

Analysis O O
of O O
histone O O
modifications O O
and O O
DNase O O
I O O
hypersensitive O O
sites O O
in O O
LCLs O O
identified O O
four O O
putative O O
regulatory O O
elements O O
( O O
PREs O O
) O O
in O O
the O O
region O O
. O O

Chromosome O O
conformation O O
capture O O
confirmed O O
that O O
two O O
PREs O O
interacted O O
with O O
the O O
PAG1 O O
promoter O O
, O O
one O O
in O O
allele O O
- O O
specific O O
fashion O O
. O O
Chromosome O O
conformation O O
capture O O
confirmed O O
that O O
two O B-Enhancer
PREs O I-Enhancer
interacted O O
with O O
the O O
PAG1 O O
promoter O O
, O O
one O O
in O O
allele O O
- O O
specific O O
fashion O O
. O O

To O O
determine O O
whether O O
these O O
PREs O O
were O O
functional O O
, O O
LCLs O O
were O O
transfected O O
with O O
PAG1 O O
promoter O O
- O O
driven O O
luciferase O O
reporter O O
constructs O O
. O O
PRE3 B-Enhancer O
acted O O
as O O
a O O
transcriptional B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
for I-Enhancer O
PAG1 I-Enhancer O
exclusively O O
when O O
it O O
carried O O
the O O
rs2370615 O O
: O O
C O O
allergy O O
predisposing O O
allele O O
, O O
a O O
variant O O
in O O
complete O O
linkage O O
disequilibrium O O
with O O
rs7009110 O O
. O O
To O O
determine O O
whether O O
these O O
PREs O O
were O O
functional O O
, O O
LCLs O O
were O O
transfected O O
with O O
PAG1 O O
promoter O O
- O O
driven O O
luciferase O O
reporter O O
constructs O O
. O O
PRE3 B-Enhancer O
acted O O
as O O
a O O
transcriptional B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
for I-Enhancer O
PAG1 I-Enhancer O
exclusively O O
when O O
it O O
carried O O
the O O
rs2370615 O O
: O O
C O O
allergy O O
predisposing O O
allele O O
, O O
a O O
variant O O
in O O
complete O O
linkage O O
disequilibrium O O
with O O
rs7009110 O O
. O O

As O O
such O O
, O O
rs2370615 O O
, O O
which O O
overlaps O O
RelA O O
transcription O O
factor O O
( O O
TF O O
) O O
binding O O
in O O
LCLs O O
and O O
was O O
found O O
to O O
disrupt O O
Foxo3a O O
binding O O
to O O
PRE3 B-Enhancer O
, O O
represents O O
the O O
putative O O
functional O O
variant O O
in O O
this O O
locus O O
. O O

Our O O
studies O O
suggest O O
that O O
the O O
risk O O
- O O
associated O O
allele O O
of O O
rs2370615 O O
predisposes O O
to O O
allergic O O
disease O O
by O O
increasing O O
PAG1 O O
expression O O
, O O
which O O
might O O
promote O O
B O O
cell O O
activation O O
and O O
have O O
a O O
pro O O
- O O
inflammatory O O
effect O O
. O O

Inhibition O O
of O O
PAG1 O O
expression O O
or O O
function O O
might O O
have O O
therapeutic O O
potential O O
for O O
allergic O O
diseases O O
. O O

MIR O O
retrotransposon O O
sequences O O
provide O O
insulators O O
to O O
the O O
human O O
genome O O
. O O

Insulators O O
are O O
regulatory O O
elements O O
that O O
help O O
to O O
organize O O
eukaryotic O O
chromatin O O
via O O
enhancer O O
- O O
blocking O O
and O O
chromatin O O
barrier O O
activity O O
. O O

Although O O
there O O
are O O
several O O
examples O O
of O O
transposable O O
element O O
( O O
TE O O
) O O
- O O
derived O O
insulators O O
, O O
the O O
contribution O O
of O O
TEs O O
to O O
human O O
insulators O O
has O O
not O O
been O O
systematically O O
explored O O
. O O
Mammalian O O
- O O
wide O O
interspersed O O
repeats O O
( O O
MIRs O O
) O O
are O O
a O O
conserved O O
family O O
of O O
TEs O O
that O O
have O O
substantial O O
regulatory O O
capacity O O
and O O
share O O
sequence O O
characteristics O O
with O O
tRNA O O
- O O
related O O
insulators O O
. O O

We O O
sought O O
to O O
evaluate O O
whether O O
MIRs O O
can O O
serve O O
as O O
insulators O O
in O O
the O O
human O O
genome O O
. O O

We O O
applied O O
a O O
bioinformatic O O
screen O O
using O O
genome O O
sequence O O
and O O
functional O O
genomic O O
data O O
from O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
to O O
identify O O
a O O
set O O
of O O
1 O O
, O O
178 O O
predicted O O
MIR O O
insulators O O
genome O O
- O O
wide O O
. O O

These O O
predicted O O
MIR O O
insulators O O
were O O
computationally O O
tested O O
to O O
serve O O
as O O
chromatin O O
barriers O O
and O O
regulators O O
of O O
gene O O
expression O O
in O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
. O O

The O O
activity O O
of O O
predicted O O
MIR O O
insulators O O
was O O
experimentally O O
validated O O
using O O
in O O
vitro O O
and O O
in O O
vivo O O
enhancer O O
- O O
blocking O O
assays O O
. O O

MIR O O
insulators O O
are O O
enriched O O
around O O
genes O O
of O O
the O O
T O O
- O O
cell O O
receptor O O
pathway O O
and O O
reside O O
at O O
T O O
- O O
cell O O
- O O
specific O O
boundaries O O
of O O
repressive O O
and O O
active O O
chromatin O O
. O O

A O O
total O O
of O O
58 O O
% O O
of O O
the O O
MIR O O
insulators O O
predicted O O
here O O
show O O
evidence O O
of O O
T O O
- O O
cell O O
- O O
specific O O
chromatin O O
barrier O O
and O O
gene O O
regulatory O O
activity O O
. O O

MIR O O
insulators O O
appear O O
to O O
be O O
CCCTC O O
- O O
binding O O
factor O O
( O O
CTCF O O
) O O
independent O O
and O O
show O O
a O O
distinct O O
local O O
chromatin O O
environment O O
with O O
marked O O
peaks O O
for O O
RNA O O
Pol O O
III O O
and O O
a O O
number O O
of O O
histone O O
modifications O O
, O O
suggesting O O
that O O
MIR O O
insulators O O
recruit O O
transcriptional O O
complexes O O
and O O
chromatin O O
modifying O O
enzymes O O
in O O
situ O O
to O O
help O O
establish O O
chromatin O O
and O O
regulatory O O
domains O O
in O O
the O O
human O O
genome O O
. O O

The O O
provisioning O O
of O O
insulators O O
by O O
MIRs O O
across O O
the O O
human O O
genome O O
suggests O O
a O O
specific O O
mechanism O O
by O O
which O O
TE O O
sequences O O
can O O
be O O
used O O
to O O
modulate O O
gene O O
regulatory O O
networks O O
. O O

The O O
Isl1 O O
/ O O
Ldb1 O O
Complex O O
Orchestrates O O
Genome O O
- O O
wide O O
Chromatin O O
Organization O O
to O O
Instruct O O
Differentiation O O
of O O
Multipotent O O
Cardiac O O
Progenitors O O
. O O
Cardiac O O
stem O O
/ O O
progenitor O O
cells O O
hold O O
great O O
potential O O
for O O
regenerative O O
therapies O O
; O O
however O O
, O O
the O O
mechanisms O O
regulating O O
their O O
expansion O O
and O O
differentiation O O
remain O O
insufficiently O O
defined O O
. O O

Here O O
we O O
show O O
that O O
Ldb1 O O
is O O
a O O
central O O
regulator O O
of O O
genome O O
organization O O
in O O
cardiac O O
progenitor O O
cells O O
, O O
which O O
is O O
crucial O O
for O O
cardiac O O
lineage O O
differentiation O O
and O O
heart O O
development O O
. O O

We O O
demonstrate O O
that O O
Ldb1 O O
binds O O
to O O
the O O
key O O
regulator O O
of O O
cardiac O O
progenitors O O
, O O
Isl1 O O
, O O
and O O
protects O O
it O O
from O O
degradation O O
. O O

Furthermore O O
, O O
the O O
Isl1 O O
/ O O
Ldb1 O O
complex O O
promotes O O
long O O
- O O
range O O
enhancer O O
- O O
promoter O O
interactions O O
at O O
the O O
loci O O
of O O
the O O
core O O
cardiac O O
transcription O O
factors O O
Mef2c O O
and O O
Hand2 O O
. O O

Chromosome O O
conformation O O
capture O O
followed O O
by O O
sequencing O O
identified O O
specific O O
Ldb1 O O
- O O
mediated O O
interactions O O
of O O
the O O
Isl1 B-Enhancer B-Enhancer
/ I-Enhancer I-Enhancer
Ldb1 I-Enhancer I-Enhancer
responsive I-Enhancer I-Enhancer
Mef2c I-Enhancer I-Enhancer
anterior I-Enhancer I-Enhancer
heart I-Enhancer I-Enhancer
field I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
with O O
genes O O
that O O
play O O
key O O
roles O O
in O O
cardiac O O
progenitor O O
cell O O
function O O
and O O
cardiovascular O O
development O O
. O O
Chromosome O O
conformation O O
capture O O
followed O O
by O O
sequencing O O
identified O O
specific O O
Ldb1 O O
- O O
mediated O O
interactions O O
of O O
the O O
Isl1 B-Enhancer B-Enhancer
/ I-Enhancer I-Enhancer
Ldb1 I-Enhancer I-Enhancer
responsive I-Enhancer I-Enhancer
Mef2c I-Enhancer I-Enhancer
anterior I-Enhancer I-Enhancer
heart I-Enhancer I-Enhancer
field I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
with O O
genes O O
that O O
play O O
key O O
roles O O
in O O
cardiac O O
progenitor O O
cell O O
function O O
and O O
cardiovascular O O
development O O
. O O

Importantly O O
, O O
the O O
expression O O
of O O
these O O
genes O O
was O O
downregulated O O
upon O O
Ldb1 O O
depletion O O
and O O
Isl1 O O
/ O O
Ldb1 O O
haplodeficiency O O
. O O

In O O
conclusion O O
, O O
the O O
Isl1 O O
/ O O
Ldb1 O O
complex O O
orchestrates O O
a O O
network O O
for O O
heart O O
- O O
specific O O
transcriptional O O
regulation O O
and O O
coordination O O
in O O
three O O
- O O
dimensional O O
space O O
during O O
cardiogenesis O O
. O O

Disruptions O O
in O O
a O O
cluster O O
of O O
computationally O O
identified O O
enhancers O B-Enhancer
near O I-Enhancer
FOXC1 O I-Enhancer
and O I-Enhancer
GMDS O I-Enhancer
may O O
influence O O
brain O O
development O O
. O O

Regulatory O O
elements O O
are O O
more O O
evolutionarily O O
conserved O O
and O O
provide O O
a O O
larger O O
mutational O O
target O O
than O O
coding O O
regions O O
of O O
the O O
human O O
genome O O
, O O
suggesting O O
that O O
mutations O O
in O O
non O O
- O O
coding O O
regions O O
contribute O O
significantly O O
to O O
development O O
and O O
disease O O
. O O

Using O O
a O O
computational O O
approach O O
to O O
predict O O
gene O O
regulatory O O
enhancers O O
, O O
we O O
found O O
that O O
many O O
known O O
and O O
predicted O O
embryonic O O
enhancers O O
cluster O O
in O O
genomic O O
loci O O
harboring O O
development O O
- O O
associated O O
genes O O
. O O

One O O
of O O
the O O
densest O O
clusters O O
of O O
predicted O O
enhancers O O
in O O
the O O
human O O
genome O O
is O O
near O O
the O O
genes O O
GMDS O O
and O O
FOXC1 O O
. O O
GMDS O O
encodes O O
a O O
short O O
- O O
chain O O
mannose O O
dehydrogenase O O
enzyme O O
involved O O
in O O
the O O
regulation O O
of O O
hindbrain O O
neural O O
migration O O
, O O
and O O
FOXC1 O O
encodes O O
a O O
developmental O O
transcription O O
factor O O
required O O
for O O
brain O O
, O O
heart O O
, O O
and O O
eye O O
development O O
. O O

We O O
experimentally O O
validate O O
four B-Enhancer B-Enhancer
novel I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
this I-Enhancer I-Enhancer
locus I-Enhancer I-Enhancer
and O O
demonstrate O O
that O O
these O O
enhancers B-Enhancer B-Enhancer
show O O
consistent O O
activity O O
during O O
embryonic O O
development O O
in O O
domains O O
that O O
overlap O O
with O O
the O O
expression O O
of O O
FOXC1 O O
and O O
GMDS O O
. O O

These O O
four B-Enhancer B-Enhancer
enhancers I-Enhancer I-Enhancer
contain O O
binding O O
motifs O O
for O O
several O O
transcription O O
factors O O
, O O
including O O
the O O
ZIC O O
family O O
of O O
transcription O O
factors O O
. O O

Removal O O
of O O
the O O
ZIC O O
binding O O
sites O O
significantly O O
alters O O
enhancer O O
activity O O
in O O
three B-Enhancer B-Enhancer
of I-Enhancer I-Enhancer
these I-Enhancer I-Enhancer
enhancers I-Enhancer I-Enhancer
, O O
reducing O O
expression O O
in O O
the O O
eye O O
, O O
hindbrain O O
, O O
and O O
limb O O
, O O
suggesting O O
a O O
mechanism O O
whereby O O
ZIC O O
family O O
members O O
may O O
transcriptionally O O
regulate O O
FOXC1 O O
and O O
/ O O
or O O
GMDS O O
expression O O
. O O

Our O O
findings O O
uncover O O
novel O O
enhancer B-Enhancer O
regions I-Enhancer O
that O O
may O O
control O O
transcription O O
in O O
a O O
topological O O
domain O O
important O O
for O O
embryonic O O
development O O
. O O

Lhx1 O O
functions O O
together O O
with O O
Otx2 O O
, O O
Foxa2 O O
, O O
and O O
Ldb1 O O
to O O
govern O O
anterior O O
mesendoderm O O
, O O
node O O
, O O
and O O
midline O O
development O O
. O O

Gene O O
regulatory O O
networks O O
controlling O O
functional O O
activities O O
of O O
spatially O O
and O O
temporally O O
distinct O O
endodermal O O
cell O O
populations O O
in O O
the O O
early O O
mouse O O
embryo O O
remain O O
ill O O
defined O O
. O O

The O O
T O O
- O O
box O O
transcription O O
factor O O
Eomes O O
, O O
acting O O
downstream O O
from O O
Nodal O O
/ O O
Smad O O
signals O O
, O O
directly O O
activates O O
the O O
LIM O O
domain O O
homeobox O O
transcription O O
factor O O
Lhx1 O O
in O O
the O O
visceral O O
endoderm O O
. O O

Here O O
we O O
demonstrate O O
Smad4 O O
/ O O
Eomes O O
- O O
dependent O O
Lhx1 O O
expression O O
in O O
the O O
epiblast O O
marks O O
the O O
entire O O
definitive O O
endoderm O O
lineage O O
, O O
the O O
anterior O O
mesendoderm O O
, O O
and O O
midline O O
progenitors O O
. O O

Conditional O O
inactivation O O
of O O
Lhx1 O O
disrupts O O
anterior O O
definitive O O
endoderm O O
development O O
and O O
impedes O O
node O O
and O O
midline O O
morphogenesis O O
in O O
part O O
due O O
to O O
severe O O
disturbances O O
in O O
visceral O O
endoderm O O
displacement O O
. O O

Transcriptional O O
profiling O O
and O O
ChIP O O
- O O
seq O O
( O O
chromatin O O
immunoprecipitation O O
[ O O
ChIP O O
] O O
followed O O
by O O
high O O
- O O
throughput O O
sequencing O O
) O O
experiments O O
identified O O
Lhx1 O O
target O O
genes O O
, O O
including O O
numerous O O
anterior O O
definitive O O
endoderm O O
markers O O
and O O
components O O
of O O
the O O
Wnt O O
signaling O O
pathway O O
. O O

Interestingly O O
, O O
Lhx1 O O
- O O
binding O O
sites O O
were O O
enriched O O
at O O
enhancers O O
, O O
including O O
the O O
Nodal B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
proximal I-Enhancer I-Enhancer
epiblast I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
controlling I-Enhancer O
Otx2 I-Enhancer O
and I-Enhancer O
Foxa2 I-Enhancer O
expression I-Enhancer O
. O O
Interestingly O O
, O O
Lhx1 O O
- O O
binding O O
sites O O
were O O
enriched O O
at O O
enhancers O O
, O O
including O O
the O O
Nodal B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
proximal I-Enhancer I-Enhancer
epiblast I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
and O O
enhancer B-Enhancer B-Enhancer
regions I-Enhancer I-Enhancer
controlling I-Enhancer O
Otx2 I-Enhancer O
and I-Enhancer O
Foxa2 I-Enhancer O
expression I-Enhancer O
. O O

Moreover O O
, O O
in O O
proteomic O O
experiments O O
, O O
we O O
characterized O O
a O O
complex O O
comprised O O
of O O
Lhx1 O O
, O O
Otx2 O O
, O O
and O O
Foxa2 O O
as O O
well O O
as O O
the O O
chromatin O O
- O O
looping O O
protein O O
Ldb1 O O
. O O

These O O
partnerships O O
cooperatively O O
regulate O O
development O O
of O O
the O O
anterior O O
mesendoderm O O
, O O
node O O
, O O
and O O
midline O O
cell O O
populations O O
responsible O O
for O O
establishment O O
of O O
the O O
left O O
- O O
right O O
body O O
axis O O
and O O
head O O
formation O O
. O O

Analysis O O
of O O
long O O
- O O
range O O
interactions O O
in O O
primary O O
human O O
cells O O
identifies O O
cooperative O O
CFTR O O
regulatory O O
elements O O
. O O

A O O
mechanism O O
by O O
which O O
control O O
DNA O O
elements O O
regulate O O
transcription O O
over O O
large O O
linear O O
genomic O O
distances O O
is O O
by O O
achieving O O
close O O
physical O O
proximity O O
with O O
genes O O
, O O
and O O
looping O O
of O O
the O O
intervening O O
chromatin O O
paths O O
. O O

Alterations O O
of O O
such O O
regulatory O O
' O O
chromatin O O
looping O O
' O O
systems O O
are O O
likely O O
to O O
play O O
a O O
critical O O
role O O
in O O
human O O
genetic O O
disease O O
at O O
large O O
. O O

Here O O
, O O
we O O
studied O O
the O O
spatial O O
organization O O
of O O
a O O
790 O O
kb O O
locus O O
encompassing O O
the O O
cystic O O
fibrosis O O
transmembrane O O
conductance O O
regulator O O
( O O
CFTR O O
) O O
gene O O
. O O

Dysregulation O O
of O O
CFTR O O
is O O
responsible O O
for O O
cystic O O
fibrosis O O
, O O
which O O
is O O
the O O
most O O
common O O
lethal O O
genetic O O
disorder O O
in O O
Caucasian O O
populations O O
. O O
CFTR O O
is O O
a O O
relatively O O
large O O
gene O O
of O O
189 O O
kb O O
with O O
a O O
rather O O
complex O O
tissue O O
- O O
specific O O
and O O
temporal O O
expression O O
profile O O
. O O

We O O
used O O
chromatin O O
conformation O O
at O O
the O O
CFTR O O
locus O O
to O O
identify O O
new O O
DNA O O
sequences O O
that O O
regulate O O
its O O
transcription O O
. O O

By O O
comparing O O
5C O O
chromatin O O
interaction O O
maps O O
of O O
the O O
CFTR O O
locus O O
in O O
expressing O O
and O O
non O O
- O O
expressing O O
human O O
primary O O
cells O O
, O O
we O O
identified O O
several O O
new O O
contact O O
points O O
between O O
the O O
CFTR O O
promoter O O
and O O
its O O
surroundings O O
, O O
in O O
addition O O
to O O
regions O O
featuring O O
previously O O
described O O
regulatory O O
elements O O
. O O
By O O
comparing O O
5C O O
chromatin O O
interaction O O
maps O O
of O O
the O O
CFTR O O
locus O O
in O O
expressing O O
and O O
non O O
- O O
expressing O O
human O O
primary O O
cells O O
, O O
we O O
identified O O
several O O
new O O
contact O O
points O O
between O O
the O O
CFTR O O
promoter O O
and O O
its O O
surroundings O O
, O O
in O O
addition O O
to O O
regions O O
featuring O O
previously O O
described O O
regulatory O O
elements O O
. O O

We O O
demonstrate O O
that O O
two O O
of O O
these O O
novel O O
interacting O O
regions O O
cooperatively O O
increase O O
CFTR O O
expression O O
, O O
and O O
suggest O O
that O O
the O O
new O O
enhancer B-Enhancer B-Enhancer
elements I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
on I-Enhancer I-Enhancer
either I-Enhancer I-Enhancer
side I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
are O O
brought O O
together O O
through O O
chromatin O O
looping O O
via O O
CTCF O O
. O O

Foxd3 O O
Promotes O O
Exit O O
from O O
Naive O O
Pluripotency O O
through O O
Enhancer O O
Decommissioning O O
and O O
Inhibits O O
Germline O O
Specification O O
. O O

Following O O
implantation O O
, O O
mouse O O
epiblast O O
cells O O
transit O O
from O O
a O O
naive O O
to O O
a O O
primed O O
state O O
in O O
which O O
they O O
are O O
competent O O
for O O
both O O
somatic O O
and O O
primordial O O
germ O O
cell O O
( O O
PGC O O
) O O
specification O O
. O O

Using O O
mouse O O
embryonic O O
stem O O
cells O O
as O O
an O O
in O O
vitro O O
model O O
to O O
study O O
the O O
transcriptional O O
regulatory O O
principles O O
orchestrating O O
peri O O
- O O
implantation O O
development O O
, O O
here O O
we O O
show O O
that O O
the O O
transcription O O
factor O O
Foxd3 O O
is O O
necessary O O
for O O
exit O O
from O O
naive O O
pluripotency O O
and O O
progression O O
to O O
a O O
primed O O
pluripotent O O
state O O
. O O

During O O
this O O
transition O O
, O O
Foxd3 O O
acts O O
as O O
a O O
repressor O O
that O O
dismantles O O
a O O
significant O O
fraction O O
of O O
the O O
naive O O
pluripotency O O
expression O O
program O O
through O O
decommissioning O O
of O O
active O O
enhancers O O
associated O O
with O O
key O O
naive O O
pluripotency O O
and O O
early O O
germline O O
genes O O
. O O

Subsequently O O
, O O
Foxd3 O O
needs O O
to O O
be O O
silenced O O
in O O
primed O O
pluripotent O O
cells O O
to O O
allow O O
re O O
- O O
activation O O
of O O
relevant O O
genes O O
required O O
for O O
proper O O
PGC O O
specification O O
. O O

Our O O
findings O O
therefore O O
uncover O O
a O O
cycle O O
of O O
activation O O
and O O
deactivation O O
of O O
Foxd3 O O
required O O
for O O
exit O O
from O O
naive O O
pluripotency O O
and O O
subsequent O O
PGC O O
specification O O
. O O

Up O O
- O O
Regulation O O
of O O
Human O O
Inducible O O
Nitric O O
Oxide O O
Synthase O O
by O O
p300 O O
Transcriptional O O
Complex O O
. O O
p300 O O
, O O
a O O
ubiquitous O O
transcription O O
coactivator O O
, O O
plays O O
an O O
important O O
role O O
in O O
gene O O
activation O O
. O O

Our O O
previous O O
work O O
demonstrated O O
that O O
human O O
inducible O O
nitric O O
oxide O O
synthase O O
( O O
hiNOS O O
) O O
expression O O
can O O
be O O
highly O O
induced O O
with O O
the O O
cytokine O O
mixture O O
( O O
CM O O
) O O
of O O
TNF O O
- O O
alpha O O
+ O O
IL O O
- O O
1beta O O
+ O O
IFN O O
- O O
gamma O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
functional O O
role O O
of O O
p300 O O
in O O
the O O
regulation O O
of O O
hiNOS O O
gene O O
expression O O
. O O

Our O O
initial O O
data O O
showed O O
that O O
overexpression O O
of O O
p300 O O
significantly O O
increased O O
the O O
basal O O
and O O
cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activities O O
in O O
A549 O O
cells O O
. O O
Our O O
initial O O
data O O
showed O O
that O O
overexpression O O
of O O
p300 O O
significantly O O
increased O O
the O O
basal O O
and O O
cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activities O O
in O O
A549 O O
cells O O
. O O

Interestingly O O
, O O
p300 O O
activated O O
cytokine O O
- O O
induced O O
hiNOS O O
transcriptional O O
activity O O
was O O
completely O O
abrogated O O
by O O
deleting O O
the O O
upstream B-Enhancer B-Enhancer
hiNOS I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
at I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
5 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
6 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
promoter I-Enhancer I-Enhancer
. I-Enhancer O
Furthermore O O
, O O
p300 O O
over O O
- O O
expression O O
increased O O
cytokine O O
- O O
induced O O
transcriptional O O
activity O O
on O O
a O O
heterologous O O
minimal O O
TK O O
promoter O O
with O O
the O O
same O O
hiNOS B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
Interestingly O O
, O O
p300 O O
activated O O
cytokine O O
- O O
induced O O
hiNOS O O
transcriptional O O
activity O O
was O O
completely O O
abrogated O O
by O O
deleting O O
the O O
upstream B-Enhancer B-Enhancer
hiNOS I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
at I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
5 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
6 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
promoter I-Enhancer I-Enhancer
. I-Enhancer O
Furthermore O O
, O O
p300 O O
over O O
- O O
expression O O
increased O O
cytokine O O
- O O
induced O O
transcriptional O O
activity O O
on O O
a O O
heterologous O O
minimal O O
TK O O
promoter O O
with O O
the O O
same O O
hiNOS B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
hiNOS O O
AP O O
- O O
1 O O
motifs O O
revealed O O
that O O
an O O
intact O O
upstream O O
( O O
- O O
5 O O
. O O
3 O O
kb O O
) O O
AP O O
- O O
1 O O
binding O O
site O O
was O O
critical O O
for O O
p300 O O
mediated O O
cytokine O O
- O O
induced O O
hiNOS O O
transcription O O
. O O
Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
hiNOS O O
AP O O
- O O
1 O O
motifs O O
revealed O O
that O O
an O O
intact O O
upstream O O
( O O
- O O
5 O O
. O O
3 O O
kb O O
) O O
AP O O
- O O
1 O O
binding O O
site O O
was O O
critical O O
for O O
p300 O O
mediated O O
cytokine O O
- O O
induced O O
hiNOS O O
transcription O O
. O O

Furthermore O O
, O O
our O O
ChIP O O
analysis O O
demonstrated O O
that O O
p300 O O
was O O
binding O O
to O O
Jun O O
D O O
and O O
Fra O O
- O O
2 O O
proteins O O
at O O
- O O
5 O O
. O O
3 O O
kb O O
AP O O
- O O
1 O O
binding O O
site O O
in O O
vivo O O
. O O
Furthermore O O
, O O
our O O
ChIP O O
analysis O O
demonstrated O O
that O O
p300 O O
was O O
binding O O
to O O
Jun O O
D O O
and O O
Fra O O
- O O
2 O O
proteins O O
at O O
- O O
5 O O
. O O
3 O O
kb O O
AP O O
- O O
1 O O
binding O O
site O O
in O O
vivo O O
. O O

Lastly O O
, O O
our O O
3C O O
assay O O
was O O
able O O
to O O
detect O O
a O O
long O O
DNA O O
loop O O
between O O
the O O
hiNOS B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
core O O
promoter O O
site O O
, O O
and O O
ChIP O O
loop O O
assay O O
confirmed O O
that O O
p300 O O
binds O O
to O O
AP O O
- O O
1 O O
and O O
RNA O O
pol O O
II O O
proteins O O
. O O
Lastly O O
, O O
our O O
3C O O
assay O O
was O O
able O O
to O O
detect O O
a O O
long O O
DNA O O
loop O O
between O O
the O O
hiNOS B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
core O O
promoter O O
site O O
, O O
and O O
ChIP O O
loop O O
assay O O
confirmed O O
that O O
p300 O O
binds O O
to O O
AP O O
- O O
1 O O
and O O
RNA O O
pol O O
II O O
proteins O O
. O O

Overall O O
, O O
our O O
results O O
suggest O O
that O O
coactivator O O
p300 O O
mediates O O
cytokine O O
- O O
induced O O
hiNOS O O
transactivation O O
by O O
forming O O
a O O
distant O O
DNA O O
loop O O
between O O
its O O
enhancer B-Enhancer B-Enhancer
and O O
core O O
promoter O O
region O O
. O O

BMP O O
Sustains O O
Embryonic O O
Stem O O
Cell O O
Self O O
- O O
Renewal O O
through O O
Distinct O O
Functions O O
of O O
Different O O
Kruppel O O
- O O
like O O
Factors O O
. O O

Bone O O
morphogenetic O O
protein O O
( O O
BMP O O
) O O
signaling O O
exerts O O
paradoxical O O
roles O O
in O O
pluripotent O O
stem O O
cells O O
( O O
PSCs O O
) O O
; O O
it O O
sustains O O
self O O
- O O
renewal O O
of O O
mouse O O
embryonic O O
stem O O
cells O O
( O O
ESCs O O
) O O
, O O
while O O
it O O
induces O O
differentiation O O
in O O
other O O
PSCs O O
, O O
including O O
human O O
ESCs O O
. O O

Here O O
, O O
we O O
revisit O O
the O O
roles O O
of O O
BMP O O
- O O
4 O O
using O O
mouse O O
ESCs O O
( O O
mESCs O O
) O O
in O O
naive O O
and O O
primed O O
states O O
. O O
SMAD1 O O
and O O
SMAD5 O O
, O O
which O O
transduce O O
BMP O O
signals O O
, O O
recognize O O
enhancer O B-Enhancer
regions O I-Enhancer
together O O
with O O
KLF4 O O
and O O
KLF5 O O
in O O
naive O O
mESCs O O
. O O
KLF4 O O
physically O O
interacts O O
with O O
SMAD1 O O
and O O
suppresses O O
its O O
activity O O
. O O

Consistently O O
, O O
a O O
subpopulation O O
of O O
cells O O
with O O
active O O
BMP O O
- O O
SMAD O O
can O O
be O O
ablated O O
without O O
disturbing O O
the O O
naive O O
state O O
of O O
the O O
culture O O
. O O

Moreover O O
, O O
Smad1 O O
/ O O
5 O O
double O O
- O O
knockout O O
mESCs O O
stay O O
in O O
the O O
naive O O
state O O
, O O
indicating O O
that O O
the O O
BMP O O
- O O
SMAD O O
pathway O O
is O O
dispensable O O
for O O
it O O
. O O

In O O
contrast O O
, O O
the O O
MEK5 O O
- O O
ERK5 O O
pathway O O
mediates O O
BMP O O
- O O
4 O O
- O O
induced O O
self O O
- O O
renewal O O
of O O
mESCs O O
by O O
inducing O O
Klf2 O O
, O O
a O O
critical O O
factor O O
for O O
the O O
ground O O
state O O
pluripotency O O
. O O

Our O O
study O O
illustrates O O
that O O
BMP O O
exerts O O
its O O
self O O
- O O
renewing O O
effect O O
through O O
distinct O O
functions O O
of O O
different O O
Kruppel O O
- O O
like O O
factors O O
. O O

Discordant O O
Haplotype O O
Sequencing O O
Identifies O O
Functional O O
Variants O O
at O O
the O O
2q33 O O
Breast O O
Cancer O O
Risk O O
Locus O O
. O O

The O O
findings O O
from O O
genome O O
- O O
wide O O
association O O
studies O O
hold O O
enormous O O
potential O O
for O O
novel O O
insight O O
into O O
disease O O
mechanisms O O
. O O

A O O
major O O
challenge O O
in O O
the O O
field O O
is O O
to O O
map O O
these O O
low O O
- O O
risk O O
association O O
signals O O
to O O
their O O
underlying O O
functional O O
sequence O O
variants O O
( O O
FSV O O
) O O
. O O

Simple O O
sequence O O
study O O
designs O O
are O O
insufficient O O
, O O
as O O
the O O
vast O O
numbers O O
of O O
statistically O O
comparable O O
variants O O
and O O
a O O
limited O O
knowledge O O
of O O
noncoding O O
regulatory O O
elements O O
complicate O O
prioritization O O
. O O

Furthermore O O
, O O
large O O
sample O O
sizes O O
are O O
typically O O
required O O
for O O
adequate O O
power O O
to O O
identify O O
the O O
initial O O
association O O
signals O O
. O O

One O O
important O O
question O O
is O O
whether O O
similar O O
sample O O
sizes O O
need O O
to O O
be O O
sequenced O O
to O O
identify O O
the O O
FSVs O O
. O O

Here O O
, O O
we O O
present O O
a O O
proof O O
- O O
of O O
- O O
principle O O
example O O
of O O
an O O
extreme O O
discordant O O
design O O
to O O
map O O
FSVs O O
within O O
the O O
2q33 O O
low O O
- O O
risk O O
breast O O
cancer O O
locus O O
. O O

Our O O
approach O O
employed O O
DNA O O
sequencing O O
of O O
a O O
small O O
number O O
of O O
discordant O O
haplotypes O O
to O O
efficiently O O
identify O O
candidate O O
FSVs O O
. O O

Our O O
results O O
were O O
consistent O O
with O O
those O O
from O O
a O O
2 O O
, O O
000 O O
- O O
fold O O
larger O O
, O O
traditional O O
imputation O O
- O O
based O O
fine O O
- O O
mapping O O
study O O
. O O

To O O
prioritize O O
further O O
, O O
we O O
used O O
expression O O
- O O
quantitative O O
trait O O
locus O O
analysis O O
of O O
RNA O O
sequencing O O
from O O
breast O O
tissues O O
, O O
gene O O
regulation O O
annotations O O
from O O
the O O
ENCODE O O
consortium O O
, O O
and O O
functional O O
assays O O
for O O
differential O O
enhancer O O
activities O O
. O O

Notably O O
, O O
we O O
implicate O O
three O O
regulatory O O
variants O O
at O O
2q33 O O
that O O
target O O
CASP8 O O
( O O
rs3769823 O O
, O O
rs3769821 O O
in O O
CASP8 O O
, O O
and O O
rs10197246 O O
in O O
ALS2CR12 O O
) O O
as O O
functionally O O
relevant O O
. O O

We O O
conclude O O
that O O
nested O O
discordant O O
haplotype O O
sequencing O O
is O O
a O O
promising O O
approach O O
to O O
aid O O
mapping O O
of O O
low O O
- O O
risk O O
association O O
loci O O
. O O

The O O
ability O O
to O O
include O O
more O O
efficient O O
sequencing O O
designs O O
into O O
mapping O O
efforts O O
presents O O
an O O
opportunity O O
for O O
the O O
field O O
to O O
capitalize O O
on O O
the O O
potential O O
of O O
association O O
loci O O
and O O
accelerate O O
translation O O
of O O
association O O
signals O O
to O O
their O O
underlying O O
FSVs O O
. O O

Cancer O O
Res O O
; O O
76 O O
( O O
7 O O
) O O
; O O
1916 O O
- O O
25 O O
. O O

2016 O O
AACR O O
. O O

An O O
oncogenic O O
MYB O O
feedback O O
loop O O
drives O O
alternate O O
cell O O
fates O O
in O O
adenoid O O
cystic O O
carcinoma O O
. O O

Translocation O O
events O O
are O O
frequent O O
in O O
cancer O O
and O O
may O O
create O O
chimeric O O
fusions O O
or O O
' O O
regulatory O O
rearrangements O O
' O O
that O O
drive O O
oncogene O O
overexpression O O
. O O

Here O O
we O O
identify O O
super O O
- O O
enhancer O O
translocations O O
that O O
drive O O
overexpression O O
of O O
the O O
oncogenic O O
transcription O O
factor O O
MYB O O
as O O
a O O
recurrent O O
theme O O
in O O
adenoid O O
cystic O O
carcinoma O O
( O O
ACC O O
) O O
. O O

Whole O O
- O O
genome O O
sequencing O O
data O O
and O O
chromatin O O
maps O O
highlight O O
distinct O O
chromosomal O O
rearrangements O O
that O O
juxtapose O O
super O O
- O O
enhancers O O
to O O
the O O
MYB O O
locus O O
. O O

Chromosome O O
conformation O O
capture O O
confirms O O
that O O
the O O
translocated O O
enhancers O O
interact O O
with O O
the O O
MYB O O
promoter O O
. O O
Chromosome O O
conformation O O
capture O O
confirms O O
that O O
the O O
translocated O O
enhancers O O
interact O O
with O O
the O O
MYB O O
promoter O O
. O O

Remarkably O O
, O O
MYB O O
protein O O
binds O O
to O O
the O O
translocated O O
enhancers O O
, O O
creating O O
a O O
positive O O
feedback O O
loop O O
that O O
sustains O O
its O O
expression O O
. O O
MYB O O
also O O
binds O O
enhancers O O
that O O
drive O O
different O O
regulatory O O
programs O O
in O O
alternate O O
cell O O
lineages O O
in O O
ACC O O
, O O
cooperating O O
with O O
TP63 O O
in O O
myoepithelial O O
cells O O
and O O
a O O
Notch O O
program O O
in O O
luminal O O
epithelial O O
cells O O
. O O

Bromodomain O O
inhibitors O O
slow O O
tumor O O
growth O O
in O O
ACC O O
primagraft O O
models O O
in O O
vivo O O
. O O

Thus O O
, O O
our O O
study O O
identifies O O
super O O
- O O
enhancer O O
translocations O O
that O O
drive O O
MYB O O
expression O O
and O O
provides O O
insight O O
into O O
downstream O O
MYB O O
functions O O
in O O
alternate O O
ACC O O
lineages O O
. O O

Enhancer O O
RNA O O
- O O
driven O O
looping O O
enhances O O
the O O
transcription O O
of O O
the O O
long O O
noncoding O O
RNA O O
DHRS4 O O
- O O
AS1 O O
, O O
a O O
controller O O
of O O
the O O
DHRS4 O O
gene O O
cluster O O
. O O

The O O
human O O
DHRS4 O O
gene O O
cluster O O
consists O O
of O O
DHRS4 O O
and O O
two O O
immediately O O
downstream O O
homologous O O
genes O O
, O O
DHRS4L2 O O
and O O
DHRS4L1 O O
, O O
generated O O
by O O
evolutionarily O O
gene O O
- O O
duplication O O
events O O
. O O

We O O
previously O O
demonstrated O O
that O O
a O O
head O O
- O O
to O O
- O O
head O O
natural O O
antisense O O
transcript O O
( O O
NAT O O
) O O
of O O
DHRS4 O O
, O O
denoted O O
DHRS4 O O
- O O
AS1 O O
, O O
regulates O O
all O O
three O O
genes O O
of O O
the O O
DHRS4 O O
gene O O
cluster O O
. O O

However O O
, O O
it O O
is O O
puzzling O O
that O O
DHRS4L2 O O
and O O
DHRS4L1 O O
did O O
not O O
evolve O O
their O O
own O O
specific O O
NATs O O
to O O
regulate O O
themselves O O
, O O
as O O
it O O
seems O O
both O O
have O O
retained O O
sequences O O
highly O O
homologous O O
to O O
DHRS4 O O
- O O
AS1 O O
. O O

In O O
a O O
search O O
of O O
the O O
DHRS4 O O
- O O
AS1 O O
region O O
for O O
nearby O O
enhancers O O
, O O
we O O
identified O O
an O O
enhancer B-Enhancer B-Enhancer
located I-Enhancer I-Enhancer
13 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
8 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
downstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
DHRS4 I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
AS1 I-Enhancer I-Enhancer
transcriptional I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
. O O
In O O
a O O
search O O
of O O
the O O
DHRS4 O O
- O O
AS1 O O
region O O
for O O
nearby O O
enhancers O O
, O O
we O O
identified O O
an O O
enhancer B-Enhancer B-Enhancer
located I-Enhancer I-Enhancer
13 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
8 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
downstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
DHRS4 I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
AS1 I-Enhancer I-Enhancer
transcriptional I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
. O O

We O O
further O O
showed O O
, O O
by O O
using O O
a O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
assay O O
, O O
that O O
this O O
enhancer B-Enhancer B-Enhancer
is O O
capable O O
of O O
physically O O
interacting O O
with O O
the O O
DHRS4 O O
- O O
AS1 O O
promoter O O
through O O
chromosomal O O
looping O O
. O O
We O O
further O O
showed O O
, O O
by O O
using O O
a O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
assay O O
, O O
that O O
this O O
enhancer B-Enhancer B-Enhancer
is O O
capable O O
of O O
physically O O
interacting O O
with O O
the O O
DHRS4 O O
- O O
AS1 O O
promoter O O
through O O
chromosomal O O
looping O O
. O O

The O O
enhancer B-Enhancer B-Enhancer
produced O O
an O O
eRNA B-Enhancer B-Enhancer
, O O
termed O O
AS1eRNA B-Enhancer B-Enhancer
, O O
that O O
enhanced O O
DHRS4 O O
- O O
AS1 O O
transcription O O
by O O
mediating O O
the O O
spatial O O
interactions O O
of O O
the O O
enhancer B-Enhancer B-Enhancer
and O O
DHRS4 O O
- O O
AS1 O O
promoter O O
in O O
cooperation O O
with O O
RNA O O
polymerase O O
II O O
and O O
p300 O O
/ O O
CBP O O
. O O
The O O
enhancer B-Enhancer B-Enhancer
produced O O
an O O
eRNA B-Enhancer B-Enhancer
, O O
termed O O
AS1eRNA B-Enhancer B-Enhancer
, O O
that O O
enhanced O O
DHRS4 O O
- O O
AS1 O O
transcription O O
by O O
mediating O O
the O O
spatial O O
interactions O O
of O O
the O O
enhancer B-Enhancer B-Enhancer
and O O
DHRS4 O O
- O O
AS1 O O
promoter O O
in O O
cooperation O O
with O O
RNA O O
polymerase O O
II O O
and O O
p300 O O
/ O O
CBP O O
. O O

Moreover O O
, O O
the O O
distributions O O
of O O
activating O O
acetyl O O
- O O
H3 O O
and O O
H3K4me3 O O
modifications O O
were O O
found O O
to O O
be O O
greater O O
at O O
the O O
DHRS4 O O
- O O
AS1 O O
promoter O O
than O O
at O O
the O O
homologous O O
duplicated O O
regions O O
. O O
Moreover O O
, O O
the O O
distributions O O
of O O
activating O O
acetyl O O
- O O
H3 O O
and O O
H3K4me3 O O
modifications O O
were O O
found O O
to O O
be O O
greater O O
at O O
the O O
DHRS4 O O
- O O
AS1 O O
promoter O O
than O O
at O O
the O O
homologous O O
duplicated O O
regions O O
. O O

We O O
propose O O
that O O
AS1eRNA B-Enhancer O
- O O
driven O O
DNA O O
looping O O
and O O
activating O O
histone O O
modifications O O
promote O O
the O O
expression O O
of O O
DHRS4 O O
- O O
AS1 O O
to O O
economically O O
control O O
the O O
DHRS4 O O
gene O O
cluster O O
. O O

Inhibition O O
of O O
Interleukin O O
1beta O O
( O O
IL O O
- O O
1beta O O
) O O
Expression O O
by O O
Anthrax O O
Lethal O O
Toxin O O
( O O
LeTx O O
) O O
Is O O
Reversed O O
by O O
Histone O O
Deacetylase O O
8 O O
( O O
HDAC8 O O
) O O
Inhibition O O
in O O
Murine O O
Macrophages O O
. O O

Many O O
pathogenic O O
microbes O O
often O O
release O O
toxins O O
that O O
subvert O O
the O O
host O O
' O O
s O O
immune O O
responses O O
to O O
render O O
the O O
environment O O
suitable O O
for O O
their O O
survival O O
and O O
proliferation O O
. O O

LeTx O O
is O O
one O O
of O O
the O O
toxins O O
causing O O
immune O O
paralysis O O
by O O
cleaving O O
and O O
inactivating O O
the O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
( O O
MAPK O O
) O O
kinases O O
( O O
MEKs O O
) O O
. O O

Here O O
, O O
we O O
show O O
that O O
inhibition O O
of O O
the O O
histone O O
deacetylase O O
8 O O
( O O
HDAC8 O O
) O O
by O O
either O O
the O O
HDAC8 O O
- O O
specific O O
inhibitor O O
PCI O O
- O O
34051 O O
or O O
small O O
interference O O
( O O
si O O
) O O
RNAs O O
rendered O O
LeTx O O
- O O
exposed O O
murine O O
macrophages O O
responsive O O
to O O
LPS O O
in O O
pro O O
- O O
IL O O
- O O
1beta O O
production O O
. O O
HDAC8 O O
selectively O O
targeted O O
acetylated O O
histone O O
H3 O O
lysine O O
27 O O
( O O
H3K27Ac O O
) O O
, O O
which O O
is O O
known O O
to O O
associate O O
with O O
active O O
enhancers O O
. O O

LeTx O O
induced O O
HDAC8 O O
expression O O
, O O
in O O
part O O
through O O
inhibiting O O
p38 O O
MAPK O O
, O O
which O O
resulted O O
in O O
a O O
decrease O O
of O O
H3K27Ac O O
levels O O
. O O

Inhibition O O
of O O
HDAC8 O O
increased O O
H3K27Ac O O
levels O O
and O O
enhanced O O
NF O O
- O O
kappaB O O
- O O
mediated O O
pro B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
IL I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
1beta I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
messenger O O
RNA O O
production O O
in O O
LeTx O O
- O O
exposed O O
macrophages O O
. O O
Inhibition O O
of O O
HDAC8 O O
increased O O
H3K27Ac O O
levels O O
and O O
enhanced O O
NF O O
- O O
kappaB O O
- O O
mediated O O
pro B-Enhancer O
- I-Enhancer O
IL I-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1beta I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
and O O
messenger O O
RNA O O
production O O
in O O
LeTx O O
- O O
exposed O O
macrophages O O
. O O

Collectively O O
, O O
this O O
study O O
demonstrates O O
a O O
novel O O
role O O
of O O
HDAC8 O O
in O O
LeTx O O
immunotoxicity O O
and O O
regulation O O
of O O
pro O O
- O O
IL O O
- O O
1beta O O
production O O
likely O O
through O O
eRNAs O O
. O O

Targeting O O
HDAC8 O O
could O O
be O O
a O O
strategy O O
for O O
enhancing O O
immune O O
responses O O
in O O
macrophages O O
exposed O O
to O O
LeTx O O
or O O
other O O
toxins O O
that O O
inhibit O O
MAPKs O O
. O O

ARID1A O O
loss O O
impairs O O
enhancer O O
- O O
mediated O O
gene O O
regulation O O
and O O
drives O O
colon O O
cancer O O
in O O
mice O O
. O O

Genes O O
encoding O O
subunits O O
of O O
SWI O O
/ O O
SNF O O
( O O
BAF O O
) O O
chromatin O O
- O O
remodeling O O
complexes O O
are O O
collectively O O
mutated O O
in O O
~ O O
20 O O
% O O
of O O
all O O
human O O
cancers O O
. O O

Although O O
ARID1A O O
is O O
the O O
most O O
frequent O O
target O O
of O O
mutations O O
, O O
the O O
mechanism O O
by O O
which O O
its O O
inactivation O O
promotes O O
tumorigenesis O O
is O O
unclear O O
. O O

Here O O
we O O
demonstrate O O
that O O
Arid1a O O
functions O O
as O O
a O O
tumor O O
suppressor O O
in O O
the O O
mouse O O
colon O O
, O O
but O O
not O O
the O O
small O O
intestine O O
, O O
and O O
that O O
invasive O O
ARID1A O O
- O O
deficient O O
adenocarcinomas O O
resemble O O
human O O
colorectal O O
cancer O O
( O O
CRC O O
) O O
. O O

These O O
tumors O O
lack O O
deregulation O O
of O O
APC O O
/ O O
beta O O
- O O
catenin O O
signaling O O
components O O
, O O
which O O
are O O
crucial O O
gatekeepers O O
in O O
common O O
forms O O
of O O
intestinal O O
cancer O O
. O O

We O O
find O O
that O O
ARID1A O O
normally O O
targets O O
SWI O O
/ O O
SNF O O
complexes O O
to O O
enhancers O O
, O O
where O O
they O O
function O O
in O O
coordination O O
with O O
transcription O O
factors O O
to O O
facilitate O O
gene O O
activation O O
. O O
ARID1B O O
preserves O O
SWI O O
/ O O
SNF O O
function O O
in O O
ARID1A O O
- O O
deficient O O
cells O O
, O O
but O O
defects O O
in O O
SWI O O
/ O O
SNF O O
targeting O O
and O O
control O O
of O O
enhancer O O
activity O O
cause O O
extensive O O
dysregulation O O
of O O
gene O O
expression O O
. O O

These O O
findings O O
represent O O
an O O
advance O O
in O O
colon O O
cancer O O
modeling O O
and O O
implicate O O
enhancer O O
- O O
mediated O O
gene O O
regulation O O
as O O
a O O
principal O O
tumor O O
- O O
suppressor O O
function O O
of O O
ARID1A O O
. O O

Altered O O
SOX9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
in O O
hypospadias O O
. O O
Human O O
mutations O O
in O O
the O O
SOX9 O O
gene O O
or O O
its O O
regulatory O O
region O O
can O O
disrupt O O
testicular O O
development O O
, O O
leading O O
to O O
disorders O O
of O O
sex O O
development O O
( O O
DSDs O O
) O O
. O O
Altered O O
SOX9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
in O O
hypospadias O O
. O O
Human O O
mutations O O
in O O
the O O
SOX9 O O
gene O O
or O O
its O O
regulatory O O
region O O
can O O
disrupt O O
testicular O O
development O O
, O O
leading O O
to O O
disorders O O
of O O
sex O O
development O O
( O O
DSDs O O
) O O
. O O

Our O O
previous O O
work O O
involving O O
the O O
genomic O O
analysis O O
of O O
isolated O O
DSD O O
patients O O
revealed O O
a O O
78kb O O
minimal O O
sex O O
determining O O
region O O
( O O
RevSex O O
) O O
far O O
upstream O O
of O O
SOX9 O O
that O O
was O O
duplicated O O
in O O
46 O O
, O O
XX O O
and O O
deleted O O
in O O
46 O O
, O O
XY O O
DSDs O O
. O O

It O O
was O O
postulated O O
that O O
RevSex O O
contains O O
a O O
gonadal B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

However O O
, O O
the O O
most O O
highly O O
conserved O O
sub O O
- O O
region O O
within O O
RevSex O O
, O O
called O O
SR4 O O
, O O
was O O
neither O O
responsive O O
to O O
sex O O
determining O O
factors O O
in O O
vitro O O
nor O O
active O O
in O O
the O O
gonads O O
of O O
transgenic O O
mice O O
, O O
suggesting O O
that O O
SR4 O O
may O O
not O O
be O O
functioning O O
as O O
a O O
testicular B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

Interestingly O O
, O O
SR4 O O
transgenic O O
mice O O
showed O O
reporter O O
activity O O
in O O
the O O
genital O O
tubercle O O
, O O
the O O
primordium O O
of O O
the O O
penis O O
and O O
clitoris O O
, O O
a O O
previously O O
unreported O O
domain O O
of O O
Sox9 O O
expression O O
. O O
SOX9 O O
protein O O
was O O
detected O O
in O O
the O O
genital O O
tubercle O O
, O O
notably O O
in O O
the O O
urethral O O
plate O O
epithelium O O
, O O
preputial O O
glands O O
, O O
ventral O O
surface O O
ectoderm O O
and O O
corpus O O
cavernosa O O
. O O

SR4 O O
may O O
therefore O O
function O O
as O O
a O O
Sox9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
mutations O O
of O O
which O O
could O O
possibly O O
lead O O
to O O
hypospadias O O
, O O
a O O
birth O O
defect O O
seen O O
in O O
the O O
DSD O O
patients O O
in O O
the O O
RevSex O O
study O O
. O O
SR4 O O
may O O
therefore O O
function O O
as O O
a O O
Sox9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
mutations O O
of O O
which O O
could O O
possibly O O
lead O O
to O O
hypospadias O O
, O O
a O O
birth O O
defect O O
seen O O
in O O
the O O
DSD O O
patients O O
in O O
the O O
RevSex O O
study O O
. O O

SR4 O O
activity O O
and O O
the O O
observed O O
SOX9 O O
expression O O
pattern O O
suggest O O
that O O
SR4 O O
may O O
function O O
as O O
a O O
Sox9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
SR4 O O
activity O O
and O O
the O O
observed O O
SOX9 O O
expression O O
pattern O O
suggest O O
that O O
SR4 O O
may O O
function O O
as O O
a O O
Sox9 B-Enhancer B-Enhancer
genital I-Enhancer I-Enhancer
tubercle I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

However O O
, O O
conditional O O
ablation O O
of O O
Sox9 O O
in O O
the O O
genital O O
tubercle O O
using O O
Shh O O
- O O
Cre O O
/ O O
+ O O
; O O
Sox9flox O O
/ O O
flox O O
mice O O
revealed O O
no O O
genital O O
tubercle O O
abnormalities O O
, O O
possibly O O
due O O
to O O
compensation O O
by O O
similar O O
Sox O O
factors O O
. O O

To O O
conclude O O
, O O
we O O
have O O
identified O O
a O O
novel O O
regulatory B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
driving O O
Sox9 O O
expression O O
during O O
external O O
genitalia O O
development O O
. O O

Normal O O
Levels O O
of O O
Sox9 O O
Expression O O
in O O
the O O
Developing O O
Mouse O O
Testis O O
Depend O O
on O O
the O O
TES B-Enhancer B-Enhancer
/ O I-Enhancer
TESCO B-Enhancer I-Enhancer
Enhancer I-Enhancer I-Enhancer
, O O
but O O
This O O
Does O O
Not O O
Act O O
Alone O O
. O O

During O O
mouse O O
sex O O
determination O O
, O O
transient O O
expression O O
of O O
the O O
Y O O
- O O
linked O O
gene O O
Sry O O
up O O
- O O
regulates O O
its O O
direct O O
target O O
gene O O
Sox9 O O
, O O
via O O
a O O
3 B-Enhancer B-Enhancer
. I-Enhancer I-Enhancer
2 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
testis I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
Sox9 I-Enhancer I-Enhancer
( O O
TES B-Enhancer O
) O O
, O O
which O O
includes O O
a O O
core B-Enhancer B-Enhancer
1 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
4 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
, I-Enhancer O
TESCO I-Enhancer O
. O O
SOX9 O O
activity O O
leads O O
to O O
differentiation O O
of O O
Sertoli O O
cells O O
, O O
rather O O
than O O
granulosa O O
cells O O
from O O
the O O
bipotential O O
supporting O O
cell O O
precursor O O
lineage O O
. O O
During O O
mouse O O
sex O O
determination O O
, O O
transient O O
expression O O
of O O
the O O
Y O O
- O O
linked O O
gene O O
Sry O O
up O O
- O O
regulates O O
its O O
direct O O
target O O
gene O O
Sox9 O O
, O O
via O O
a O O
3 B-Enhancer B-Enhancer
. I-Enhancer I-Enhancer
2 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
testis I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
Sox9 I-Enhancer I-Enhancer
( O O
TES B-Enhancer O
) O O
, O O
which O O
includes O O
a O O
core B-Enhancer B-Enhancer
1 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
4 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
element I-Enhancer I-Enhancer
, I-Enhancer O
TESCO I-Enhancer O
. O O
SOX9 O O
activity O O
leads O O
to O O
differentiation O O
of O O
Sertoli O O
cells O O
, O O
rather O O
than O O
granulosa O O
cells O O
from O O
the O O
bipotential O O
supporting O O
cell O O
precursor O O
lineage O O
. O O

Here O O
, O O
we O O
present O O
functional O O
analysis O O
of O O
TES B-Enhancer O
/ O O
TESCO B-Enhancer O
, O O
using O O
CRISPR O O
/ O O
Cas9 O O
genome O O
editing O O
in O O
mice O O
. O O

Deletion O O
of O O
TESCO B-Enhancer O
or O O
TES B-Enhancer O
reduced O O
Sox9 O O
expression O O
levels O O
in O O
XY O O
fetal O O
gonads O O
to O O
60 O O
or O O
45 O O
% O O
respectively O O
relative O O
to O O
wild O O
type O O
gonads O O
, O O
and O O
reduced O O
expression O O
of O O
the O O
SOX9 O O
target O O
Amh O O
. O O

Although O O
human O O
patients O O
heterozygous O O
for O O
null O O
mutations O O
in O O
SOX9 O O
, O O
which O O
are O O
assumed O O
to O O
have O O
50 O O
% O O
of O O
normal O O
expression O O
, O O
often O O
show O O
XY O O
female O O
sex O O
reversal O O
, O O
mice O O
deleted O O
for O O
one O O
copy O O
of O O
Sox9 O O
do O O
not O O
. O O

Consistent O O
with O O
this O O
, O O
we O O
did O O
not O O
observe O O
sex O O
reversal O O
in O O
either O O
TESCO B-Enhancer O
- O O
/ O O
- O O
or O O
TES B-Enhancer O
- O O
/ O O
- O O
XY O O
embryos O O
or O O
adult O O
mice O O
. O O

However O O
, O O
embryos O O
carrying O O
both O O
a O O
conditional O O
Sox9 O O
null O O
allele O O
and O O
the O O
TES B-Enhancer O
deletion O O
developed O O
ovotestes O O
. O O

Quantitative O O
analysis O O
of O O
these O O
revealed O O
levels O O
of O O
23 O O
% O O
expression O O
of O O
Sox9 O O
compared O O
to O O
wild O O
type O O
, O O
and O O
a O O
significant O O
increase O O
in O O
the O O
expression O O
of O O
the O O
granulosa O O
cell O O
marker O O
Foxl2 O O
. O O

This O O
indicates O O
that O O
the O O
threshold O O
in O O
mice O O
where O O
sex O O
reversal O O
begins O O
to O O
be O O
seen O O
is O O
about O O
half O O
that O O
of O O
the O O
~ O O
50 O O
% O O
levels O O
predicted O O
in O O
humans O O
. O O

Our O O
results O O
demonstrate O O
that O O
TES B-Enhancer O
/ O O
TESCO B-Enhancer O
is O O
a O O
crucial O O
enhancer B-Enhancer B-Enhancer
regulating O O
Sox9 O O
expression O O
in O O
the O O
gonad O O
, O O
but O O
point O O
to O O
the O O
existence O O
of O O
additional O O
enhancers O O
that O O
act O O
redundantly O O
. O O

APOBEC O O
signature O O
mutation O O
generates O O
an O O
oncogenic B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
that O O
drives O O
LMO1 O O
expression O O
in O O
T O O
- O O
ALL O O
. O O

Oncogenic O O
driver O O
mutations O O
are O O
those O O
that O O
provide O O
a O O
proliferative O O
or O O
survival O O
advantage O O
to O O
neoplastic O O
cells O O
, O O
resulting O O
in O O
clonal O O
selection O O
. O O

Although O O
most O O
cancer O O
- O O
causing O O
mutations O O
have O O
been O O
detected O O
in O O
the O O
protein O O
- O O
coding O O
regions O O
of O O
the O O
cancer O O
genome O O
; O O
driver O O
mutations O O
have O O
recently O O
also O O
been O O
discovered O O
within O O
noncoding O O
genomic O O
sequences O O
. O O

Thus O O
, O O
a O O
current O O
challenge O O
is O O
to O O
gain O O
precise O O
understanding O O
of O O
how O O
these O O
unique O O
genomic O O
elements O O
function O O
in O O
cancer O O
pathogenesis O O
, O O
while O O
clarifying O O
mechanisms O O
of O O
gene O O
regulation O O
and O O
identifying O O
new O O
targets O O
for O O
therapeutic O O
intervention O O
. O O

Here O O
we O O
report O O
a O O
C O O
- O O
to O O
- O O
T O O
single O O
nucleotide O O
transition O O
that O O
occurs O O
as O O
a O O
somatic O O
mutation O O
in O O
noncoding O B-Enhancer
sequences O I-Enhancer
4 O I-Enhancer
kb O I-Enhancer
upstream O I-Enhancer
of O I-Enhancer
the O I-Enhancer
transcriptional O I-Enhancer
start O I-Enhancer
site O I-Enhancer
of O I-Enhancer
the O I-Enhancer
LMO1 O I-Enhancer
oncogene O I-Enhancer
in O O
primary O O
samples O O
from O O
patients O O
with O O
T O O
- O O
cell O O
acute O O
lymphoblastic O O
leukaemia O O
. O O

This O O
single O O
nucleotide O O
alteration O O
conforms O O
to O O
an O O
APOBEC O O
- O O
like O O
cytidine O O
deaminase O O
mutational O O
signature O O
, O O
and O O
generates O O
a O O
new O O
binding O O
site O O
for O O
the O O
MYB O O
transcription O O
factor O O
, O O
leading O O
to O O
the O O
formation O O
of O O
an O O
aberrant O O
transcriptional B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
complex I-Enhancer I-Enhancer
that O O
drives O O
high O O
levels O O
of O O
expression O O
of O O
the O O
LMO1 O O
oncogene O O
. O O
This O O
single O O
nucleotide O O
alteration O O
conforms O O
to O O
an O O
APOBEC O O
- O O
like O O
cytidine O O
deaminase O O
mutational O O
signature O O
, O O
and O O
generates O O
a O O
new O O
binding O O
site O O
for O O
the O O
MYB O O
transcription O O
factor O O
, O O
leading O O
to O O
the O O
formation O O
of O O
an O O
aberrant O O
transcriptional B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
complex I-Enhancer I-Enhancer
that O O
drives O O
high O O
levels O O
of O O
expression O O
of O O
the O O
LMO1 O O
oncogene O O
. O O

Since O O
APOBEC O O
- O O
signature O O
mutations O O
are O O
common O O
in O O
a O O
broad O O
spectrum O O
of O O
human O O
cancers O O
, O O
we O O
suggest O O
that O O
noncoding O O
nucleotide O O
transitions O O
such O O
as O O
the O O
one O O
described O O
here O O
may O O
activate O O
potent O O
oncogenic O O
enhancers O O
not O O
only O O
in O O
T O O
- O O
lymphoid O O
cells O O
but O O
in O O
other O O
cell O O
lineages O O
as O O
well O O
. O O

Dynamic O O
regulation O O
of O O
VEGF O O
- O O
inducible O O
genes O O
by O O
an O O
ERK O O
/ O O
ERG O O
/ O O
p300 O O
transcriptional O O
network O O
. O O

The O O
transcriptional O O
pathways O O
activated O O
downstream O O
of O O
vascular O O
endothelial O O
growth O O
factor O O
( O O
VEGF O O
) O O
signaling O O
during O O
angiogenesis O O
remain O O
incompletely O O
characterized O O
. O O

By O O
assessing O O
the O O
signals O O
responsible O O
for O O
induction O O
of O O
the O O
Notch O O
ligand O O
delta O O
- O O
like O O
4 O O
( O O
DLL4 O O
) O O
in O O
endothelial O O
cells O O
, O O
we O O
find O O
that O O
activation O O
of O O
the O O
MAPK O O
/ O O
ERK O O
pathway O O
mirrors O O
the O O
rapid O O
and O O
dynamic O O
induction O O
of O O
DLL4 O O
transcription O O
and O O
that O O
this O O
pathway O O
is O O
required O O
for O O
DLL4 O O
expression O O
. O O

Furthermore O O
, O O
VEGF O O
/ O O
ERK O O
signaling O O
induces O O
phosphorylation O O
and O O
activation O O
of O O
the O O
ETS O O
transcription O O
factor O O
ERG O O
, O O
a O O
prerequisite O O
for O O
DLL4 O O
induction O O
. O O

Transcription O O
of O O
DLL4 O O
coincides O O
with O O
dynamic O O
ERG O O
- O O
dependent O O
recruitment O O
of O O
the O O
transcriptional O O
co O O
- O O
activator O O
p300 O O
. O O

Genome O O
- O O
wide O O
gene O O
expression O O
profiling O O
identified O O
a O O
network O O
of O O
VEGF O O
- O O
responsive O O
and O O
ERG O O
- O O
dependent O O
genes O O
, O O
and O O
ERG O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
- O O
seq O O
revealed O O
the O O
presence O O
of O O
conserved O O
ERG B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bound I-Enhancer I-Enhancer
putative I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
elements I-Enhancer I-Enhancer
near I-Enhancer I-Enhancer
these I-Enhancer I-Enhancer
target I-Enhancer I-Enhancer
genes I-Enhancer I-Enhancer
. O O
Genome O O
- O O
wide O O
gene O O
expression O O
profiling O O
identified O O
a O O
network O O
of O O
VEGF O O
- O O
responsive O O
and O O
ERG O O
- O O
dependent O O
genes O O
, O O
and O O
ERG O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
- O O
seq O O
revealed O O
the O O
presence O O
of O O
conserved O O
ERG B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bound I-Enhancer I-Enhancer
putative I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
elements I-Enhancer I-Enhancer
near I-Enhancer I-Enhancer
these I-Enhancer I-Enhancer
target I-Enhancer I-Enhancer
genes I-Enhancer I-Enhancer
. O O

Functional O O
experiments O O
performed O O
in O O
vitro O O
and O O
in O O
vivo O O
confirm O O
that O O
this O O
network O O
of O O
genes O O
requires O O
ERK O O
, O O
ERG O O
and O O
p300 O O
activity O O
. O O

Finally O O
, O O
genome O O
- O O
editing O O
and O O
transgenic O O
approaches O O
demonstrate O O
that O O
a O O
highly O O
conserved O O
ERG B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bound I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
HLX I-Enhancer I-Enhancer
( O O
which O O
encodes O O
a O O
transcription O O
factor O O
implicated O O
in O O
sprouting O O
angiogenesis O O
) O O
is O O
required O O
for O O
its O O
VEGF O O
- O O
mediated O O
induction O O
. O O
Finally O O
, O O
genome O O
- O O
editing O O
and O O
transgenic O O
approaches O O
demonstrate O O
that O O
a O O
highly O O
conserved O O
ERG B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
bound I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
located I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
HLX I-Enhancer I-Enhancer
( O O
which O O
encodes O O
a O O
transcription O O
factor O O
implicated O O
in O O
sprouting O O
angiogenesis O O
) O O
is O O
required O O
for O O
its O O
VEGF O O
- O O
mediated O O
induction O O
. O O

Collectively O O
, O O
these O O
findings O O
elucidate O O
a O O
novel O O
transcriptional O O
pathway O O
contributing O O
to O O
VEGF O O
- O O
dependent O O
angiogenesis O O
. O O

SERPINB2 O O
is O O
regulated O O
by O O
dynamic O O
interactions O O
with O O
pause O O
- O O
release O O
proteins O O
and O O
enhancer O O
RNAs O O
. O O

The O O
SERPINB2 O O
gene O O
is O O
strongly O O
upregulated O O
in O O
inflammatory O O
states O O
. O O

In O O
monocytes O O
, O O
it O O
can O O
constitute O O
up O O
to O O
1 O O
% O O
of O O
total O O
cellular O O
protein O O
. O O

It O O
functions O O
in O O
protection O O
from O O
proteotoxic O O
stress O O
and O O
plays O O
a O O
role O O
in O O
angioedema O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
define O O
the O O
roles O O
of O O
enhancer B-Enhancer O
RNAs I-Enhancer O
embedded I-Enhancer O
in I-Enhancer O
the I-Enhancer O
SERPIN I-Enhancer O
gene I-Enhancer O
complex I-Enhancer O
. O O

We O O
found O O
that O O
the O O
upstream B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
RNAs I-Enhancer I-Enhancer
upregulated O O
SERPINB2 O O
and O O
the O O
enhancer B-Enhancer B-Enhancer
RNAs I-Enhancer I-Enhancer
were O O
expressed O O
prior O O
to O O
those O O
of O O
SERPINB2 O O
mRNA O O
. O O

Studies O O
of O O
the O O
SERPINB2 O O
promoter O O
demonstrated O O
the O O
presence O O
of O O
an O O
RNA O O
polymerase O O
II O O
pause O O
- O O
inducing O O
protein O O
, O O
NELF O O
. O O
Studies O O
of O O
the O O
SERPINB2 O O
promoter O O
demonstrated O O
the O O
presence O O
of O O
an O O
RNA O O
polymerase O O
II O O
pause O O
- O O
inducing O O
protein O O
, O O
NELF O O
. O O

Stimulation O O
with O O
LPS O O
led O O
to O O
recruitment O O
of O O
the O O
pause O O
- O O
releasing O O
kinase O O
P O O
- O O
TEFb O O
and O O
departure O O
of O O
the O O
pause O O
- O O
inducing O O
protein O O
NELF O O
. O O

RNA O O
immunoprecipitation O O
revealed O O
that O O
NELF O O
and O O
the O O
CDK9 O O
component O O
of O O
P O O
- O O
TEFb O O
bound O O
to O O
the O O
enhancer B-Enhancer B-Enhancer
RNAs I-Enhancer I-Enhancer
after O O
stimulation O O
with O O
distinct O O
kinetics O O
. O O

Knock O O
- O O
down O O
of O O
the O O
enhancer B-Enhancer B-Enhancer
RNAs I-Enhancer I-Enhancer
compromised O O
stimulus O O
induction O O
of O O
promoter O O
and O O
enhancer O O
chromatin O O
changes O O
. O O

Conversely O O
, O O
over O O
- O O
expression O O
was O O
associated O O
with O O
enhanced O O
recruitment O O
of O O
c O O
- O O
JUN O O
and O O
increased O O
expression O O
of O O
SERPINB2 O O
mRNA O O
expression O O
. O O

This O O
study O O
is O O
the O O
first O O
to O O
associate O O
enhancer B-Enhancer O
RNAs I-Enhancer O
with O O
SERPINB2 O O
and O O
is O O
the O O
first O O
demonstration O O
of O O
acquisition O O
of O O
NELF O O
binding O O
by O O
enhancer B-Enhancer O
RNAs I-Enhancer O
on O O
chromatin O O
. O O

Identification O O
of O O
an O O
Enhancer B-Enhancer B-Enhancer
Critical O O
for O O
the O O
ephirn O O
- O O
A5 O O
Gene O O
Expression O O
in O O
the O O
Posterior O O
Region O O
of O O
the O O
Mesencephalon O O
. O O
Ephrin O O
- O O
A5 O O
has O O
been O O
implicated O O
in O O
the O O
regulation O O
of O O
brain O O
morphogenesis O O
and O O
axon O O
pathfinding O O
. O O

In O O
this O O
study O O
, O O
we O O
used O O
bacterial O O
homologous O O
recombination O O
to O O
express O O
a O O
LacZ O O
reporter O O
in O O
various O O
ephrin O O
- O O
A5 O O
BAC O O
clones O O
to O O
identify O O
elements O O
that O O
regulate O O
ephrin O O
- O O
A5 O O
gene O O
expression O O
during O O
mesencephalon O O
development O O
. O O

We O O
found O O
that O O
there O O
is O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
activity I-Enhancer I-Enhancer
localized I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
a I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
+ I-Enhancer I-Enhancer
25 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
0 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
+ I-Enhancer I-Enhancer
30 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
5 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
genomic I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
ephrin I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
A5 I-Enhancer I-Enhancer
. O O
We O O
found O O
that O O
there O O
is O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
activity I-Enhancer I-Enhancer
localized I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
a I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
+ I-Enhancer I-Enhancer
25 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
0 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
+ I-Enhancer I-Enhancer
30 I-Enhancer I-Enhancer
. I-Enhancer I-Enhancer
5 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
genomic I-Enhancer I-Enhancer
region I-Enhancer I-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
first I-Enhancer I-Enhancer
intron I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
ephrin I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
A5 I-Enhancer I-Enhancer
. O O

Further O O
comparative O O
genomic O O
analysis O O
indicated O O
that O O
two O O
evolutionary O O
conserved O O
regions O O
, O O
ECR1 O O
and O O
ECR2 O O
, O O
were O O
present O O
within O O
this O O
5 O B-Enhancer
. O I-Enhancer
5 O I-Enhancer
kb O I-Enhancer
region O I-Enhancer
. O O

Deletion O O
of O O
ECR1 O O
from O O
the O O
enhancer B-Enhancer B-Enhancer
resulted O O
in O O
disrupted O O
mesencephalon B-Enhancer O
- I-Enhancer O
specific I-Enhancer O
enhancer I-Enhancer O
activity O O
in O O
transgenic O O
embryos O O
. O O
Deletion O O
of O O
ECR1 O O
from O O
the O O
enhancer B-Enhancer B-Enhancer
resulted O O
in O O
disrupted O O
mesencephalon B-Enhancer O
- I-Enhancer O
specific I-Enhancer O
enhancer I-Enhancer O
activity O O
in O O
transgenic O O
embryos O O
. O O

We O O
also O O
found O O
a O O
consensus O O
binding O O
site O O
for O O
basic O O
helix O O
- O O
loop O O
- O O
helix O O
( O O
bHLH O O
) O O
transcription O O
factors O O
( O O
TFs O O
) O O
in O O
a O O
highly O O
conserved O O
region O O
at O O
the O O
3 O B-Enhancer
' O I-Enhancer
- O I-Enhancer
end O I-Enhancer
of O I-Enhancer
ECR1 O I-Enhancer
. O O

We O O
further O O
demonstrated O O
that O O
specific O O
deletion O O
of O O
the O O
bHLH O O
TF O O
binding O O
site O O
abrogated O O
the O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
activity O O
in O O
transgenic O O
embryos O O
. O O
We O O
further O O
demonstrated O O
that O O
specific O O
deletion O O
of O O
the O O
bHLH O O
TF O O
binding O O
site O O
abrogated O O
the O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
activity O O
in O O
transgenic O O
embryos O O
. O O

Finally O O
, O O
both O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
luciferase O O
- O O
based O O
transactivation O O
assay O O
revealed O O
that O O
the O O
transcription O O
factor O O
Ascl1 O O
bound O O
the O O
bHLH O O
consensus O O
binding O O
site O O
in O O
the O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
ephrin I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
A5 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
vitro O O
. O O
Finally O O
, O O
both O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
luciferase O O
- O O
based O O
transactivation O O
assay O O
revealed O O
that O O
the O O
transcription O O
factor O O
Ascl1 O O
bound O O
the O O
bHLH O O
consensus O O
binding O O
site O O
in O O
the O O
mesencephalon B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
specific I-Enhancer I-Enhancer
ephrin I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
A5 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
vitro O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
bHLH O O
TF O O
binding O O
site O O
in O O
ECR1 O O
is O O
involved O O
in O O
the O O
positive O O
regulation O O
of O O
ephrin O O
- O O
A5 O O
gene O O
expression O O
during O O
the O O
development O O
of O O
the O O
mesencephalon O O
. O O

Characterization O O
of O O
Mesenchymal O O
- O O
Fibroblast O O
Cells O O
Using O O
the O O
Col1a2 O O
Promoter O O
/ O O
Enhancer O O
. O O

Excessive O O
deposition O O
of O O
extracellular O O
matrix O O
( O O
ECM O O
) O O
is O O
a O O
common O O
hallmark O O
of O O
fibrotic O O
diseases O O
in O O
various O O
organs O O
. O O

Chiefly O O
among O O
this O O
ECM O O
are O O
collagen O O
types O O
I O O
and O O
III O O
, O O
secreted O O
by O O
local O O
fibroblasts O O
, O O
and O O
other O O
mesenchymal O O
cells O O
recruited O O
for O O
repair O O
purposes O O
. O O

In O O
the O O
last O O
two O O
decades O O
, O O
the O O
search O O
for O O
a O O
fibroblast O B-Enhancer
- O I-Enhancer
specific O I-Enhancer
promoter O I-Enhancer
/ O I-Enhancer
enhancer O I-Enhancer
has O O
intensified O O
in O O
order O O
to O O
control O O
the O O
regulation O O
of O O
ECM O O
in O O
these O O
cells O O
and O O
limit O O
the O O
scarring O O
of O O
the O O
fibrotic O O
process O O
. O O

In O O
our O O
previous O O
work O O
, O O
we O O
characterized O O
an O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
17 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
Col1a2 I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
transcription I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
. O O
In O O
our O O
previous O O
work O O
, O O
we O O
characterized O O
an O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
17 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
Col1a2 I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
transcription I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
. O O

This O O
enhancer O B-Enhancer
in O O
transgenic O O
mice O O
is O O
expressed O O
mainly O O
in O O
mesenchymal O O
cells O O
during O O
development O O
and O O
in O O
adults O O
upon O O
injury O O
. O O

When O O
driving O O
transgenes O O
such O O
as O O
beta O O
- O O
galactosidase O O
or O O
luciferase O O
, O O
this O O
construct O O
acts O O
as O O
an O O
informative O O
reporter O O
of O O
collagen O O
transcription O O
and O O
is O O
predictive O O
of O O
collagen O O
type O O
I O O
deposition O O
. O O

In O O
this O O
chapter O O
, O O
we O O
provide O O
detailed O O
protocols O O
for O O
identifying O O
similar O O
enhancers O O
and O O
using O O
the O O
sequence O O
to O O
generate O O
a O O
construct O O
for O O
transfection O O
and O O
producing O O
transgenic O O
animals O O
. O O

We O O
also O O
provided O O
information O O
on O O
the O O
use O O
of O O
luminescence O O
in O O
transgenic O O
mice O O
, O O
tissue O O
processing O O
, O O
as O O
well O O
as O O
using O O
cre O O
/ O O
lox O O
system O O
to O O
obtain O O
conditional O O
gain O O
and O O
loss O O
of O O
function O O
in O O
mice O O
. O O

Characterization O O
of O O
enhancers O O
and O O
the O O
role O O
of O O
the O O
transcription O O
factor O O
KLF7 O O
in O O
regulating O O
corneal O O
epithelial O O
differentiation O O
. O O

During O O
tissue O O
development O O
, O O
transcription O O
factors O O
bind O O
regulatory O O
DNA O O
regions O O
called O O
enhancers O O
, O O
often O O
located O O
at O O
great O O
distances O O
from O O
the O O
genes O O
they O O
regulate O O
, O O
to O O
control O O
gene O O
expression O O
. O O

The O O
enhancer O O
landscape O O
during O O
embryonic O O
stem O O
cell O O
differentiation O O
has O O
been O O
well O O
characterized O O
. O O

By O O
contrast O O
, O O
little O O
is O O
known O O
about O O
the O O
shared O O
and O O
unique O O
enhancer O O
regulatory O O
mechanisms O O
in O O
different O O
ectodermally O O
derived O O
epithelial O O
cells O O
. O O

Here O O
we O O
use O O
ChIP O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
to O O
identify O O
domains O O
enriched O O
for O O
the O O
histone O O
marks O O
histone O O
H3 O O
lysine O O
4 O O
trimethylation O O
, O O
histone O O
H3 O O
lysine O O
4 O O
monomethylation O O
, O O
and O O
histone O O
H3 O O
lysine O O
27 O O
acetylation O O
( O O
H3K4me3 O O
, O O
H3K4me1 O O
, O O
and O O
H3K27ac O O
) O O
and O O
define O O
, O O
for O O
the O O
first O O
time O O
, O O
the O O
super O B-Enhancer
enhancers O I-Enhancer
and O O
typical O O
enhancers O O
active O O
in O O
primary O O
human O O
corneal O O
epithelial O O
cells O O
. O O

We O O
show O O
that O O
regulatory O O
regions O O
are O O
often O O
shared O O
between O O
cell O O
types O O
of O O
the O O
ectodermal O O
lineage O O
and O O
that O O
corneal O O
epithelial O O
super O O
enhancers O O
are O O
already O O
marked O O
as O O
potential O O
regulatory O O
domains O O
in O O
embryonic O O
stem O O
cells O O
. O O
Kruppel O O
- O O
like O O
factor O O
( O O
KLF O O
) O O
motifs O O
were O O
enriched O O
in O O
corneal O O
epithelial O O
enhancers O O
, O O
consistent O O
with O O
the O O
important O O
roles O O
of O O
KLF4 O O
and O O
KLF5 O O
in O O
promoting O O
corneal O O
epithelial O O
differentiation O O
. O O

We O O
now O O
show O O
that O O
the O O
Kruppel O O
family O O
member O O
KLF7 O O
promotes O O
the O O
corneal O O
progenitor O O
cell O O
state O O
; O O
on O O
many O O
genes O O
, O O
KLF7 O O
antagonized O O
the O O
corneal O O
differentiation O O
- O O
promoting O O
KLF4 O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
two O O
SNPs O O
linked O O
previously O O
to O O
corneal O O
diseases O O
, O O
astigmatism O O
, O O
and O O
Stevens O O
- O O
Johnson O O
syndrome O O
fall O O
within O O
corneal O O
epithelial O O
enhancers O O
and O O
alter O O
their O O
activity O O
by O O
disrupting O O
transcription O O
factor O O
motifs O O
that O O
overlap O O
these O O
SNPs O O
. O O

Taken O O
together O O
, O O
our O O
work O O
defines O O
regulatory O O
enhancers O O
in O O
corneal O O
epithelial O O
cells O O
, O O
highlights O O
global O O
gene O O
- O O
regulatory O O
relationships O O
shared O O
among O O
different O O
epithelial O O
cells O O
, O O
identifies O O
a O O
role O O
for O O
KLF7 O O
as O O
a O O
KLF4 O O
antagonist O O
in O O
corneal O O
epithelial O O
cell O O
differentiation O O
, O O
and O O
explains O O
how O O
two O O
SNPs O O
may O O
contribute O O
to O O
corneal O O
diseases O O
. O O

Enhancer O O
invasion O O
shapes O O
MYCN O O
- O O
dependent O O
transcriptional O O
amplification O O
in O O
neuroblastoma O O
. O O

Amplification O O
of O O
the O O
locus O O
encoding O O
the O O
oncogenic O O
transcription O O
factor O O
MYCN O O
is O O
a O O
defining O O
feature O O
of O O
high O O
- O O
risk O O
neuroblastoma O O
. O O

Here O O
we O O
present O O
the O O
first O O
dynamic O O
chromatin O O
and O O
transcriptional O O
landscape O O
of O O
MYCN O O
perturbation O O
in O O
neuroblastoma O O
. O O

At O O
oncogenic O O
levels O O
, O O
MYCN O O
associates O O
with O O
E O O
- O O
box O O
binding O O
motifs O O
in O O
an O O
affinity O O
- O O
dependent O O
manner O O
, O O
binding O O
to O O
strong O O
canonical O O
E O O
- O O
boxes O O
at O O
promoters O O
and O O
invading O O
abundant O O
weaker O O
non O O
- O O
canonical O O
E O O
- O O
boxes O O
clustered O O
at O O
enhancers O O
. O O

Loss O O
of O O
MYCN O O
leads O O
to O O
a O O
global O O
reduction O O
in O O
transcription O O
, O O
which O O
is O O
most O O
pronounced O O
at O O
MYCN O O
target O O
genes O O
with O O
the O O
greatest O O
enhancer O O
occupancy O O
. O O

These O O
highly O O
occupied O O
MYCN O O
target O O
genes O O
show O O
tissue O O
- O O
specific O O
expression O O
and O O
are O O
linked O O
to O O
poor O O
patient O O
survival O O
. O O

The O O
activity O O
of O O
genes O O
with O O
MYCN O B-Enhancer
- O I-Enhancer
occupied O I-Enhancer
enhancers O I-Enhancer
is O O
dependent O O
on O O
the O O
tissue O O
- O O
specific O O
transcription O O
factor O O
TWIST1 O O
, O O
which O O
co O O
- O O
occupies O O
enhancers O O
with O O
MYCN O O
and O O
is O O
required O O
for O O
MYCN O O
- O O
dependent O O
proliferation O O
. O O

These O O
data O O
implicate O O
tissue O O
- O O
specific O O
enhancers O O
in O O
defining O O
often O O
highly O O
tumor O O
- O O
specific O O
' O O
MYC O O
target O O
gene O O
signatures O O
' O O
and O O
identify O O
disruption O O
of O O
the O O
MYCN O B-Enhancer
enhancer O I-Enhancer
regulatory O O
axis O O
as O O
a O O
promising O O
therapeutic O O
strategy O O
in O O
neuroblastoma O O
. O O

The O O
distal B-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
insulin I-Enhancer O
- I-Enhancer O
like I-Enhancer O
growth I-Enhancer O
factor I-Enhancer O
- I-Enhancer O
binding I-Enhancer O
protein I-Enhancer O
- I-Enhancer O
1 I-Enhancer O
enhances O O
its O O
expression O O
in O O
endometrial O O
stromal O O
cells O O
during O O
decidualization O O
. O O
The O O
distal B-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
of I-Enhancer O
insulin I-Enhancer O
- I-Enhancer O
like I-Enhancer O
growth I-Enhancer O
factor I-Enhancer O
- I-Enhancer O
binding I-Enhancer O
protein I-Enhancer O
- I-Enhancer O
1 I-Enhancer O
enhances O O
its O O
expression O O
in O O
endometrial O O
stromal O O
cells O O
during O O
decidualization O O
. O O

We O O
have O O
previously O O
shown O O
that O O
decidualization O O
of O O
human O O
endometrial O O
stromal O O
cells O O
( O O
ESCs O O
) O O
causes O O
a O O
genome O O
- O O
wide O O
increase O O
in O O
the O O
levels O O
of O O
acetylation O O
of O O
histone O O
- O O
H3 O O
Lys O O
- O O
27 O O
( O O
H3K27ac O O
) O O
. O O

We O O
also O O
reported O O
that O O
the O O
distal O O
gene O O
regions O O
, O O
more O O
than O O
3 O O
kb O O
up O O
- O O
or O O
downstream O O
of O O
gene O O
transcription O O
start O O
sites O O
have O O
increased O O
H3K27ac O O
levels O O
. O O
Insulin O O
- O O
like O O
growth O O
factor O O
- O O
binding O O
protein O O
- O O
1 O O
( O O
IGFBP O O
- O O
1 O O
) O O
is O O
a O O
specific O O
decidualization O O
marker O O
and O O
has O O
increased O O
H3K27ac O O
levels O O
in O O
its O O
distal B-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
( I-Enhancer O
- I-Enhancer O
4701 I-Enhancer O
to I-Enhancer O
- I-Enhancer O
7501 I-Enhancer O
bp I-Enhancer O
) I-Enhancer O
. O O

Here O O
, O O
using O O
a O O
luciferase O O
reporter O O
gene O O
construct O O
containing O O
this O O
IGFBP B-Enhancer O
- I-Enhancer O
1 I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
, O O
we O O
tested O O
the O O
hypothesis O O
that O O
it O O
is O O
an O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
Here O O
, O O
using O O
a O O
luciferase O O
reporter O O
gene O O
construct O O
containing O O
this O O
IGFBP B-Enhancer O
- I-Enhancer O
1 I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
, O O
we O O
tested O O
the O O
hypothesis O O
that O O
it O O
is O O
an O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

To O O
induce O O
decidualization O O
, O O
we O O
incubated O O
ESCs O O
with O O
cAMP O O
and O O
found O O
that O O
cAMP O O
increased O O
luciferase O O
expression O O
, O O
indicating O O
that O O
decidualization O O
increased O O
the O O
transcriptional O O
activity O O
from O O
the O O
IGFBP B-Enhancer O
- I-Enhancer O
1 I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
. O O
To O O
induce O O
decidualization O O
, O O
we O O
incubated O O
ESCs O O
with O O
cAMP O O
and O O
found O O
that O O
cAMP O O
increased O O
luciferase O O
expression O O
, O O
indicating O O
that O O
decidualization O O
increased O O
the O O
transcriptional O O
activity O O
from O O
the O O
IGFBP B-Enhancer O
- I-Enhancer O
1 I-Enhancer O
upstream I-Enhancer O
region I-Enhancer O
. O O

Furthermore O O
, O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
deletion O O
of O O
this O O
region O O
in O O
HepG2 O O
cells O O
significantly O O
reduced O O
IGFBP O O
- O O
1 O O
expression O O
, O O
confirming O O
its O O
role O O
as O O
an O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
Furthermore O O
, O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
deletion O O
of O O
this O O
region O O
in O O
HepG2 O O
cells O O
significantly O O
reduced O O
IGFBP O O
- O O
1 O O
expression O O
, O O
confirming O O
its O O
role O O
as O O
an O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

A O O
ChIP O O
assay O O
revealed O O
that O O
cAMP O O
increased O O
the O O
recruitment O O
of O O
the O O
transcriptional O O
regulators O O
CCAAT O B-Enhancer
enhancer O I-Enhancer
- O I-Enhancer
binding O I-Enhancer
protein O I-Enhancer
beta O I-Enhancer
( O O
C O O
/ O O
EBPbeta O O
) O O
, O O
forkhead O O
box O O
O1 O O
( O O
FOXO1 O O
) O O
, O O
and O O
p300 O O
to O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
ESCs O O
. O O
A O O
ChIP O O
assay O O
revealed O O
that O O
cAMP O O
increased O O
the O O
recruitment O O
of O O
the O O
transcriptional O O
regulators O O
CCAAT O B-Enhancer
enhancer O I-Enhancer
- O I-Enhancer
binding O I-Enhancer
protein O I-Enhancer
beta O I-Enhancer
( O O
C O O
/ O O
EBPbeta O O
) O O
, O O
forkhead O O
box O O
O1 O O
( O O
FOXO1 O O
) O O
, O O
and O O
p300 O O
to O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
in O O
ESCs O O
. O O

Of O O
note O O
, O O
C O O
/ O O
EBPbeta O O
knockdown O O
inhibited O O
the O O
stimulatory O O
effects O O
of O O
cAMP O O
on O O
the O O
levels O O
of O O
H3K27ac O O
, O O
chromatin O O
opening O O
, O O
and O O
p300 O O
recruitment O O
at O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
Of O O
note O O
, O O
C O O
/ O O
EBPbeta O O
knockdown O O
inhibited O O
the O O
stimulatory O O
effects O O
of O O
cAMP O O
on O O
the O O
levels O O
of O O
H3K27ac O O
, O O
chromatin O O
opening O O
, O O
and O O
p300 O O
recruitment O O
at O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

These O O
results O O
indicate O O
that O O
the O O
region B-Enhancer O
- I-Enhancer O
4701 I-Enhancer O
to I-Enhancer O
- I-Enhancer O
7501 I-Enhancer O
bp I-Enhancer O
upstream I-Enhancer O
of I-Enhancer O
IGFBP I-Enhancer O
- I-Enhancer O
1 I-Enhancer O
functions O O
as O O
an O O
enhancer B-Enhancer B-Enhancer
for I-Enhancer O
IGFBP I-Enhancer O
- I-Enhancer O
1 I-Enhancer O
expression O O
in O O
ESCs O O
undergoing O O
decidualization O O
, O O
that O O
C O O
/ O O
EBPbeta O O
and O O
FOXO1 O O
bind O O
to O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
to O O
up O O
- O O
regulate O O
IGFBP O O
- O O
1 O O
expression O O
, O O
and O O
that O O
C O O
/ O O
EBPbeta O O
induces O O
H3K27ac O O
by O O
recruiting O O
p300 O O
to O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
These O O
results O O
indicate O O
that O O
the O O
region B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
4701 I-Enhancer I-Enhancer
to I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
7501 I-Enhancer I-Enhancer
bp I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
IGFBP I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
functions O O
as O O
an O O
enhancer B-Enhancer B-Enhancer
for I-Enhancer O
IGFBP I-Enhancer O
- I-Enhancer O
1 I-Enhancer O
expression O O
in O O
ESCs O O
undergoing O O
decidualization O O
, O O
that O O
C O O
/ O O
EBPbeta O O
and O O
FOXO1 O O
bind O O
to O O
the O O
enhancer B-Enhancer B-Enhancer
region I-Enhancer I-Enhancer
to O O
up O O
- O O
regulate O O
IGFBP O O
- O O
1 O O
expression O O
, O O
and O O
that O O
C O O
/ O O
EBPbeta O O
induces O O
H3K27ac O O
by O O
recruiting O O
p300 O O
to O O
the O O
IGFBP B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
1 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

Dissecting O O
super O O
- O O
enhancer O O
hierarchy O O
based O O
on O O
chromatin O O
interactions O O
. O O

Recent O O
studies O O
have O O
highlighted O O
super O O
- O O
enhancers O O
( O O
SEs O O
) O O
as O O
important O O
regulatory O O
elements O O
for O O
gene O O
expression O O
, O O
but O O
their O O
intrinsic O O
properties O O
remain O O
incompletely O O
characterized O O
. O O

Through O O
an O O
integrative O O
analysis O O
of O O
Hi O O
- O O
C O O
and O O
ChIP O O
- O O
seq O O
data O O
, O O
here O O
we O O
find O O
that O O
a O O
significant O O
fraction O O
of O O
SEs O O
are O O
hierarchically O O
organized O O
, O O
containing O O
both O O
hub O O
and O O
non O O
- O O
hub O O
enhancers O O
. O O

Hub O O
enhancers O O
share O O
similar O O
histone O O
marks O O
with O O
non O O
- O O
hub O O
enhancers O O
, O O
but O O
are O O
distinctly O O
associated O O
with O O
cohesin O O
and O O
CTCF O O
binding O O
sites O O
and O O
disease O O
- O O
associated O O
genetic O O
variants O O
. O O
Hub O B-Enhancer
enhancers O I-Enhancer
share O O
similar O O
histone O O
marks O O
with O O
non O O
- O O
hub O O
enhancers O O
, O O
but O O
are O O
distinctly O O
associated O O
with O O
cohesin O O
and O O
CTCF O O
binding O O
sites O O
and O O
disease O O
- O O
associated O O
genetic O O
variants O O
. O O

Genetic O O
ablation O O
of O O
hub O O
enhancers O O
results O O
in O O
profound O O
defects O O
in O O
gene O O
activation O O
and O O
local O O
chromatin O O
landscape O O
. O O

As O O
such O O
, O O
hub O O
enhancers O O
are O O
the O O
major O O
constituents O O
responsible O O
for O O
SE O O
functional O O
and O O
structural O O
organization O O
. O O

TFAP2C O O
regulates O O
transcription O O
in O O
human O O
naive O O
pluripotency O O
by O O
opening O O
enhancers O O
. O O

Naive O O
and O O
primed O O
pluripotent O O
human O O
embryonic O O
stem O O
cells O O
bear O O
transcriptional O O
similarity O O
to O O
pre O O
- O O
and O O
post O O
- O O
implantation O O
epiblast O O
and O O
thus O O
constitute O O
a O O
developmental O O
model O O
for O O
understanding O O
the O O
pluripotent O O
stages O O
in O O
human O O
embryo O O
development O O
. O O

To O O
identify O O
new O O
transcription O O
factors O O
that O O
differentially O O
regulate O O
the O O
unique O O
pluripotent O O
stages O O
, O O
we O O
mapped O O
open O O
chromatin O O
using O O
ATAC O O
- O O
seq O O
and O O
found O O
enrichment O O
of O O
the O O
activator O O
protein O O
- O O
2 O O
( O O
AP2 O O
) O O
transcription O O
factor O O
binding O O
motif O O
at O O
naive O O
- O O
specific O O
open O O
chromatin O O
. O O
To O O
identify O O
new O O
transcription O O
factors O O
that O O
differentially O O
regulate O O
the O O
unique O O
pluripotent O O
stages O O
, O O
we O O
mapped O O
open O O
chromatin O O
using O O
ATAC O O
- O O
seq O O
and O O
found O O
enrichment O O
of O O
the O O
activator O O
protein O O
- O O
2 O O
( O O
AP2 O O
) O O
transcription O O
factor O O
binding O O
motif O O
at O O
naive O O
- O O
specific O O
open O O
chromatin O O
. O O

We O O
determined O O
that O O
the O O
AP2 O O
family O O
member O O
TFAP2C O O
is O O
upregulated O O
during O O
primed O O
to O O
naive O O
reversion O O
and O O
becomes O O
widespread O O
at O O
naive O O
- O O
specific O O
enhancers O O
. O O
TFAP2C O O
functions O O
to O O
maintain O O
pluripotency O O
and O O
repress O O
neuroectodermal O O
differentiation O O
during O O
the O O
transition O O
from O O
primed O O
to O O
naive O O
by O O
facilitating O O
the O O
opening O O
of O O
enhancers O O
proximal O O
to O O
pluripotency O O
factors O O
. O O

Additionally O O
, O O
we O O
identify O O
a O O
previously O O
undiscovered O O
naive B-Enhancer O
- I-Enhancer O
specific I-Enhancer O
POU5F1 I-Enhancer B-Enhancer
( I-Enhancer I-Enhancer
OCT4 I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
enriched O O
for O O
TFAP2C O O
binding O O
. O O
Additionally O O
, O O
we O O
identify O O
a O O
previously O O
undiscovered O O
naive B-Enhancer O
- I-Enhancer O
specific I-Enhancer O
POU5F1 I-Enhancer B-Enhancer
( I-Enhancer I-Enhancer
OCT4 I-Enhancer I-Enhancer
) I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
enriched O O
for O O
TFAP2C O O
binding O O
. O O

Taken O O
together O O
, O O
TFAP2C O O
establishes O O
and O O
maintains O O
naive O O
human O O
pluripotency O O
and O O
regulates O O
OCT4 O O
expression O O
by O O
mechanisms O O
that O O
are O O
distinct O O
from O O
mouse O O
. O O

Identification O O
of O O
Smoking O O
- O O
Associated O O
Differentially O O
Methylated O O
Regions O O
Using O O
Reduced O O
Representation O O
Bisulfite O O
Sequencing O O
and O O
Cell O O
type O O
- O O
Specific O O
Enhancer O O
Activation O O
and O O
Gene O O
Expression O O
. O O

BACKGROUND O O
: O O
Cigarette O O
smoke O O
is O O
a O O
causal O O
factor O O
in O O
cancers O O
and O O
cardiovascular O O
disease O O
. O O

Smoking O O
- O O
associated O O
differentially O O
methylated O O
regions O O
( O O
SM O O
- O O
DMRs O O
) O O
have O O
been O O
observed O O
in O O
disease O O
studies O O
, O O
but O O
the O O
causal O O
link O O
between O O
altered O O
DNA O O
methylation O O
and O O
transcriptional O O
change O O
is O O
obscure O O
. O O

OBJECTIVE O O
: O O
Our O O
objectives O O
were O O
to O O
finely O O
resolve O O
SM O O
- O O
DMRs O O
and O O
to O O
interrogate O O
the O O
mechanistic O O
link O O
between O O
SM O O
- O O
DMRs O O
and O O
altered O O
transcription O O
of O O
enhancer O O
noncoding O O
RNA O O
( O O
eRNA O O
) O O
and O O
mRNA O O
in O O
human O O
circulating O O
monocytes O O
. O O

METHOD O O
: O O
We O O
integrated O O
SM O O
- O O
DMRs O O
identified O O
by O O
reduced O O
representation O O
bisulfite O O
sequencing O O
( O O
RRBS O O
) O O
of O O
circulating O O
CD14 O O
+ O O
monocyte O O
DNA O O
collected O O
from O O
two O O
independent O O
human O O
studies O O
[ O O
n O O
= O O
38 O O
from O O
Clinical O O
Research O O
Unit O O
( O O
CRU O O
) O O
and O O
n O O
= O O
55 O O
from O O
the O O
Multi O O
- O O
Ethnic O O
Study O O
of O O
Atherosclerosis O O
( O O
MESA O O
) O O
, O O
about O O
half O O
of O O
whom O O
were O O
active O O
smokers O O
] O O
with O O
gene O O
expression O O
for O O
protein O O
- O O
coding O O
genes O O
and O O
noncoding O O
RNAs O O
measured O O
by O O
RT O O
- O O
PCR O O
or O O
RNA O O
sequencing O O
. O O

Candidate O O
SM O O
- O O
DMRs O O
were O O
compared O O
with O O
RRBS O O
of O O
purified O O
CD4 O O
+ O O
T O O
cells O O
, O O
CD8 O O
+ O O
T O O
cells O O
, O O
CD15 O O
+ O O
granulocytes O O
, O O
CD19 O O
+ O O
B O O
cells O O
, O O
and O O
CD56 O O
+ O O
NK O O
cells O O
( O O
n O O
= O O
19 O O
females O O
, O O
CRU O O
) O O
. O O

DMRs O O
were O O
validated O O
using O O
pyrosequencing O O
or O O
bisulfite O O
amplicon O O
sequencing O O
in O O
up O O
to O O
85 O O
CRU O O
volunteers O O
, O O
who O O
also O O
provided O O
saliva O O
DNA O O
. O O

RESULTS O O
: O O
RRBS O O
identified O O
monocyte O O
SM O O
- O O
DMRs O O
frequently O O
located O O
in O O
putative O O
gene O O
regulatory O O
regions O O
. O O

The O O
most O O
significant O O
monocyte O O
DMR O O
occurred O O
at O O
a O O
poised O O
enhancer B-Enhancer B-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
aryl I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
hydrocarbon I-Enhancer I-Enhancer
receptor I-Enhancer I-Enhancer
repressor I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
( O O
AHRR O O
) O O
and O O
it O O
was O O
also O O
detected O O
in O O
both O O
granulocytes O O
and O O
saliva O O
DNA O O
. O O
The O O
most O O
significant O O
monocyte O O
DMR O O
occurred O O
at O O
a O O
poised O O
enhancer B-Enhancer B-Enhancer
in I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
aryl I-Enhancer I-Enhancer
- I-Enhancer I-Enhancer
hydrocarbon I-Enhancer I-Enhancer
receptor I-Enhancer I-Enhancer
repressor I-Enhancer I-Enhancer
gene I-Enhancer I-Enhancer
( O O
AHRR O O
) O O
and O O
it O O
was O O
also O O
detected O O
in O O
both O O
granulocytes O O
and O O
saliva O O
DNA O O
. O O

To O O
our O O
knowledge O O
, O O
we O O
identify O O
for O O
the O O
first O O
time O O
that O O
SM O O
- O O
DMRs O O
in O O
or O O
near O O
AHRR O O
, O O
C5orf55 O O
- O O
EXOC O O
- O O
AS O O
, O O
and O O
SASH1 O O
were O O
associated O O
with O O
increased O O
noncoding O O
eRNA O O
as O O
well O O
as O O
mRNA O O
in O O
monocytes O O
. O O

Functionally O O
, O O
the O O
AHRR O O
SM O O
- O O
DMR O O
appeared O O
to O O
up O O
- O O
regulate O O
AHRR O O
mRNA O O
through O O
activating O O
the O O
AHRR B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
as O O
suggested O O
by O O
increased O O
eRNA O O
in O O
the O O
monocytes O O
, O O
but O O
not O O
granulocytes O O
, O O
from O O
smokers O O
compared O O
with O O
nonsmokers O O
. O O
Functionally O O
, O O
the O O
AHRR O O
SM O O
- O O
DMR O O
appeared O O
to O O
up O O
- O O
regulate O O
AHRR O O
mRNA O O
through O O
activating O O
the O O
AHRR B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
, O O
as O O
suggested O O
by O O
increased O O
eRNA O O
in O O
the O O
monocytes O O
, O O
but O O
not O O
granulocytes O O
, O O
from O O
smokers O O
compared O O
with O O
nonsmokers O O
. O O

CONCLUSIONS O O
: O O
Our O O
findings O O
suggest O O
that O O
AHRR O O
SM O O
- O O
DMR O O
up O O
- O O
regulates O O
AHRR O O
mRNA O O
in O O
a O O
monocyte O O
- O O
specific O O
manner O O
by O O
activating O O
the O O
AHRR B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O
CONCLUSIONS O O
: O O
Our O O
findings O O
suggest O O
that O O
AHRR O O
SM O O
- O O
DMR O O
up O O
- O O
regulates O O
AHRR O O
mRNA O O
in O O
a O O
monocyte O O
- O O
specific O O
manner O O
by O O
activating O O
the O O
AHRR B-Enhancer B-Enhancer
enhancer I-Enhancer I-Enhancer
. O O

Cell O O
type O O
- O O
specific O O
activation O O
of O O
enhancers O O
at O O
SM O O
- O O
DMRs O O
may O O
represent O O
a O O
mechanism O O
driving O O
smoking O O
- O O
related O O
disease O O
. O O
https O O
: O O
/ O O
/ O O
doi O O
. O O
org O O
/ O O
10 O O
. O O
1289 O O
/ O O
EHP2395 O O
. O O

Disruption O O
of O O
a O O
- B-Enhancer B-Enhancer
35 I-Enhancer I-Enhancer
kb I-Enhancer I-Enhancer
Enhancer I-Enhancer I-Enhancer
Impairs O O
CTCF O O
Binding O O
and O O
MLH1 O O
Expression O O
in O O
Colorectal O O
Cells O O
. O O

Purpose O O
: O O
MLH1 O O
is O O
a O O
major O O
tumor O O
suppressor O O
gene O O
involved O O
in O O
the O O
pathogenesis O O
of O O
Lynch O O
syndrome O O
and O O
various O O
sporadic O O
cancers O O
. O O

Despite O O
their O O
potential O O
pathogenic O O
importance O O
, O O
genomic O O
regions O O
capable O O
of O O
regulating O O
MLH1 O O
expression O O
over O O
long O O
distances O O
have O O
yet O O
to O O
be O O
identified O O
. O O
Experimental O O
Design O O
: O O
Here O O
, O O
we O O
use O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
to O O
screen O O
a O O
650 O O
- O O
kb O O
region O O
flanking O O
the O O
MLH1 O O
locus O O
to O O
identify O O
interactions O O
between O O
the O O
MLH1 O O
promoter O O
and O O
distal O O
regions O O
in O O
MLH1 O O
- O O
expressing O O
and O O
nonexpressing O O
cells O O
. O O
Despite O O
their O O
potential O O
pathogenic O O
importance O O
, O O
genomic O O
regions O O
capable O O
of O O
regulating O O
MLH1 O O
expression O O
over O O
long O O
distances O O
have O O
yet O O
to O O
be O O
identified O O
. O O
Experimental O O
Design O O
: O O
Here O O
, O O
we O O
use O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
to O O
screen O O
a O O
650 O O
- O O
kb O O
region O O
flanking O O
the O O
MLH1 O O
locus O O
to O O
identify O O
interactions O O
between O O
the O O
MLH1 O O
promoter O O
and O O
distal O O
regions O O
in O O
MLH1 O O
- O O
expressing O O
and O O
nonexpressing O O
cells O O
. O O

Putative O O
enhancers O B-Enhancer
were O O
functionally O O
validated O O
using O O
luciferase O O
reporter O O
assays O O
, O O
chromatin O O
immunoprecipitation O O
, O O
and O O
CRISPR O O
- O O
Cas9 O O
- O O
mediated O O
deletion O O
of O O
endogenous O O
regions O O
. O O

To O O
evaluate O O
whether O O
germline O O
variants O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
might O O
contribute O O
to O O
impaired O O
MLH1 O O
expression O O
in O O
patients O O
with O O
suspected O O
Lynch O O
syndrome O O
, O O
we O O
also O O
screened O O
germline O O
DNA O O
from O O
a O O
cohort O O
of O O
74 O O
patients O O
with O O
no O O
known O O
coding O O
mutations O O
or O O
epimutations O O
at O O
the O O
MLH1 O O
promoter O O
. O O
Results O O
: O O
A O O
1 B-Enhancer O
. I-Enhancer O
8 I-Enhancer O
- I-Enhancer O
kb I-Enhancer O
DNA I-Enhancer O
fragment I-Enhancer O
, I-Enhancer O
35 I-Enhancer B-Enhancer
kb I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
MLH1 I-Enhancer I-Enhancer
transcription I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
enhances O O
MLH1 O O
gene O O
expression O O
in O O
colorectal O O
cells O O
. O O
To O O
evaluate O O
whether O O
germline O O
variants O O
in O O
the O O
enhancer B-Enhancer B-Enhancer
might O O
contribute O O
to O O
impaired O O
MLH1 O O
expression O O
in O O
patients O O
with O O
suspected O O
Lynch O O
syndrome O O
, O O
we O O
also O O
screened O O
germline O O
DNA O O
from O O
a O O
cohort O O
of O O
74 O O
patients O O
with O O
no O O
known O O
coding O O
mutations O O
or O O
epimutations O O
at O O
the O O
MLH1 O O
promoter O O
. O O
Results O O
: O O
A O O
1 B-Enhancer O
. I-Enhancer O
8 I-Enhancer O
- I-Enhancer O
kb I-Enhancer O
DNA I-Enhancer O
fragment I-Enhancer O
, I-Enhancer O
35 I-Enhancer B-Enhancer
kb I-Enhancer I-Enhancer
upstream I-Enhancer I-Enhancer
of I-Enhancer I-Enhancer
the I-Enhancer I-Enhancer
MLH1 I-Enhancer I-Enhancer
transcription I-Enhancer I-Enhancer
start I-Enhancer I-Enhancer
site I-Enhancer I-Enhancer
enhances O O
MLH1 O O
gene O O
expression O O
in O O
colorectal O O
cells O O
. O O

The O O
enhancer B-Enhancer B-Enhancer
was O O
bound O O
by O O
CTCF O O
and O O
CRISPR O O
- O O
Cas9 O O
- O O
mediated O O
deletion O O
of O O
a O O
core O O
binding O O
region O O
impairs O O
endogenous O O
MLH1 O O
expression O O
. O O

A O O
total O O
of O O
5 O O
. O O
4 O O
% O O
of O O
suspected O O
Lynch O O
syndrome O O
patients O O
have O O
a O O
rare O O
single O O
- O O
nucleotide O O
variant O O
( O O
G O O
> O O
A O O
; O O
rs143969848 O O
; O O
2 O O
. O O
5 O O
% O O
in O O
gnomAD O O
European O O
, O O
non O O
- O O
Finnish O O
) O O
within O O
a O O
highly O O
conserved O O
CTCF O O
- O O
binding O O
motif O O
, O O
which O O
disrupts O O
enhancer O O
activity O O
in O O
SW620 O O
colorectal O O
carcinoma O O
cells O O
. O O
Conclusions O O
: O O
A O O
CTCF O O
- O O
bound O O
region O O
within O O
the O O
MLH1 B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
35 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
regulates O O
MLH1 O O
expression O O
in O O
colorectal O O
cells O O
and O O
is O O
worthy O O
of O O
scrutiny O O
in O O
future O O
genetic O O
screening O O
strategies O O
for O O
suspected O O
Lynch O O
syndrome O O
associated O O
with O O
loss O O
of O O
MLH1 O O
expression O O
. O O
A O O
total O O
of O O
5 O O
. O O
4 O O
% O O
of O O
suspected O O
Lynch O O
syndrome O O
patients O O
have O O
a O O
rare O O
single O O
- O O
nucleotide O O
variant O O
( O O
G O O
> O O
A O O
; O O
rs143969848 O O
; O O
2 O O
. O O
5 O O
% O O
in O O
gnomAD O O
European O O
, O O
non O O
- O O
Finnish O O
) O O
within O O
a O O
highly O O
conserved O O
CTCF O O
- O O
binding O O
motif O O
, O O
which O O
disrupts O O
enhancer O O
activity O O
in O O
SW620 O O
colorectal O O
carcinoma O O
cells O O
. O O
Conclusions O O
: O O
A O O
CTCF O O
- O O
bound O O
region O O
within O O
the O O
MLH1 B-Enhancer B-Enhancer
- I-Enhancer I-Enhancer
35 I-Enhancer I-Enhancer
enhancer I-Enhancer I-Enhancer
regulates O O
MLH1 O O
expression O O
in O O
colorectal O O
cells O O
and O O
is O O
worthy O O
of O O
scrutiny O O
in O O
future O O
genetic O O
screening O O
strategies O O
for O O
suspected O O
Lynch O O
syndrome O O
associated O O
with O O
loss O O
of O O
MLH1 O O
expression O O
. O O

Clin O O
Cancer O O
Res O O
; O O
24 O O
( O O
18 O O
) O O
; O O
4602 O O
- O O
11 O O
. O O

2018 O O
AACR O O
. O O

Polycomb O O
complexes O O
associate O O
with O O
enhancers O O
and O O
promote O O
oncogenic O O
transcriptional O O
programs O O
in O O
cancer O O
through O O
multiple O O
mechanisms O O
. O O
Polycomb O O
repressive O O
complex O O
1 O O
( O O
PRC1 O O
) O O
plays O O
essential O O
roles O O
in O O
cell O O
fate O O
decisions O O
and O O
development O O
. O O

However O O
, O O
its O O
role O O
in O O
cancer O O
is O O
less O O
well O O
understood O O
. O O

Here O O
, O O
we O O
show O O
that O O
RNF2 O O
, O O
encoding O O
RING1B O O
, O O
and O O
canonical O O
PRC1 O O
( O O
cPRC1 O O
) O O
genes O O
are O O
overexpressed O O
in O O
breast O O
cancer O O
. O O

We O O
find O O
that O O
cPRC1 O O
complexes O O
functionally O O
associate O O
with O O
ERalpha O O
and O O
its O O
pioneer O O
factor O O
FOXA1 O O
in O O
ER O O
+ O O
breast O O
cancer O O
cells O O
, O O
and O O
with O O
BRD4 O O
in O O
triple O O
- O O
negative O O
breast O O
cancer O O
cells O O
( O O
TNBC O O
) O O
. O O

While O O
cPRC1 O O
still O O
exerts O O
its O O
repressive O O
function O O
, O O
it O O
is O O
also O O
recruited O O
to O O
oncogenic O O
active O O
enhancers O O
. O O
RING1B O O
regulates O O
enhancer O O
activity O O
and O O
gene O O
transcription O O
not O O
only O O
by O O
promoting O O
the O O
expression O O
of O O
oncogenes O O
but O O
also O O
by O O
regulating O O
chromatin O O
accessibility O O
. O O

Functionally O O
, O O
RING1B O O
plays O O
a O O
divergent O O
role O O
in O O
ER O O
+ O O
and O O
TNBC O O
metastasis O O
. O O

Finally O O
, O O
we O O
show O O
that O O
concomitant O O
recruitment O O
of O O
RING1B O O
to O O
active O O
enhancers O O
occurs O O
across O O
multiple O O
cancers O O
, O O
highlighting O O
an O O
under O O
- O O
explored O O
function O O
of O O
cPRC1 O O
in O O
regulating O O
oncogenic O O
transcriptional O O
programs O O
in O O
cancer O O
. O O

High O O
- O O
resolution O O
genome O O
- O O
wide O O
functional O O
dissection O O
of O O
transcriptional O O
regulatory O O
regions O O
and O O
nucleotides O O
in O O
human O O
. O O

Genome O O
- O O
wide O O
epigenomic O O
maps O O
have O O
revealed O O
millions O O
of O O
putative O O
enhancers O O
and O O
promoters O O
, O O
but O O
experimental O O
validation O O
of O O
their O O
function O O
and O O
high O O
- O O
resolution O O
dissection O O
of O O
their O O
driver O O
nucleotides O O
remain O O
limited O O
. O O

Here O O
, O O
we O O
present O O
HiDRA O O
( O O
High O O
- O O
resolution O O
Dissection O O
of O O
Regulatory O O
Activity O O
) O O
, O O
a O O
combined O O
experimental O O
and O O
computational O O
method O O
for O O
high O O
- O O
resolution O O
genome O O
- O O
wide O O
testing O O
and O O
dissection O O
of O O
putative O O
regulatory O O
regions O O
. O O

We O O
test O O
~ O O
7 O O
million O O
accessible O O
DNA O O
fragments O O
in O O
a O O
single O O
experiment O O
, O O
by O O
coupling O O
accessible O O
chromatin O O
extraction O O
with O O
self O O
- O O
transcribing O O
episomal O O
reporters O O
( O O
ATAC O O
- O O
STARR O O
- O O
seq O O
) O O
. O O

By O O
design O O
, O O
fragments O O
are O O
highly O O
overlapping O O
in O O
densely O O
- O O
sampled O O
accessible O O
regions O O
, O O
enabling O O
us O O
to O O
pinpoint O O
driver O O
regulatory O O
nucleotides O O
by O O
exploiting O O
differences O O
in O O
activity O O
between O O
partially O O
- O O
overlapping O O
fragments O O
using O O
a O O
machine O O
learning O O
model O O
( O O
SHARPR O O
- O O
RE O O
) O O
. O O

In O O
GM12878 O O
lymphoblastoid O O
cells O O
, O O
we O O
find O O
~ O O
65 O O
, O O
000 O O
regions O O
showing O O
enhancer O O
function O O
, O O
and O O
pinpoint O O
~ O O
13 O O
, O O
000 O O
high O O
- O O
resolution O O
driver O O
elements O O
. O O

These O O
are O O
enriched O O
for O O
regulatory O O
motifs O O
, O O
evolutionarily O O
- O O
conserved O O
nucleotides O O
, O O
and O O
disease O O
- O O
associated O O
genetic O O
variants O O
from O O
genome O O
- O O
wide O O
association O O
studies O O
. O O

Overall O O
, O O
HiDRA O O
provides O O
a O O
high O O
- O O
throughput O O
, O O
high O O
- O O
resolution O O
approach O O
for O O
dissecting O O
regulatory O O
regions O O
and O O
driver O O
nucleotides O O
. O O

